



# Third Grade

# Third Year Curriculum: Building the Foundations of Medical Knowledge College of Medicine – University of Al-Ameed

| Third year cur | Third year curriculum map (30 weeks) |        |          |       |  |
|----------------|--------------------------------------|--------|----------|-------|--|
| code           | Subject                              | Theory | Practice | Units |  |
| (MICR 301)     | Microbiology                         | 120    | 60       | 10    |  |
| (PHAR 302)     | Pharmacology                         | 90     | 60       | 8     |  |
| (PATH 303)     | Pathology                            | 60     | 45       | 5.5   |  |
| (PARS 304)     | <u>Parasitology</u>                  | 30     | 60       | 4     |  |
| (MEDI 305)     | Internal medicine                    | 45     | 60       | 5     |  |
| (SURG 306)     | Surgery                              | 30     |          | 2     |  |
| (BIPH 307)     | Biostatistics and public health      | 30     |          | 2     |  |
|                | Extracurricular Activity             | 30     |          |       |  |
|                |                                      | 405    | 285      | 36.5  |  |

# Microbiology



Third grade

### **Academic program discretion**

This academic program description provides a brief overview of the key features of the program and the expected learning outcomes for the student, demonstrating whether the student has made the most of the available opportunities. It is accompanied by a description of each course within the program.

| Educational Establishment                  | University of Al-Ameed   |
|--|--|
| Scientific Department                      | College of Medicine  |
| Name of the Professional Academic Program. | Modified traditional curriculum  |
| Final Graduation Certificate               | M.B.Ch.B   |
| Educational system: Annual/courses/other   | Annual   |
| Approved accreditation program             | Iraqi National Guidelines on Standards for<br>Established and Accrediting Medical<br>Schools |
| Other external factors                     | WHO  |
| Date the description was written           | 2025/4/1   |

#### Objectives of the academic program:

- 1. Understanding Microbial Characteristics: Study the biological properties of various pathogens, including bacteria, viruses, fungi, and parasites, and their mechanisms of impact on the human body.
- 2. Immunology and Its Relation to Microbiology: Understand the interaction between microbes and the immune system, and how the body defends itself against infections.
- 3. Infection Diagnosis: Learn the methods of diagnosing infectious diseases through microbiological testing.
- 4. Treatment and Prevention of Infectious Diseases: Understand the appropriate treatment methods for microbial pathogens, including antibiotics, antiviral therapies, and immunotherapy.
- 5. Environmental Impact on Microorganisms: Study the effect of environmental factors such as temperature, humidity, and chemicals on the growth and reproduction of microorganisms.
- 6. Ethical Aspects of Microbiological Research: Apply ethical principles in scientific and medical research, including the handling of biological samples and patient privacy.

#### **Resources:**

- Jawetz, Melnik & Adelbergs
- Medical Microbiology,
- 28th Edition, LANCE Medical Publications, 2019.
- Kuby Immunology,
- Jenni Punt, Shron Stanford & Co.
- 8th Edition, 2019
- W. H.Freeman & Company

## Microbiology \ Grade 3

Code: MICR 301 Credits 10

| Number    | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |  |
|-----------|--|-------------------|---------------------------------|------------------------------|--|
| Bacterial | Bacterial cell structure and classification  |                   |                                 |                              |  |
| MICR 1    | Remember the main components of bacterial cells (cell wall, membrane, genetic material) and their functions. Understand the differences between Gram-positive and Gram-negative bacteria and the significance of Gram staining. Apply the classification techniques for bacterial identification based on shape, metabolism, and genetic material. Clinical Benefits: Accurate bacterial identification is crucial for diagnosing infections and determining the best treatment options. Understanding Gram staining and classification helps in rapid diagnosis and effective treatment strategies, especially in emergency situations. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |  |
| Bacterial | nutrition  |                   |                                 |                              |  |
| MICR 2    | Remember the essential nutritional requirements of bacteria, such as carbon, nitrogen, and minerals. Understand how bacteria adapt to various media in laboratory conditions. Evaluate the suitability of different culture media for specific bacterial species in clinical settings. Clinical Benefits: Helps in understanding how to grow and cultivate bacterial pathogens in a laboratory, ensuring accurate diagnostic testing. Knowledge of bacterial nutrition can assist in identifying the optimal growth conditions for clinical testing.   | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |  |

| Number    | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|-----------|--|-------------------|---------------------------------|------------------------------|
| Bacterial | growth and growth curve  |                   |                                 |                              |
| MICR 3    | Understand the phases of bacterial growth: lag, log, stationary, and death, and the factors that affect them.  Analyze the implications of growth patterns in relation to bacterial infection progress.  Apply knowledge of bacterial growth kinetics to predict treatment outcomes and antibiotic effectiveness.  Clinical Benefits:  Understanding bacterial growth helps predict infection progression and adjust treatment accordingly.  Provides insight into how bacteria develop resistance over time, which helps in refining therapy.         | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |
| Bacterial | cultivation and types of cultures  |                   |                                 |                              |
| MICR 4    | Remember the basic techniques for cultivating bacteria in solid and liquid media.  Understand the significance of anaerobic and aerobic conditions for bacterial growth.  Apply appropriate culture methods to identify pathogens and assess their antibiotic resistance profiles.  Clinical Benefits:  Essential for isolation and identification of bacterial pathogens, ensuring accurate diagnosis and the correct treatment approach.  Antibiotic sensitivity testing is key in treating infections effectively, particularly in resistant cases. | K                 | Large group lecture             | MCQ & Short answer questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|---|-------------------|---------------------------------|------------------------------|
| Bacterial  | genetics  |                   |                                 |                              |
| MICR 5     | Recall the structure and function of bacterial DNA, plasmids, and operons. Understand the processes of horizontal gene transfer in bacteria (transformation, conjugation, and transduction).  Analyze the role of bacterial genetics in the development of virulence and antibiotic resistance.  Clinical Benefits:  Bacterial genetics knowledge helps understand resistance mechanisms, guiding more effective treatment strategies.  Identifying genetic factors responsible for virulence aids in developing targeted therapies for infections.   | K                 | Large group lecture             | MCQ & Short answer questions |
| Antibiotic | es  |                   | ,                               |                              |
| MICR 6     | Remember the mechanisms of action of common antibiotic classes (e.g., betalactams, tetracycline's).  Understand the factors that influence antibiotic selection, including the pathogen's resistance patterns.  Apply the appropriate antibiotic therapy based on the susceptibility patterns of pathogens in clinical cases.  Clinical Benefits:  Choosing the right antibiotic based on the infection type and pathogen susceptibility reduces treatment failure.  Knowledge of antibiotic mechanisms allows for tailored therapies, improving clinical outcomes and minimizing resistance development. | K                 | Large group lecture             | MCQ & Short answer questions |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|--|-------------------|---------------------------------|------------------------------|
| Antibiotic | c resistance   |                   |                                 |                              |
| MICR 7     | Understand the mechanisms through which bacteria develop resistance to antibiotics (e.g., mutations, efflux pumps).  Analyze the impact of antibiotic misuse on the development of resistance in clinical settings.  Evaluate the role of antibiotic stewardship programs in preventing resistance.  Clinical Benefits:  Preventing antibiotic resistance ensures that treatments remain effective over time, particularly for serious infections.  Knowledge of resistance mechanisms helps in choosing alternative antibiotics and optimizing treatment regimens to combat resistant infections. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |
| Bacterial  | pathogenicity  |                   |                                 |                              |
| MICR 8     | Remember the key virulence factors of bacteria (e.g., toxins, adhesion molecules).  Understand how bacteria invade and evade host immune responses.  Analyze the relationship between virulence factors and the severity of bacterial infections.  Clinical Benefits:  Understanding bacterial pathogenicity helps in developing preventive measures and targeted therapies to combat infections.  Knowledge of virulence factors aids in designing vaccines and other therapeutic interventions.  | K                 | Large group lecture             | MCQ & Short answer questions |

| Number                  | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|-------------------------|--|-------------------|---------------------------------|---------------------------------------|
| MICR 9                  | Recall the types of bacteria that make up the normal human flora. Understand how disturbances in normal flora can lead to opportunistic infections. Evaluate the role of probiotics and prebiotics in maintaining a healthy microbiome. Clinical Benefits: Understanding normal flora helps in avoiding unnecessary antibiotic use, which can disrupt the microbiome. Knowledge of flora disturbances guides the treatment of infections like Clostridium difficile associated with antibiotics.                                     | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions          |
| MICR<br>10              | Remember the species of Staphylococcus responsible for common infections (e.g., Staphylococcus aureus). Understand the clinical presentations of Staphylococcus infections. Apply knowledge of Staphylococcus pathogenesis in the diagnosis and management of infections. Clinical Benefits: Timely diagnosis of Staphylococcal infections is crucial for preventing serious conditions like sepsis and endocarditis. Identifying resistance patterns helps guide appropriate treatment, especially in hospital-acquired infections. | K                 | Large group lecture             |                                       |
| Staphyloo<br>MICR<br>11 | Recall the clinical signs and symptoms of Staphylococcus infections, such as skin abscesses and pneumonia. Understand the role of antibiotic resistance in the treatment of Staphylococcus infections.   | K                 | Large<br>group<br>lecture       | MCQ &<br>Short<br>answer<br>questions |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|--|-------------------|---------------------------------|------------------------------|
|            | Analyze the factors contributing to Staphylococcus infection outbreaks in hospital settings. Clinical Benefits: Understanding the clinical manifestations of Staphylococcal diseases improves the ability to diagnose and treat infections. Helps prevent nosocomial infections by implementing effective infection control measures.  |                   |                                 |                              |
| Streptoco  | cci  |                   |                                 |                              |
| MICR<br>12 | Remember the key species of Streptococcus (e.g., Streptococcus pyogenesis). Understand the diseases caused by Streptococcus species, including their pathogenesis. Apply knowledge of Streptococcus infections to select the appropriate diagnostic and therapeutic strategies. Clinical Benefits: Rapid diagnosis of Streptococcal infections helps prevent complications like rheumatic fever and glomerulonephritis. Appropriate antibiotic therapy can prevent the spread of infection and reduce complications. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |
|            | ccal diseases and post-streptococcal ogical diseases   |                   |                                 |                              |
| MICR<br>13 | Recall the complications associated with Streptococcus infections, such as rheumatic fever and glomerulonephritis. Understand the mechanisms behind post-streptococcal autoimmune diseases. Evaluate strategies for preventing and managing the sequelae of untreated Streptococcus infections. Clinical Benefits:  Early treatment can prevent long-term complications of Streptococcus infections like rheumatic heart disease.  Knowledge of autoimmune sequelae informs post-infection care and monitoring.      | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|---|-------------------|---------------------------------|------------------------------|
| Pneumoc    | occi and pneumococcal diseases  |                   |                                 | ,                            |
| MICR<br>14 | Remember the key characteristics of Streptococcus pneumonia. Understand the clinical features of pneumococcal diseases such as pneumonia and meningitis. Apply preventive measures, including vaccination, in managing pneumococcal infections. Clinical Benefits: Pneumococcal vaccines are essential in preventing infections in high-risk populations, such as children and the elderly. Early diagnosis and treatment of pneumococcal infections can reduce mortality and morbidity, especially in immunocompromised patients   | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |
| Neisseria  | gonorrhea and Neisseria meningitides  |                   |                                 |                              |
| MICR<br>15 | Remember the diseases caused by Neisseria species, such as gonorrhea and meningococcal meningitis. Understand the pathogenesis and transmission of Neisseria gonorrhea and Neisseria meningitides. Apply the principles of diagnosis and treatment for Neisseria infections, including prophylaxis. Clinical Benefits: Timely diagnosis of gonorrhea and meningococcal meningitis helps to reduce transmission and improve patient outcomes. Prophylactic treatment and vaccination strategies prevent the spread of these infections, particularly in high-risk populations. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|---|-------------------|---------------------------------|------------------------------|
| Coryneba   | cterium diphtheria  |                   |                                 |                              |
| MICR<br>16 | Remember the key characteristics of Corynebacterium diphtheria, including its morphology and toxin production. Understand the pathogenesis of diphtheria, including the role of diphtheria toxin in tissue damage. Apply knowledge of Corynebacterium diphtheria for diagnostic techniques and appropriate treatment strategies. Clinical Benefits: Early identification of diphtheria is critical for preventing severe complications like myocarditis and nerve damage. Vaccination against diphtheria provides effective prevention, especially in children and immunocompromised individuals  | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |
| Listeria   |   |                   |                                 |                              |
| MICR<br>17 | Recall the pathogenic characteristics of Listeria monocytogenes, including its intracellular survival and ability to cross barriers like the placenta and blood-brain barrier. Understand the clinical manifestations of listeriosis, particularly in vulnerable populations (e.g., pregnant women, neonates, immunocompromised). Evaluate treatment options for listeriosis, including the role of antibiotics in managing infection. Clinical Benefits: Early diagnosis of listeriosis allows for prompt antibiotic treatment, reducing the risk of complications such as neonatal sepsis and meningitis. Awareness of Listeria risk is essential for preventing infection, especially in pregnant women and immunocompromised individuals. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|--|-------------------|---------------------------------|---------------------------------------|
| MICR<br>18 | Remember the characteristics of Bacillus anthracis and its ability to form spores. Understand the pathogenic mechanisms of anthrax, including toxin production and spore germination. Apply knowledge of anthrax diagnosis and treatment, including the role of antibiotics and vaccines in prevention. Clinical Benefits: Recognizing anthrax symptoms early allows for early treatment and reduces mortality, especially in cases of inhalation anthrax. Vaccination and appropriate antibiotic treatment are key for preventing outbreaks, particularly in high-risk occupational settings.   | K                 | Large group lecture             | MCQ & Short answer questions          |
| Clostridia |  |                   |                                 |                                       |
| MICR<br>19 | Remember the main species of Clostridium, such as Clostridium tetani, Clostridium botulinum, and Clostridium perfringens. Understand the diseases caused by Clostridium species, including tetanus, botulism, and gas gangrene. Analyze the clinical presentation and management of Clostridia infections, focusing on toxin production and treatment options. Clinical Benefits: Timely administration of antitoxins and antibiotics can save lives in cases of tetanus and botulism. Awareness of gas gangrene and its rapid progression is essential for early surgical intervention and antibiotic therapy to prevent tissue necrosis. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions          |
| Clostridia | ıl diseases  |                   |                                 |                                       |
| MICR<br>20 | Understand the clinical manifestations of Clostridial diseases such as botulism, tetanus, and gas gangrene.  Evaluate the role of toxin production in the pathogenesis of these diseases.  | K                 | Large<br>group<br>lecture       | MCQ &<br>Short<br>answer<br>questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|---|-------------------|---------------------------------|---------------------------------------|
|            | Apply knowledge of preventive measures, including vaccination and proper wound care, to reduce the risk of Clostridial infections. Clinical Benefits: Vaccination for tetanus and botulism prevents life-threatening complications, particularly in high-risk groups. Early recognition of gas gangrene and the use of broad-spectrum antibiotics can prevent sepsis and death.   |                   |                                 |                                       |
| Mycobact   | eria  |                   |                                 |                                       |
| MICR<br>21 | Recall the characteristics of Mycobacterium tuberculosis, Mycobacterium leprae, and other non- tuberculous mycobacteria. Understand the pathogenesis of tuberculosis and leprosy, including the immune response and chronicity of the diseases. Evaluate treatment strategies for mycobacterial infections, including the importance of long-term antibiotic therapy. Clinical Benefits: Timely diagnosis and appropriate treatment of tuberculosis can prevent transmission and drug resistance. Leprosy management requires early detection to avoid nerve damage and disability, with multidrug therapy providing a successful treatment option. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions          |
| Mycobact   | terium tuberculosis   |                   |                                 |                                       |
| MICR<br>22 | Recall the pathophysiology of Mycobacterium tuberculosis and its ability to form granulomas in the lungs. Understand the clinical signs and diagnostic methods for tuberculosis, including chest X-ray and sputum culture. Apply the principles of multi-drug therapy (DOTS) in the treatment of tuberculosis. Clinical Benefits:   | K                 | Large<br>group<br>lecture       | MCQ &<br>Short<br>answer<br>questions |

| Number                 | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------------------|--|-------------------|---------------------------------|------------------------------|
|                        | Early diagnosis and proper treatment of tuberculosis prevent its spread in the community and reduce complications. Directly observed treatment (DOT) ensures adherence to therapy, reducing the emergence of drug-resistant tuberculosis.  |                   |                                 |                              |
| Mycobac                | terium leprae  |                   |                                 |                              |
| MICR<br>23             | Remember the characteristics of Mycobacterium leprae and its impact on peripheral nerves and skin. Understand the pathogenesis of leprosy and the role of the immune system in disease progression. Analyze the treatment options for leprosy, including the use of multidrug therapy (MDT). Clinical Benefits: Early detection of leprosy allows for appropriate treatment to prevent nerve damage and disfigurement. Multidrug therapy (MDT) is highly effective in curing leprosy and preventing its spread.  | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |
|                        | terium avium and other forms of  |                   |                                 |                              |
| mycobact<br>MICR<br>24 | Recall the types of non-tuberculous mycobacteria (NTM) such as Mycobacterium avium and their environmental reservoirs.  Understand the risk factors for infection with NTM, particularly in immunocompromised patients.  Evaluate the treatment strategies for infections caused by non-tuberculous mycobacteria.  Clinical Benefits:  Early identification of NTM infections allows for tailored antimicrobial therapy, improving outcomes, especially in HIV/AIDS patients.  Awareness of environmental exposure and immunocompromised status helps prevent infections in susceptible individuals. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|--|-------------------|---------------------------------|------------------------------|
| Introduct  | ion to immunology  |                   |                                 |                              |
| MICR<br>25 | Remember the key components and functions of the immune system, including primary and secondary lymphoid organs.  Understand the basic principles of innate and adaptive immunity and how they work together to protect the body from infections.  Apply the concepts of immunology to real-life clinical situations, such as vaccination and infection control.  Clinical Benefits:  Understanding the immune system is essential for diagnosing and treating immune-related disorders and infectious diseases.  Knowledge of the immune system is foundational for vaccine development and improving immunization strategies. Helps in understanding the immune response to infections, which guides treatment protocols in infectious diseases. | K                 | Large group lecture             | MCQ & Short answer questions |
| Innate and | d Adaptive Immunity  |                   |                                 |                              |
| MICR<br>26 | Recall the main differences between innate and adaptive immunity, including their components (e.g., phagocytes vs. lymphocytes).  Understand how both systems cooperate to provide defense against pathogens.  Analyze the role of antigen-presenting cells (APCs) in linking innate and adaptive immunity.  Clinical Benefits:  Knowledge of innate and adaptive immunity helps in diagnosing autoimmune diseases, inflammatory conditions, and allergic reactions.  Understanding how immune responses work is critical in designing immunotherapies for cancer and chronic infections.  Provides insights into the importance of the immune response in vaccination and its role in immunological memory.                                       | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|--|-------------------|---------------------------------|------------------------------|
| Cells of I | mmune System (B & T Cells)   |                   |                                 |                              |
| MICR<br>27 | Understand the roles of B cells and T cells in the immune response, including the formation of antibodies and cytotoxic activity.  Analyze the processes of clonal selection and clonal expansion in both B and T lymphocytes.  Evaluate the importance of immune tolerance and its relationship to the function of B and T cells.  Clinical Benefits:  Key for diagnosing B and T cell deficiencies which can lead to immunodeficiencies such as SCID (Severe Combined Immunodeficiency).  Understanding B and T cell functions helps in the treatment of autoimmune diseases (e.g., Rheumatoid Arthritis, Multiple Sclerosis) and immunotherapies.  Cancer immunotherapies like CAR T-cell therapy depend on manipulating these cells for effective treatment of hematological malignancies. | K                 | Large group lecture             | MCQ & Short answer questions |
|            | peration in Immune Response  |                   |                                 | 1                            |
| MICR<br>28 | Understand how immune cells, such as macrophages, dendritic cells, T-helper cells, and cytotoxic T cells, cooperate during an immune response.  Analyze the process of antigen presentation and the activation of T cells in both cellular and humoral immune responses.  Evaluate the impact of defective cell cooperation on the development of autoimmune diseases and chronic infections.  Clinical Benefits:  Knowledge of cell cooperation is essential for understanding the pathophysiology of diseases such as HIV/AIDS, where T cell cooperation is impaired.  Understanding cell interaction helps in immunotherapy development, such as  | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |  |  |
|------------|---|-------------------|---------------------------------|------------------------------|--|--|
|            | enhancing T-cell responses against cancers. Key for managing immune suppression in patients after organ transplants,  |                   |                                 |                              |  |  |
| Hypersen   | Hypersensitivity  |                   |                                 |                              |  |  |
| MICR<br>29 | Recall the four types of hypersensitivity reactions (Type I, II, III, IV) and their underlying mechanisms.  Understand the clinical manifestations of hypersensitivity reactions, such as anaphylaxis, autoimmune hemolytic anemia, and contact dermatitis.  Apply knowledge of hypersensitivity to manage and treat allergic reactions and immune-mediated diseases.  Clinical Benefits:  Hypersensitivity management is essential for treating allergic reactions like anaphylaxis and rashes caused by contact allergens.  Helps in diagnosing and managing autoimmune diseases and understanding the role of immune responses in conditions like rheumatoid arthritis and lupus.  Immunotherapy and desensitization techniques can be applied to treat allergies by understanding the mechanisms behind Type I hypersensitivity | K                 | Large group lecture             | MCQ & Short answer questions |  |  |
| Autoimm    | •   |                   |                                 |                              |  |  |
| MICR<br>30 | Understand the mechanisms that lead to the development of autoimmunity, including loss of immune tolerance.  Analyze the role of genetic predisposition and environmental factors in triggering autoimmune diseases.  Apply knowledge of autoimmunity to diagnose and manage common autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.  Clinical Benefits:  Knowledge of autoimmunity is crucial for the early diagnosis and management of  | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |  |  |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|--|-------------------|---------------------------------|---------------------------------------|
|            | diseases like lupus, multiple sclerosis, and Graves' disease.  Aids in personalized medicine, helping to tailor treatments for patients based on their specific autoimmune profile.  Improves understanding of immunemodulating therapies and the development of biological treatments for autoimmune diseases.  |                   |                                 |                                       |
| Autoimm    | nune Diseases  |                   |                                 |                                       |
| MICR<br>31 | Recall common autoimmune diseases and their associated clinical features (e.g., Hashimoto's thyroiditis, Rheumatoid arthritis, Type 1 diabetes). Understand how immune dysregulation leads to the destruction of self-tissues in autoimmune diseases. Evaluate treatment strategies, including immunosuppressive drugs, biologics, and plasmapheresis for autoimmune diseases. Clinical Benefits: Early recognition and treatment of autoimmune diseases can help in preventing long-term organ damage and improving patient outcomes. Helps in immunosuppressive therapy, which is crucial for preventing autoimmune flare-ups and managing organ transplant rejection. Provides a foundation for understanding biologic therapies that target specific immune pathways in diseases like rheumatoid arthritis and psoriasis | K                 | Large group lecture             | MCQ & Short answer questions          |
| Immune 1   | Deficiency Diseases  |                   |                                 |                                       |
| MICR<br>32 | Understand the distinction between primary and secondary immunodeficiencies and their causes. Analyze the clinical manifestations of immune deficiencies, including recurrent infections and poor vaccine responses. Evaluate diagnostic methods and therapeutic strategies for immune deficiencies, such as gene therapy and immunoglobulin replacement therapy.  | K                 | Large<br>group<br>lecture       | MCQ &<br>Short<br>answer<br>questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|---|-------------------|---------------------------------|---------------------------------------|
|            | Clinical Benefits: Early diagnosis of immune deficiencies allows for timely treatment, including antibiotics, immunoglobulin therapy, and bone marrow transplants. Knowledge of immunodeficiencies helps prevent and treat opportunistic infections, especially in HIV/AIDS and primary immunodeficiencies. Advances in gene therapy offer hope for curative treatments for conditions like SCID (Severe Combined Immunodeficiency) and other genetic immune defects.   |                   |                                 |                                       |
| Immunog    | lobulins  |                   |                                 |                                       |
| MICR<br>33 | Learning Objectives: Understand the structure and function of different types of immunoglobulins (IgA, IgD, IgE, IgG, IgM). Analyze how immunoglobulins play a role in immune responses such as neutralization of pathogens, opsonization, and complement activation. Apply knowledge of immunoglobulin deficiencies to diagnose and manage conditions like X-linked agammaglobulinemia. Clinical Benefits: Understanding immunoglobulins helps in diagnosing and managing antibody deficiencies like IgA deficiency and Selective IgM deficiency. Key for the use of immunoglobulin therapy in treating immunodeficiencies, including primary immunodeficiencies and autoimmune diseases. Helps in understanding vaccination responses, as certain immunoglobulins are crucial for long-term immunity. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions          |
| -          | ent System  |                   |                                 |                                       |
| MICR<br>34 | Recall the components of the complement system and how they contribute to immune defense.   | K                 | Large<br>group<br>lecture       | MCQ &<br>Short<br>answer<br>questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|---|-------------------|---------------------------------|------------------------------|
|            | Understand the role of the complement system in inflammation, phagocytosis, and immune complex clearance.  Analyze the clinical implications of complement system deficiencies in diseases like SLE and paroxysmal nocturnal hemoglobinuria.  Clinical Benefits:  Knowledge of the complement system is vital for diagnosing and managing immune complex diseases like lupus.  Provides insights into complement deficiencies, which can increase susceptibility to infections.  Essential for understanding the mechanisms behind complement-mediated tissue damage in diseases like autoimmune vasculitis.  |                   |                                 |                              |
| Immune 7   |   |                   |                                 |                              |
| MICR<br>35 | Understand the mechanisms of immune tolerance, including central and peripheral tolerance.  Analyze the relationship between immune tolerance and the development of autoimmunity.  Evaluate the role of immune tolerance in organ transplantation and cancer immunotherapy.  Clinical Benefits:  Organ Transplantation: Knowledge of immune tolerance is essential in preventing organ rejection following transplants. Understanding how tolerance mechanisms are manipulated helps in immunosuppressive therapy to prevent immune-mediated rejection of the transplanted organ.  Autoimmunity Prevention: Insights into immune tolerance mechanisms help in understanding how autoimmune diseases develop and how tolerance breakdown leads to disorders such as lupus or rheumatoid arthritis. This is critical for developing strategies to prevent or treat these conditions. | K                 | Large group lecture             | MCQ & Short answer questions |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|--|-------------------|---------------------------------|---------------------------------------|
|            | Cancer Immunotherapy: Understanding immune tolerance is key for improving cancer immunotherapy, as tumor cells can evade immune responses by exploiting tolerance mechanisms.  |                   |                                 |                                       |
| Introduct  | ion to virology  |                   |                                 |                                       |
| MICR<br>36 | Understand the basic principles of virology, including viral structures, replication mechanisms, and classification.  Analyze the differences between DNA and RNA viruses, and their clinical implications.  Evaluate the impact of virus classification on diagnosis and treatment strategies.  Clinical Benefits:  Accurate viral classification helps in selecting diagnostic techniques and antiviral therapies.  Understanding viral replication is critical in developing antiviral treatments | K                 | Large group lecture             | MCQ & Short answer questions          |
| Viral clas | sification and structure   |                   |                                 |                                       |
| MICR<br>37 | Remember how viruses are classified based on their genetic material (DNA/RNA), shape, and replication strategy. Understand the role of viral structure in host cell invasion. Analyze how viral classification impacts treatment options and prevention strategies. Clinical Benefits: Viral classification aids in choosing the correct diagnostic test and tailoring treatment strategies. Helps identify emerging viral threats and determine appropriate vaccines.                               | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions          |
| -          | on of viruses  | IZ.               | Louis                           | MCO 0                                 |
| MICR<br>38 | Study the process of viral replication within the host cell. Understand the significance of viral attachment, entry, replication, and release.   | K                 | Large<br>group<br>lecture       | MCQ &<br>Short<br>answer<br>questions |

| Number      | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|-------------|--|-------------------|---------------------------------|------------------------------|
|             | Apply knowledge of viral replication to the development of antiviral therapies. Clinical Benefits: Understanding viral replication is essential for developing antiviral drugs that target specific steps in the replication process. Knowledge of how viruses spread helps in controlling outbreaks and preventing infections.  |                   |                                 |                              |
| Cultivation | on of viruses  |                   |                                 |                              |
| MICR<br>38  | Understand the methods used to cultivate viruses in laboratory settings.  Analyze the importance of cultivating viruses for diagnostic and research purposes.  Evaluate how viral cultivation can impact the development of vaccines and therapies.  Clinical Benefits:  Virus cultivation is critical for diagnosis and development of vaccines and antiviral drugs.  Helps isolate novel viruses, which is important for emerging viral infections and pandemic preparedness.                    | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |
| Orthomy     | koviruses (Influenza)  |                   |                                 |                              |
| MICR<br>39  | Recall the characteristics of influenza viruses and their subtypes. Understand the pathogenesis and transmission dynamics of influenza. Evaluate the clinical implications of flu vaccines and antiviral treatments. Clinical Benefits: Influenza vaccines are key in preventing outbreaks and protecting vulnerable populations, such as the elderly and immunocompromised individuals. Antiviral treatments help reduce the severity and duration of symptoms, particularly in high-risk groups. | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|---|-------------------|---------------------------------|------------------------------|
| Herpes vi  | ruses   |                   |                                 |                              |
| MICR<br>40 | Identify the different types of herpesviruses and the diseases they cause. Analyze the replication cycle of herpesviruses, including latency and reactivation.  Evaluate the clinical manifestations of herpesvirus infections and the available antiviral treatments.  Clinical Benefits:  Diagnosis and Treatment: Understanding herpesvirus infections is essential for diagnosing conditions like oral herpes, genital herpes, and shingles. Early diagnosis allows for effective antiviral treatment, reducing morbidity.  Neonatal Infections: Herpes simplex virus can cause neonatal infections, potentially leading to life-threatening conditions such as encephalitis. Early diagnosis and treatment are critical to preventing severe complications.  Prevention and Vaccination: Knowledge of the varicella-zoster virus and its vaccine is key for preventing chickenpox and shingles, especially in at-risk populations like the elderly and immunocompromised patients. | K                 | Large group lecture             | MCQ & Short answer questions |
| Rhabdovi   | ruses - Rabies  |                   |                                 |                              |
| MICR<br>41 | Describe the structure and replication cycle of the rabies virus. Understand the transmission mechanisms of rabies and the clinical symptoms in humans. Evaluate the available prophylactic and therapeutic interventions for rabies. Clinical Benefits: Early Intervention: Knowledge of rabies transmission and symptoms helps healthcare professionals initiate post-exposure prophylaxis (PEP) promptly, preventing the progression of the disease. Public Health Awareness: Understanding rabies transmission in animals helps reduce the risk of human exposure,  | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |

| Learning Objective  | Domain<br>K/S/A/C  | Teaching Learning Methods   | Assessment<br>Methods  |
|---|--|---|--|
| especially in endemic regions. Educating patients and communities about preventive measures can save lives.   |  |   |  |
| ses, Coronavirus  |  |   |  |
| Identify the different types of arboviruses and coronaviruses, including Zika virus, Dengue, and SARS-CoV-2. Understand the transmission routes, pathogenesis, and clinical presentations of diseases caused by arboviruses and coronaviruses. Evaluate the role of public health interventions, vaccines, and antiviral treatments in controlling outbreaks of these viruses. Clinical Benefits: Outbreak Management: Knowledge of arboviruses and coronaviruses is crucial for managing emergency outbreaks, such as the COVID-19 pandemic and Zika virus outbreaks, guiding effective public health responses. Vaccine Administration: Understanding the mechanisms of vaccine development for coronaviruses (e.g., COVID-19 vaccines) and arboviruses helps students in advising patients about immunization schedules and post-vaccine care. Symptom Recognition: Healthcare providers can recognize symptoms of infections like Dengue fever or COVID-19, leading to timely diagnosis, treatment, and preventive measures to minimize transmission. | K  | Large group lecture   | MCQ & Short answer questions   |
| Viruses  Distinguish between the different types of hepatitis viruses and their modes of transmission.  Analyze the clinical manifestations and complications of chronic hepatitis  | K  | Large<br>group<br>lecture   | MCQ &<br>Short<br>answer<br>questions  |
|   | especially in endemic regions. Educating patients and communities about preventive measures can save lives.  Ses, Coronavirus  Identify the different types of arboviruses and coronaviruses, including Zika virus, Dengue, and SARS-CoV-2.  Understand the transmission routes, pathogenesis, and clinical presentations of diseases caused by arboviruses and coronaviruses.  Evaluate the role of public health interventions, vaccines, and antiviral treatments in controlling outbreaks of these viruses.  Clinical Benefits: Outbreak Management: Knowledge of arboviruses and coronaviruses is crucial for managing emergency outbreaks, such as the COVID-19 pandemic and Zika virus outbreaks, guiding effective public health responses.  Vaccine Administration: Understanding the mechanisms of vaccine development for coronaviruses (e.g., COVID-19 vaccines) and arboviruses helps students in advising patients about immunization schedules and post-vaccine care.  Symptom Recognition: Healthcare providers can recognize symptoms of infections like Dengue fever or COVID-19, leading to timely diagnosis, treatment, and preventive measures to minimize transmission.  Viruses  Distinguish between the different types of hepatitis viruses and their modes of transmission.  Analyze the clinical manifestations and | especially in endemic regions. Educating patients and communities about preventive measures can save lives.  Ses, Coronavirus  Identify the different types of arboviruses and coronaviruses, including Zika virus, Dengue, and SARS-CoV-2.  Understand the transmission routes, pathogenesis, and clinical presentations of diseases caused by arboviruses and coronaviruses.  Evaluate the role of public health interventions, vaccines, and antiviral treatments in controlling outbreaks of these viruses.  Clinical Benefits: Outbreak Management: Knowledge of arboviruses and coronaviruses is crucial for managing emergency outbreaks, such as the COVID-19 pandemic and Zika virus outbreaks, guiding effective public health responses.  Vaccine Administration: Understanding the mechanisms of vaccine development for coronaviruses (e.g., COVID-19 vaccines) and arboviruses helps students in advising patients about immunization schedules and post-vaccine care.  Symptom Recognition: Healthcare providers can recognize symptoms of infections like Dengue fever or COVID-19, leading to timely diagnosis, treatment, and preventive measures to minimize transmission.  Viruses  Distinguish between the different types of hepatitis viruses and their modes of transmission.  Analyze the clinical manifestations and complications of chronic hepatitis | especially in endemic regions. Educating patients and communities about preventive measures can save lives.  Ses, Coronavirus  Identify the different types of arboviruses and coronaviruses, including Zika virus, Dengue, and SARS-CoV-2. Understand the transmission routes, pathogenesis, and clinical presentations of diseases caused by arboviruses and coronaviruses.  Evaluate the role of public health interventions, vaccines, and antiviral treatments in controlling outbreaks of these viruses.  Clinical Benefits: Outbreak Management: Knowledge of arboviruses and coronaviruses is crucial for managing emergency outbreaks, such as the COVID-19 pandemic and Zika virus outbreaks, guiding effective public health responses.  Vaccine Administration: Understanding the mechanisms of vaccine development for coronaviruses (e.g., COVID-19 vaccines) and arboviruses helps students in advising patients about immunization schedules and post-vaccine care.  Symptom Recognition: Healthcare providers can recognize symptoms of infections like Dengue fever or COVID-19, leading to timely diagnosis, treatment, and preventive measures to minimize transmission.  Viruses  Distinguish between the different types of hepatitis viruses and their modes of transmission.  Viruses  Distinguish between the different types of hepatitis viruses and their modes of transmission.  Analyze the clinical manifestations and complications of chronic hepatitis |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|------------|--|-------------------|---------------------------------|------------------------------|
|            | Evaluate the current treatments and vaccination strategies for hepatitis infections. Clinical Benefits: Diagnosis and Management: Knowledge of hepatitis viruses' aids in diagnosing various hepatitis-related diseases and determining the appropriate antiviral therapy, reducing liver-related morbidity and mortality. Prevention and Vaccination: Vaccination strategies for Hepatitis A and Hepatitis B are essential in preventing infection, particularly in high-risk groups such as healthcare workers and intravenous drug users. Chronic Hepatitis Care: Understanding the chronic effects of hepatitis infections (e.g., Hepatitis C) enables early detection   |                   |                                 |                              |
| Retroviru  | ses  |                   |                                 |                              |
| MICR<br>43 | Explain the structure and replication cycle of retroviruses, with a focus on HIV. Understand the mechanisms of HIV pathogenesis, including the acute phase and AIDS progression.  Evaluate the available antiretroviral therapies and their role in managing HIV infections.  Clinical Benefits:  HIV Diagnosis and Management:  Understanding HIV pathogenesis helps in the early diagnosis of HIV infection and the initiation of antiretroviral therapy (ART), which significantly improves patient quality of life and reduces transmission.  Prevention of Transmission: Knowledge of HIV transmission modes (sexual, vertical, etc.) aids in counseling patients on prevention strategies, such as safe sexual practices and mother-to-child transmission prevention.  AIDS Complication Management:  Clinicians can identify and manage opportunistic infections associated with HIV/AIDS, improving patient outcomes | K                 | Large group lecture             | MCQ & Short answer questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |  |  |
|------------|---|-------------------|---------------------------------|------------------------------|--|--|
|            | and reducing complications in immunocompromised individuals.  |                   |                                 |                              |  |  |
| Pathogen   | Pathogenicity of Viruses  |                   |                                 |                              |  |  |
| MICR<br>44 | Define viral pathogenicity and understand the factors that contribute to viral virulence, such as genetic variability and host interaction.  Analyze how different viruses evade host immune responses through mechanisms like antigenic variation, latency, and immune suppression.  Evaluate the impact of viral mutations on disease progression and treatment efficacy.  Clinical Benefits:  Early Detection and Diagnosis:  Understanding viral pathogenicity helps healthcare providers recognize early signs of infection, facilitating timely diagnosis and treatment.  Treatment Approaches: Knowledge of how viruses interact with the immune system aids in developing targeted antiviral therapies and immunotherapies. Prevention Strategies: Insight into viral pathogenicity is critical for developing effective vaccines and public health strategies to prevent viral outbreaks and reduce transmission | K                 | Large group lecture             | MCQ & Short answer questions |  |  |
| Immunity   | to Viral Diseases   |                   |                                 |                              |  |  |
| MICR<br>45 | Describe the innate and adaptive immune responses to viral infections, including the roles of interferons, T-cells, and antibodies.  Analyze how immunization and natural immunity protect against viral diseases. Evaluate the immune evasion strategies used by viruses and their impact on the effectiveness of vaccines and treatments. Clinical Benefits:  Vaccine Development: Understanding immunity to viruses helps in the development of vaccines, improving patient protection against infectious  | K                 | Large<br>group<br>lecture       | MCQ & Short answer questions |  |  |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|---|-------------------|---------------------------------|---------------------------------------|
|            | diseases like influenza, hepatitis, and COVID-19. Immune Response Monitoring: Knowledge of immune responses to viral infections aids in monitoring patients for immune system deficiencies and evaluating vaccine efficacy. Management of Viral Infections: Helps clinicians choose appropriate antiviral therapies and immune-modulating treatments based on the virus's ability to evade the immune system.   |                   |                                 |                                       |
| Arbovirus  | ses - Hemorrhagic Fever   |                   |                                 |                                       |
| MICR<br>46 | Identify the key arboviruses responsible for hemorrhagic fever, such as Dengue, Ebola, Yellow Fever, and Zika virus. Understand the transmission cycle of arboviruses, focusing on vectors like mosquitoes, and the epidemiology of hemorrhagic fever outbreaks. Evaluate the clinical manifestations, complications, and management of hemorrhagic fever viruses. Clinical Benefits:  Early Recognition: Knowledge of arboviral hemorrhagic fever symptoms allows for early diagnosis and intervention, improving survival rates. Infection Control: Understanding the transmission cycle of arboviruses aids in vector control strategies, reducing the spread of diseases  Supportive Care: In severe cases, fluid resuscitation and management of coagulopathies are crucial to patient survival. | K                 | Large group lecture             | MCQ & Short answer questions          |
| Parvoviru  | ises  |                   |                                 |                                       |
| MICR<br>47 | Describe the structure and replication cycle of Parvovirus B19, the virus responsible for erythema infectiosum (fifth disease).  Analyze the clinical manifestations and complications associated with parvovirus   | K                 | Large<br>group<br>lecture       | MCQ &<br>Short<br>answer<br>questions |

| Number | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------|--|-------------------|---------------------------------|-----------------------|
|        | B19 infections, including fetal hydrops  |                   |                                 |                       |
|        | and aplastic anemia.  Evaluate diagnostic approaches and   |                   |                                 |                       |
|        | management strategies for parvovirus B19   |                   |                                 |                       |
|        | infections, particularly in  |                   |                                 |                       |
|        | immunocompromised patients and   |                   |                                 |                       |
|        | pregnant women. Clinical Benefits:   |                   |                                 |                       |
|        | Early Diagnosis of Erythema Infectiosum:   |                   |                                 |                       |
|        | Understanding parvovirus B19 aids in   |                   |                                 |                       |
|        | early diagnosis of fifth disease enabling  |                   |                                 |                       |
|        | proper management in pediatric patients.   |                   |                                 |                       |
|        | Fetal Risk Management: Knowledge of the risks associated with parvovirus B19                       |                   |                                 |                       |
|        | in pregnant women helps clinicians   |                   |                                 |                       |
|        | manage fetal hydrops and make informed   |                   |                                 |                       |
|        | decisions regarding prenatal care.   |                   |                                 |                       |
|        | Management of Aplastic Crisis:   |                   |                                 |                       |
|        | Recognizing the complications of   |                   |                                 |                       |
|        | parvovirus B19, such as aplastic anemia in immunocompromised individuals, ensures timely treatment |                   |                                 |                       |

### **Practical**

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|------------|---|-------------------|---------------------------------|-----------------------|
| How to dea | ll with microbiology laboratory   |                   |                                 |                       |
| MICR 1     | Understand laboratory safety protocols and the correct use of equipment.  | K/S/C             | Small group<br>Lab              | MCQ                   |
|            | Identify and follow the proper procedures for handling bacterial cultures and samples.  |                   |                                 |                       |
|            | Apply effective hygiene and safety measures to prevent contamination in the microbiology lab.                                   |                   |                                 |                       |
|            | Clinical Benefits:  |                   |                                 |                       |
|            | Essential for maintaining a safe and contamination-free working environment.  |                   |                                 |                       |
|            | Helps in preventing cross-contamination of samples, which ensures accurate diagnostic results.                                  |                   |                                 |                       |
|            | Develops an understanding of biosafety principles, critical for healthcare professionals working in clinical microbiology labs. |                   |                                 |                       |
| Methods of | Sterilization   |                   |                                 |                       |
| MICR 2     | Identify different sterilization methods (e.g., autoclaving, filtration, chemical sterilization).                               | K/S/C             | Small group<br>Lab              | MCQ                   |
|            | Understand the principles and appropriate use of each sterilization method.   |                   |                                 |                       |
|            | Apply sterilization techniques to ensure the aseptic preparation of laboratory materials.                                       |                   |                                 |                       |
|            | Clinical Benefits:  |                   |                                 |                       |
|            | Knowledge of sterilization is crucial for preventing hospital-acquired infections.  |                   |                                 |                       |
|            | Ensures proper sterilization of laboratory tools, improving diagnostic accuracy.  |                   |                                 |                       |

| Number      | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|-------------|--|-------------------|---------------------------------|-----------------------|
|             | Contributes to patient safety by preventing contamination during diagnostic procedures.                |                   |                                 |                       |
| Bacteria is | anywhere   |                   |                                 |                       |
| MICR 3      | Understand the ubiquity of bacteria in the environment and the human body.                             | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Learn methods for isolating bacteria from various surfaces and environments.                           |                   |                                 |                       |
|             | Explore how bacteria can influence human health in both positive and negative ways.                    |                   |                                 |                       |
|             | Clinical Benefits:   |                   |                                 |                       |
|             | Helps in identifying and controlling bacterial contamination in clinical settings.                     |                   |                                 |                       |
|             | Improves the understanding of bacterial spread, which is important for infection control in hospitals. |                   |                                 |                       |
|             | Offers insights into the role of bacteria in health, such as normal flora and potential pathogens.     |                   |                                 |                       |
| Culture me  | edia and staining methods  |                   | 1                               | l                     |
| MICR 4      | Identify different types of culture media used in microbiology for bacterial growth.                   | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Understand the principles of bacterial staining (e.g., Gram stain, acid-fast stain).                   |                   |                                 |                       |
|             | Apply appropriate media and staining techniques for bacterial identification.                          |                   |                                 |                       |
|             | Clinical Benefits:   |                   |                                 |                       |
|             | Crucial for diagnosing bacterial infections by enabling bacterial isolation and identification.        |                   |                                 |                       |
|             | Helps in distinguishing between different bacterial types, influencing treatment decisions.            |                   |                                 |                       |
|             | Improves laboratory skills in preparing bacterial cultures and interpreting staining results.          |                   |                                 |                       |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|---|-------------------|---------------------------------|-----------------------|
| Antibiotic s | susceptibility tests  |                   |                                 |                       |
| MICR 5       | Understand the principles of antibiotic susceptibility testing (e.g., disk diffusion method).     | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | Learn how to interpret results from antibiotic susceptibility tests.                              |                   |                                 |                       |
|              | Apply knowledge of bacterial resistance to select appropriate antibiotics for treatment.          |                   |                                 |                       |
|              | Clinical Benefits:  |                   |                                 |                       |
|              | Facilitates the correct selection of antibiotics to treat bacterial infections.                   |                   |                                 |                       |
|              | Contributes to effective antibiotic stewardship by preventing the overuse of antibiotics.         |                   |                                 |                       |
|              | Helps clinicians manage antibiotic-resistant infections by choosing the most effective therapy.   |                   |                                 |                       |
| Antibiotic s | susceptibility tests, Bacterial motility test   |                   |                                 |                       |
| MICR 6       | Learn how to perform and interpret antibiotic susceptibility tests and bacterial motility tests.  | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | Understand how bacterial motility can influence infection and treatment outcomes.                 |                   |                                 |                       |
|              | Analyze the correlation between motility and bacterial pathogenicity.                             |                   |                                 |                       |
|              | Clinical Benefits:  |                   |                                 |                       |
|              | Essential for identifying antibiotic resistance patterns in clinical isolates.                    |                   |                                 |                       |
|              | Helps in differentiating bacterial species based on their motility, aiding in accurate diagnosis. |                   |                                 |                       |
|              | Contributes to the understanding of how motility affects bacterial virulence and infection        |                   |                                 |                       |
|              |   |                   |                                 |                       |

| Number      | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|-------------|---|-------------------|---------------------------------|-----------------------|
| Staphyloco  | ccus aureus cultivation   |                   |                                 |                       |
| MICR 7      | Learn the techniques for isolating and cultivating Staphylococcus aureus.   | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Understand the growth requirements and characteristics of Staphylococcus aureus.  |                   |                                 |                       |
|             | Identify different types of Staphylococcus aureus through colony morphology and biochemical tests.                              |                   |                                 |                       |
|             | Clinical Benefits:  |                   |                                 |                       |
|             | Critical for diagnosing infections caused by Staphylococcus aureus, such as abscesses, pneumonia, and sepsis.                   |                   |                                 |                       |
|             | Facilitates the identification of methicillin-<br>resistant Staphylococcus aureus (MRSA),<br>which impacts treatment decisions. |                   |                                 |                       |
|             | Improves understanding of the pathogenicity of Staphylococcus aureus in healthcare-associated infections.                       |                   |                                 |                       |
| Staph. aure | us coagulase test   |                   |                                 |                       |
| MICR 8      | Understand the principle of the coagulase test and its role in identifying Staphylococcus aureus.                               | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Learn the technique for performing the coagulase test in a microbiology laboratory.   |                   |                                 |                       |
|             | Interpret the results of the coagulase test for diagnostic purposes.  |                   |                                 |                       |
|             | Clinical Benefits:  |                   |                                 |                       |
|             | Aids in distinguishing Staphylococcus aureus from other Staphylococcus species, which is vital for diagnosis and treatment.     |                   |                                 |                       |
|             | Helps in identifying virulent strains of Staphylococcus aureus that may be more difficult to treat.                             |                   |                                 |                       |
|             | Critical for rapid diagnosis in hospital settings to prevent the spread of infections.  |                   |                                 |                       |
|             |   |                   |                                 |                       |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|------------|--|-------------------|---------------------------------|-----------------------|
| Streptococ | cus pyogens cultivation  |                   |                                 |                       |
| MICR 9     | Learn how to isolate and cultivate<br>Streptococcus pyogenes from clinical<br>samples.                             | K/S/C             | Small group<br>Lab              | MCQ                   |
|            | Understand the culture requirements for optimal growth of Streptococcus pyogenes.                                  |                   |                                 |                       |
|            | Identify Streptococcus pyogenes through characteristic growth patterns and biochemical reactions.                  |                   |                                 |                       |
|            | Clinical Benefits:   |                   |                                 |                       |
|            | Essential for diagnosing diseases caused by Streptococcus pyogenes, such as strep throat and rheumatic fever.      |                   |                                 |                       |
|            | Facilitates the early identification and treatment of Streptococcus pyogenes infections, preventing complications. |                   |                                 |                       |
|            | Aids in the identification of potential carriers to reduce the spread of infection.                                |                   |                                 |                       |
| Pneumocoo  | c & Capsule staining technique   |                   |                                 |                       |
| MICR 10    | Learn the capsule staining technique for identifying Streptococcus pneumoniae.                                     | K/S/C             | Small group<br>Lab              | MCQ                   |
|            | Understand the role of the capsule in bacterial virulence and pathogenesis.  |                   |                                 |                       |
|            | Apply capsule staining in the diagnosis of pneumococcal infections.  |                   |                                 |                       |
|            | Clinical Benefits:   |                   |                                 |                       |
|            | Critical for diagnosing pneumococcal infections, such as pneumonia, meningitis, and otitis media.                  |                   |                                 |                       |
|            | Helps identify the virulent forms of Streptococcus pneumoniae, guiding treatment decisions.                        |                   |                                 |                       |
|            | Aids in understanding how the bacterial capsule contributes to immune evasion during infection.                    |                   |                                 |                       |
|            |  |                   |                                 |                       |

| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|--|-------------------|---------------------------------|-----------------------|
| Neisseria st | taining and oxidase test   |                   |                                 |                       |
| MICR 11      | Learn how to perform Gram staining and oxidase testing for Neisseria species.  | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | Understand the diagnostic importance of these tests in identifying Neisseria gonorrhoeae and Neisseria meningitidis. |                   |                                 |                       |
|              | Apply the oxidase test to differentiate between Neisseria species and other Gramnegative bacteria.                   |                   |                                 |                       |
|              | Clinical Benefits:   |                   |                                 |                       |
|              | Essential for diagnosing gonorrhea and bacterial meningitis caused by Neisseria species.                             |                   |                                 |                       |
|              | Helps in the rapid identification of<br>Neisseria species in clinical settings,<br>leading to prompt treatment.      |                   |                                 |                       |
|              | Contributes to understanding antibiotic resistance in Neisseria species.   |                   |                                 |                       |
| Mycobacte    | ria & Acid fast staining technique   |                   |                                 |                       |
| MICR 12      | Understand the principle and application of acid-fast staining for identifying Mycobacterium species.                | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | Learn the procedure for performing acid-<br>fast staining in laboratory settings.                                    |                   |                                 |                       |
|              | Identify Mycobacterium tuberculosis and other Mycobacterium species based on staining characteristics.               |                   |                                 |                       |
|              | Critical for diagnosing tuberculosis and leprosy, particularly in endemic areas.                                     |                   |                                 |                       |
|              | Helps in the early detection of Mycobacterium infections, facilitating appropriate treatment.                        |                   |                                 |                       |
|              | Assists in identifying drug-resistant strains, improving treatment outcomes.   |                   |                                 |                       |
|              |  |                   |                                 |                       |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|---|-------------------|---------------------------------|-----------------------|
| Clostridia t | etani, perfringens lab techniques   |                   |                                 |                       |
| MICR 13      | Learn the techniques for isolating and identifying Clostridium tetani and Clostridium perfringens.      | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | Understand the clinical significance of these pathogens in tetanus and gas gangrene.                    |                   |                                 |                       |
|              | Apply appropriate laboratory tests to diagnose infections caused by Clostridium species.                |                   |                                 |                       |
|              | Clinical Benefits:  |                   |                                 |                       |
|              | Vital for the rapid diagnosis and treatment of tetanus and gas gangrene, which can be life-threatening. |                   |                                 |                       |
|              | Contributes to understanding the virulence mechanisms of Clostridium species, such as toxin production. |                   |                                 |                       |
|              | Helps in preventing the spread of Clostridium infections in clinical environments.                      |                   |                                 |                       |
| Immunolog    | gical principles in lab diagnosis   |                   | L                               |                       |
| MICR 14      | Understand the role of immunological principles in microbiological diagnostics.                         | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | Learn how immune responses can be used to detect bacterial and viral infections.                        |                   |                                 |                       |
|              | Apply immunological techniques in the laboratory for detecting antibodies and antigens.                 |                   |                                 |                       |
|              | Clinical Benefits:  |                   |                                 |                       |
|              | Enhances the accuracy of diagnostic tests for infectious diseases through immunological techniques.     |                   |                                 |                       |
|              | Aids in the rapid diagnosis of infections, reducing the time to treatment.                              |                   |                                 |                       |
|              | Contributes to understanding the body's immune response to infections, guiding treatment options.       |                   |                                 |                       |

| Number      | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|-------------|--|-------------------|---------------------------------|-----------------------|
| Some imm    | unological tests - Widal test, ABO test  |                   |                                 |                       |
| MICR 15     | Understand the principles behind the Widal test and the ABO blood group test.  | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Learn how to perform and interpret the results of these immunological tests.   |                   |                                 |                       |
|             | Analyze the clinical significance of the Widal test in diagnosing typhoid fever and the ABO test for blood transfusions. |                   |                                 |                       |
|             | Clinical Benefits:   |                   |                                 |                       |
|             | Widal test: Crucial for diagnosing typhoid fever, especially in endemic areas.   |                   |                                 |                       |
|             | ABO test: Vital for ensuring compatibility in blood transfusions and preventing transfusion reactions.                   |                   |                                 |                       |
|             | Provides valuable diagnostic tools for identifying bacterial infections and ensuring safe blood transfusions.            |                   |                                 |                       |
| Enterobacte | eriaceae   |                   |                                 |                       |
| MICR 16     | Understand the characteristics of Enterobacteriaceae family members, including their classification and pathogenicity.   | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Learn how to culture and identify members of the Enterobacteriaceae family.  |                   |                                 |                       |
|             | Understand the diagnostic importance of differentiating between different Enterobacteriaceae species.                    |                   |                                 |                       |
|             | Clinical Benefits:   |                   |                                 |                       |
|             | Important for diagnosing infections caused by members of the Enterobacteriaceae family,                                  |                   |                                 |                       |
|             | Assists in selecting appropriate antimicrobial treatment for infections caused by Enterobacteriaceae.                    |                   |                                 |                       |
|             | Helps in identifying antibiotic-resistant strains, which are common in hospital-acquired infections.                     |                   |                                 |                       |

| Number      | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|-------------|--|-------------------|---------------------------------|-----------------------|
| E. coli & K | lebsiella cultivation and diagnosis  |                   |                                 |                       |
| MICR 17     | Learn how to cultivate and diagnose<br>Escherichia coli and Klebsiella species<br>from clinical samples.                       | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Understand the pathogenicity and diseases caused by E. coli and Klebsiella.  |                   |                                 |                       |
|             | Apply biochemical tests to differentiate between E. coli and Klebsiella species.   |                   |                                 |                       |
|             | Clinical Benefits:   |                   |                                 |                       |
|             | Critical for diagnosing urinary tract infections, gastrointestinal infections, and pneumonia caused by E. coli and Klebsiella. |                   |                                 |                       |
|             | Helps in identifying multidrug-resistant strains, particularly in hospital settings.   |                   |                                 |                       |
|             | Aids in selecting appropriate antibiotics to treat infections caused by E. coli and Klebsiella.                                |                   |                                 |                       |
| E. coli and | Klebsiella   |                   |                                 |                       |
| MICR 18     | Study the microbiological characteristics of E. coli and Klebsiella species.   | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Learn the mechanisms of virulence and resistance in E. coli and Klebsiella.  |                   |                                 |                       |
|             | Analyze the clinical presentation and diagnostic techniques for infections caused by these bacteria.                           |                   |                                 |                       |
|             | Clinical Benefits:   |                   |                                 |                       |
|             | Assists in the timely diagnosis and treatment of infections caused by E. coli and Klebsiella.                                  |                   |                                 |                       |
|             | Contributes to understanding antibiotic resistance patterns in these pathogens.  |                   |                                 |                       |
|             | Helps in managing and preventing hospital-<br>acquired infections, particularly those<br>caused by Klebsiella pneumoniae.      |                   |                                 |                       |
|             |  |                   |                                 |                       |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|------------|---|-------------------|---------------------------------|-----------------------|
| Salmonella | and Shigella  |                   |                                 |                       |
| MICR 19    | Learn the diagnostic methods for identifying Salmonella and Shigella species.                           | K/S/C             | Small group<br>Lab              | MCQ                   |
|            | Understand the diseases caused by Salmonella and Shigella, including typhoid fever and dysentery.       |                   |                                 |                       |
|            | Apply laboratory techniques to differentiate between Salmonella and Shigella infections.                |                   |                                 |                       |
|            | Clinical Benefits:  |                   |                                 |                       |
|            | Critical for diagnosing enteric infections caused by Salmonella and Shigella.                           |                   |                                 |                       |
|            | Helps in preventing the spread of these pathogens, particularly in community settings.                  |                   |                                 |                       |
|            | Facilitates the selection of appropriate antibiotics for treatment, reducing the risk of complications. |                   |                                 |                       |
| Salmonella | and Shigella  |                   |                                 |                       |
| MICR 20    | Understand the epidemiology and pathogenesis of Salmonella and Shigella species.                        | K/S/C             | Small group<br>Lab              | MCQ                   |
|            | Learn about the laboratory diagnostic tests used for Salmonella and Shigella.                           |                   |                                 |                       |
|            | Interpret laboratory results to accurately diagnose infections caused by Salmonella and Shigella.       |                   |                                 |                       |
|            | Clinical Benefits:  |                   |                                 |                       |
|            | Important for diagnosing gastrointestinal infections and systemic diseases caused by these pathogens.   |                   |                                 |                       |
|            | Assists in the proper management of patients with Salmonella and Shigella infections.                   |                   |                                 |                       |
|            | Facilitates infection control measures to prevent the spread of these pathogens.                        |                   |                                 |                       |


| Number      | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|-------------|--|-------------------|---------------------------------|-----------------------|
| Pseudomon   | aas  |                   |                                 |                       |
| MICR 21     | Learn the characteristics of Pseudomonas species, particularly Pseudomonas aeruginosa.   | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Understand the diagnostic methods used to identify Pseudomonas species in clinical samples.  |                   |                                 |                       |
|             | Analyze the pathogenicity and virulence factors of Pseudomonas aeruginosa.   |                   |                                 |                       |
|             | Clinical Benefits:   |                   |                                 |                       |
|             | Essential for diagnosing infections caused by Pseudomonas aeruginosa, such as pneumonia, wound infections, and urinary tract infections. |                   |                                 |                       |
|             | Helps in identifying multidrug-resistant strains, which are common in immunocompromised patients.  |                   |                                 |                       |
|             | Assists in selecting appropriate antimicrobial therapy for Pseudomonas infections  |                   |                                 |                       |
| Proteus, Sv | varming phenomenon, Urease test  |                   |                                 |                       |
| MICR 22     | Learn the techniques for isolating and cultivating Staphylococcus aureus.  | K/S/C             | Small group<br>Lab              | MCQ                   |
|             | Understand the growth requirements and characteristics of Staphylococcus aureus.   |                   |                                 |                       |
|             | Identify different types of Staphylococcus aureus through colony morphology and biochemical tests.                                       |                   |                                 |                       |
|             | Clinical Benefits:   |                   |                                 |                       |
|             | Critical for diagnosing infections caused by Staphylococcus aureus, such as abscesses, pneumonia, and sepsis.                            |                   |                                 |                       |
|             | Facilitates the identification of methicillin-<br>resistant Staphylococcus aureus (MRSA),<br>which impacts treatment decisions.          |                   |                                 |                       |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|---|-------------------|---------------------------------|-----------------------|
|              | Improves understanding of the pathogenicity of Staphylococcus aureus in healthcare-associated   |                   |                                 |                       |
| Vibrio, slid | e & Sea Water Cultivation, TCBS   |                   |                                 |                       |
| MICR 23      | Understand the characteristics of Vibrio species and their role in waterborne infections.   | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | Learn the technique for isolating Vibrio species from sea water samples and clinical specimens.   |                   |                                 |                       |
|              | Understand the principles and application of Thiosulfate Citrate Bile Salts Sucrose (TCBS) agar in the identification of Vibrio species.  |                   |                                 |                       |
|              | Clinical Benefits:  |                   |                                 |                       |
|              | Critical for diagnosing Vibrio infections, including cholera and gastroenteritis, especially in coastal and endemic areas.  |                   |                                 |                       |
|              | Helps in the timely diagnosis and treatment of Vibrio-related diseases, improving patient outcomes.   |                   |                                 |                       |
|              | Essential for epidemiological surveillance and prevention of outbreaks, particularly in regions with contaminated water sources.  |                   |                                 |                       |
| Brucella, Pr | rinciples of Lab Diagnosis  |                   |                                 |                       |
| MICR 24      | Learn the diagnostic methods for identifying Brucella species, including blood cultures and serological tests.  Understand the principles behind laboratory diagnosis of brucellosis, including bacterial | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | isolation and biochemical tests.  Explore the clinical manifestations of brucellosis and the importance of early diagnosis.   |                   |                                 |                       |
|              | Clinical Benefits:  |                   |                                 |                       |

| Number     | Crucial for diagnosing brucellosis, a zoonotic infection, which is important for occupational health in livestock workers.  Aids in preventing chronic brucellosis by enabling early detection and appropriate antibiotic treatment.  Improves understanding of brucellosis transmission, helping in public health efforts to control outbreaks.   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|------------|--|-------------------|---------------------------------|-----------------------|
| Corynebact |  |                   |                                 |                       |
| MICR 25    | Understand the microbiological characteristics and pathogenicity of Corynebacterium species, particularly Corynebacterium diphtheriae.  Learn the laboratory techniques used to isolate and identify Corynebacterium species from clinical samples.  Study the biochemical and cultural characteristics used to differentiate Corynebacterium species.  Clinical Benefits:  Important for diagnosing diphtheria, particularly in children and unvaccinated individuals.  Facilitates rapid identification of Corynebacterium species, guiding appropriate treatment and prevention strategies.  Aids in understanding the virulence mechanisms of Corynebacterium diphtheriae, such as toxin production. | K/S/C             | Small group<br>Lab              | MCQ                   |
| Mycology   |  |                   |                                 |                       |
| MICR 26    | Understand the principles and techniques used in the isolation and identification of fungal species in clinical microbiology.  Learn to differentiate between pathogenic and non-pathogenic fungi using laboratory   | K/S/C             | Small group<br>Lab              | MCQ                   |

| Number | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------|---|-------------------|---------------------------------|-----------------------|
|        | tests, such as fungal culture, microscopy, and biochemical assays.  Apply proper staining techniques (e.g., KOH, India ink) and culturing methods to identify common fungi.   |                   |                                 |                       |
|        | Clinical Benefits:  Essential for diagnosing fungal infections, including candidiasis, aspergillosis, and dermatophyte infections.  Helps in distinguishing between fungal and bacterial infections, which is crucial for |                   |                                 |                       |
|        | appropriate treatment.  Contributes to the management of immunocompromised patients who are at higher risk for invasive fungal infections.  |                   |                                 |                       |

# **Pharmacology**



# Third grade

### Academic program discretion

This academic program description provides a brief overview of the key features of the program and the expected learning outcomes for the student, demonstrating whether the student has made the most of the available opportunities. It is accompanied by a description of each course within the program.

| Educational 1- Establishment                   | University of Al-Ameed   |
|--|--|
| 2-Scientific Department                        | College of Medicine  |
| 3-Name of the Professional Academic Program.   | Modified traditional curriculum  |
| 4-Final Graduation Certificate                 | M.B.Ch.B   |
| 5- Educational system:<br>Annual/courses/other | Annual   |
| 6-Approved accreditation program               | Applied for Iraqi National Guidelines on<br>Standards for Established and Accrediting<br>Medical Schools   |
| 7-Other external factors                       | 1-Availability of relevant scientific research in the field of specialization 2-Access to global electronic networks 3-Access to traditional and digital libraries 4- Teaching aids such as data show and PowerPoint presentations 5- Availability of equipped classrooms 6- Use of free online communication platforms (e.g., Free Conference Call) |
| 8-Date the description was written             | 2024/9/15  |

#### 9- Objectives of the academic program:

Here are the key objectives of the pharmacology program for third-stage medical students, summarized in 5 points:

Understanding Drug Mechanisms: Learn how drugs interact with the body at the molecular and cellular levels, including their therapeutic effects and adverse reactions.

Pharmacokinetics and Pharmacodynamics: Grasp the processes of drug absorption, distribution, metabolism, excretion (ADME), and how these influence drug action and effectiveness.

Therapeutic Application and Side Effects: Gain knowledge of drug uses in various medical conditions and recognize potential side effects and toxicities.

Pharmacovigilance and Safety: Learn the importance of monitoring drug safety, reporting adverse reactions, and ensuring safe medication practices.

Clinical Integration and Ethical Considerations: Apply pharmacological knowledge in clinical settings, making informed drug choices, while considering ethical, legal, and patient safety aspects in drug therapy

#### 10- Resources:

Text- and Supplementary Books

Approved Online Scientific Resources and Databases

Clinical Pharmacology (by Bennett, and Brown), 8th edition, Churchill Livingstone

## Pharmacology \ Grade 3

Code: PHAR 302 8 Credits

| Number        | Learning Objective to pharmacology   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|---------------|--|-------------------|---------------------------------|------------------------------|
| Introduction  | to pharmacology  |                   |                                 |                              |
| PHAR 1.1      | Understand general terms used in pharmacology, expiry date, counterfeit medicine,  | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 1.2      | Describe cellular targets for drug action<br>and Outline general requirements for<br>studying pharmacology   | K                 | Large group lecture             | MCQ & short answer questions |
| Drug adminis  | stration   |                   |                                 |                              |
| PHAR 2.1      | Define pharmacokinetics and explain major divisions  | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 2.2      | Discuss routes of drug administration  Describe major characteristics of each route of drug administration   | K                 | Large group lecture             | MCQ & short answer questions |
| Drug absorpt  | ion  |                   |                                 |                              |
| PHAR 3.1      | Discuss mechanisms of drug absorption of drugs from the GI tract   | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 3.2      | Determine factors influencing drug absorption  Define the term "bioavailability" of drugs and factors influencing it.                                      | K                 | Large group lecture             | MCQ & short answer questions |
| Drug distribu | tion   |                   |                                 |                              |
| PHAR 4.1      | Define factors affecting drug<br>distribution: including blood flow,<br>capillary perme-ability, plasma protein<br>binding, and chemical properties of the | K                 | Large group lecture             | MCQ & short answer questions |

| Number       | drug, such as hydrophobicity or hydrophilicity. Volume of distribution as a measure of drug distribution.  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|--------------|--|-------------------|---------------------------------|------------------------------|
| PHAR 4.2     | Clinical significance of drug distribution: Impacts on drug efficacy, duration of action, and dosing. Competition and displacement from protein binding sites as a source of significant drug inter-actions, such as increased warfarin effect when displaced from albumin by most NSAIDs.   | K                 | Large group lecture             | MCQ & short answer questions |
| Metabolism a | and elimination  |                   |                                 |                              |
| PHAR 5.1     | Understand the processes of drug metabolism and elimination, explaining the role of the liver and kidney in drug clearance, including phase I and phase II metabolic reactions, enzyme induction/inhibition, and renal role in drug clearance.   | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 5.2     | Apply pharmacokinetic principles to drug clearance; differentiate between first-order and zero-order kinetics, describe factors affecting drug elimination, and understand concepts such as half-life, steady-state concentration, and creatin-ine clearance in clinical settings.   | K                 | Large group lecture             | MCQ & short answer questions |
| Pharmacodyr  | namics   |                   |                                 |                              |
| PHAR 6.1     | Understand the mechanisms of drug action  Explain the different types of drug targets (e.g. receptors, enzymes, transport proteins, ion channels) and describe how drugs interact with these targets to produce biological effects.  Compare and contrast the four major types of receptors (ligand-gated ion channels, G-protein-coupled receptors, | K                 | Large group lecture             | MCQ & short answer questions |

| Number       | Learning Objective  enzyme-linked receptors, and intracellular receptors) in terms of structure, function, and response duration.  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|--------------|--|-------------------|---------------------------------|------------------------------|
| PHAR 6.2     | Analyze drug-receptor interactions and their clinical implications:  Differentiate between agonists (full, partial, inverse) and antagonists (competitive, irreversible, function-al, chemical) and their effects on receptor activity.  Evaluate the concepts of potency, efficacy, therapeutic index, and receptor desensitization, and apply these principles to predict drug behavior in therapeutic or toxic contexts | K                 | Large group lecture             | MCQ & short answer questions |
| Introduction | for autonomic nervous system   |                   |                                 |                              |
| PHAR 7.1     | Describe the anatomical divisions of the nervous system, including the central nervous system (CNS) and peripheral nervous system (PNS)  explain their primary components (brain, spinal cord, and peripheral nerves).   | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 7.2     | Understand the role and significance of the autonomic nervous system (ANS) within the nervous system, identify its key functions in regulating involuntary physiological processes.  | K                 | Large group lecture             | MCQ & short answer questions |
| Adrenergic p | harmacology part 1   |                   |                                 |                              |
| PHAR 8.1     | Understand the mechanism of action of adrenergic drugs, gain knowledge of how adrenergic drugs interact with alpha and beta adrenergic receptors to either stimulate or block their activity   | K                 | Large group lecture             | MCQ & short answer questions |

| Number PHAR 8.2 | Learning Objective  Identify the therapeutic applications and side effects of adrenergic medications; recognizing the therapeutic uses of common adrenergic drugs (e.g. for treatment of asthma, hypertension, heart failure, anaphylaxis,), as well as their potential side effects (e.g., tachycardia, hypertension, arrhythmias, | Domain<br>K/S/A/C<br>K | Teaching Learning Methods Large group lecture | Assessment Methods  MCQ & short answer questions |
|-----------------|---|------------------------|---|--|
| Adrenergic p    | harmacology part 2  |                        |   |  |
| PHAR 9.1        | Understand the mechanism of action of adrenergic agonists and antagonists apart from those acting directly on adrenergic receptors e.g. centrally-acting medica-tions, MAO and COMT enzyme inhibitors, adrenergic neuron blockers, adrenergic neuron uptake inhibitors, ganglion blockers,  | K                      | Large group lecture                           | MCQ & short answer questions                     |
| PHAR 9.2        | Identify the therapeutic applications and side effects of adrenergic medications; apart from those acting directly on adrenergic receptors as shown above in PHAR 9.1.  | K                      | Large<br>groups<br>lecture                    | MCQ & short answer questions                     |
| Cholinergic a   | gonist  |                        |   |  |
| PHAR 10.1       | Understand the mechanism of action and therapeutic applications of cholinergic agonists: Students will be able to explain how cholinergic agonists interact with muscarinic and nicotinic receptors, and describe their clinical uses in conditions such as glaucoma, myasthenia gravis, and Alzheimer's disease.                   | K                      | Large group lecture                           | MCQ & short answer questions                     |
| PHAR 10.2       | Discuss the physiological effects and side effects of cholinergic agonists on the autonomic nervous system, such as bradycardia, increased glandular secretions, and smooth muscle contraction, and discuss the side effects resulting from these effects.  | K                      | Large group lecture                           | MCQ & short answer questions                     |

| Number        | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|---------------|--|-------------------|---------------------------------|------------------------------|
| Cholinergic a | ntagonist  |                   |                                 |                              |
| PHAR 11.1     | Understand the mechanisms of action and therapeutic uses of cholinergic antagonists: Students will be able to describe how cholinergic antagonists block muscarinic and nicotinic receptors, and outline their clinical applications in conditions like motion sickness, intestinal and ureteral colic, overactive bladder, and Parkinson's disease. | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 11.1     | Students should be able to explain the physiological outcomes of cholinergic antagonism, including tachycardia, reduced glandular secretions, and smooth muscle relaxation, and discuss how these effects are utilized in various therapeutic settings or contribute to the side effects resulting from their use.                                   | K                 | Large group lecture             | MCQ & short answer questions |
| Neuromuscul   | ar-blocking drugs  |                   |                                 |                              |
| PHAR 12.1     | Classify neuromuscular-blocking drugs into depolarizing and non-depolarizing agents, and explain their mechanisms of action.   | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 12.2     | Describe the clinical applications and side effects of neuromuscular blockers in anesthesia, surgery, and critical care, as well as their reversal strategies.   | K                 | Large group lecture             | MCQ & short answer questions |
| Autacoids par | rt 1   |                   |                                 |                              |
| PHAR 13.1     | Discuss the types and physiological roles of the autacoids (e.g. histamine, serotonin, eicosanoids, bradykinin,) in the body.  | K                 | Large group<br>lecture          | MCQ & short answer questions |
| PHAR 13.2     | Explain the clinical relevance of autacoids, including their role in inflammation, allergic reactions, and their therapeutic applications in conditions like asthma, peptic ulcer, inflammatory diseases, and for analgesia.   | K                 | Large group lecture             | MCQ & short answer questions |

| Number Autocoids por | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|----------------------|--|-------------------|---------------------------------|------------------------------|
| Autacoids par        | rt 2   |                   |                                 |                              |
| PHAR 14.1            | Describe the biosynthesis, metabolism, and mechanism of action of key autacoids.   | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 14.2            | Discuss the therapeutic applications of autacoid-modulating drugs, such as NSAIDs, antihistamines, and serotonin antagonists, in managing pain, inflammation, migraine, and cardiovascular conditions.   | K                 | Large group lecture             | MCQ & short answer questions |
| Respiratory D        | Drugs  |                   |                                 |                              |
| PHAR 15.1            | Understand the Pharmacology and Mechanism of Action of Respiratory Drugs  Explain how bronchodilators (e.g., β2-agonists, anticholinergics), corticosteroids, leukotriene inhibitors, and mucolytics work in treating respiratory conditions like asthma and COPD.  Clinical Benefit: Helps in selecting the right drug for optimal airway management, improving patient outcomes.                                   | K                 | Large group lecture             | MCQ & short answer questions |
| PHAR 15.2            | Demonstrate Safe and Effective Use of Respiratory Medications  Identify appropriate indications, dosages, and potential side effects of common respiratory drugs.  Recognize adverse effects such as tachycardia with β2-agonists or oral thrush with inhaled corticosteroids and implement preventive measures.  Clinical Benefit: Enhances patient adherence, minimizes side effects, and improves disease control | K                 | Large group lecture             | MCQ & short answer questions |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|--------------|---|-------------------|---------------------------------|-----------------------------------|
| Antihyperten | sive drugs  |                   |                                 |                                   |
| PHAR 16.1    | classify antihypertensive drugs based on their mechanisms of action, including diuretics, beta-blockers, calcium channel blockers, ACE inhibitors, and ARBs   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 16.2    | Explain the clinical applications of antihypertensive drugs, their benefits in managing hypertension, and their role in preventing cardiovascular complications such as stroke and heart failure    | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Anti-anginal | drugs   |                   |                                 |                                   |
| PHAR 17.1    | classify anti-anginal drugs into nitrates,<br>beta-blockers, and calcium channel<br>blockers, and explain their mechanisms<br>of action in relieving myocardial<br>ischemia.                        | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 17.2    | Describe the clinical applications of anti-anginal drugs in managing stable, unstable, and variant angina, along with their benefits in improving exercise tolerance and reducing cardiac workload. | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Antiarrhythm | ic drugs  |                   |                                 |                                   |
| PHAR 18.1    | Classify antiarrhythmic drugs based on<br>the Vaughan Williams classification<br>and explain their mechanisms of action<br>in regulating cardiac rhythm  .Describe the                              | K                 | Large group<br>lecture          | MCQ&<br>short answer<br>questions |
| PHAR 18.2    | clinical applications of antiarrhythmic drugs in managing conditions like atrial fibrillation, ventricular tachycardia, and other arrhythmias, along with their potential side effects.             | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |

| Number        | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|---------------|---|-------------------|---------------------------------|-----------------------------------|
| Heart failure |   |                   |                                 |                                   |
| PHAR 19.1     | Explain the pathophysiology of heart failure, including its types (systolic vs. diastolic) and compensatory mechanisms.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 19.2     | 2Describe the clinical use of drugs such as ACE inhibitors, beta-blockers, diuretics, and inotropes in managing heart failure and improving patient outcomes1   | K                 | QQ                              | MCQ&<br>short answer<br>questions |
| Anticoagulan  | ts  |                   |                                 |                                   |
| PHAR 20.1     | Classify anticoagulants into heparins, vitamin K antagonists, and direct oral anticoagulants (DOACs), and explain their mechanisms of action.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 20.2     | Describe the clinical applications of anticoagulants in preventing and treating thromboembolic disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation, along with their monitoring and potential complications. | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Diuretics     |   |                   |                                 |                                   |
| PHAR 21.1     | Classify diuretics based on their site of action in the nephron, including loop diuretics, thiazides, potassium-sparing diuretics, and osmotic diuretics, and explain their mechanisms of action.   |                   | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 21.2     | describe the clinical applications of<br>diuretics in managing conditions such<br>as hypertension, heart failure, and<br>edema, along with their potential side<br>effects and electrolyte imbalances   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Drugs for dys | slipidemia  |                   |                                 |                                   |
| PHAR 22.1     | classify the main classes of drugs used<br>to treat dyslipidemia, including statins,<br>fibrates, bile acid sequestrants, niacin,   | K                 | Large group<br>lecture          | MCQ&<br>short answer<br>questions |

| Number PHAR 22.2                       | Learning Objective  and PCSK9 inhibitors, and explain their mechanisms of action.  describe the clinical applications of  | Domain<br>K/S/A/C | Teaching Learning Methods  Large group | Assessment Methods  MCQ&          |
|--|---|-------------------|--|-----------------------------------|
|  | dyslipidemia drugs in managing conditions such as hypercholesterolemia, hypertriglyceridemia, and their role in preventing cardiovascular diseases, including atherosclerosis and stroke.                         |                   | lecture                                | short answer<br>questions         |
| Anemia                                 |   |                   |  |                                   |
| PHAR 23.1                              | classify the types of anemia (e.g., iron-<br>deficiency anemia, megaloblastic<br>anemia, hemolytic anemia) and explain<br>their underlying pathophysiology  | K                 | Large group lecture                    | MCQ&<br>short answer<br>questions |
| PHAR 23.2                              | describe the clinical use of pharmacological agents in the treatment of anemia, including iron supplements, vitamin B12 and folic acid, erythropoiesis-stimulating agents (ESAs), and their potential side effect | K                 | Large group lecture                    | MCQ&<br>short answer<br>questions |
| Introduction                           | to CNS pharmacology   |                   |  |                                   |
| PHAR 24.1                              | Explain the basic principles of pharmacokinetics and pharmacodynamics as they relate to drugs acting on the central nervous system (CNS).   | K                 | Large group lecture                    | MCQ&<br>short answer<br>questions |
| PHAR 24.2                              | classify major classes of CNS drugs (e.g., analgesics, anesthetics, antipsychotics, antidepressants, anticonvulsants) and describe their mechanisms of action, therapeutic uses, and potential side effects.      | K                 | Large group lecture                    | MCQ&<br>short answer<br>questions |
| Drugs used to treat headache disorders |   |                   |  |                                   |
| PHAR 25.1                              | Classify the drugs used to treat<br>different types of headaches, including<br>acute and preventive treatments for<br>migraines, tension-type headaches, and  | K                 | Large group<br>lecture                 | MCQ&<br>short answer<br>questions |

| Number        | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|---------------|---|-------------------|---------------------------------|-----------------------------------|
|               | cluster headaches, and explain their mechanisms of action.  |                   |                                 |                                   |
| PHAR 25.2     | Describe the clinical applications and potential side effects of common headache treatments.  | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Alzheimer dis | sease and sclerosis   |                   |                                 | l                                 |
| PHAR 26.1     | Explain the pathophysiology of Alzheimer's disease and multiple sclerosis, focusing on the underlying mechanisms such as amyloid plaques and neurofibrillary tangles in Alzheimer's, and demyelination in multiple sclerosis.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 26.2     | .Describe the pharmacological treatments for Alzheimer's disease (e.g., cholinesterase inhibitors, NMDA antagonists) and multiple sclerosis (e.g., disease-modifying therapies, corticosteroids), including their mechanisms of action, clinical applications, and potential side effects | k                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Drugs of Park | cinson disease  |                   |                                 |                                   |
| PHAR 27.1     | Classify the main pharmacological treatments for Parkinson's disease, including dopaminergic agents (e.g., levodopa, dopamine agonists), MAO-B inhibitors, and COMT inhibitors, and explain their mechanisms of action.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 27.2     | Describe the clinical applications, benefits, and potential side effects of Parkinson's disease medications, focusing on improving motor symptoms and managing side effects such as dyskinesia and motor fluctuations.  | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Anti-depressa | ant drugs   |                   |                                 |                                   |

| Number PHAR 28.1 | Classify the major classes of antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), and explain their     | Domain<br>K/S/A/C<br>K | Teaching Learning Methods  Large group lecture | Assessment<br>Methods  MCQ&<br>short answer<br>questions |
|------------------|--|------------------------|--|--|
| PHAR 28.2        | mechanisms of action.  Describe the clinical applications, benefits, and potential side effects of antidepressant drugs in managing depression, anxiety disorders, and other mood disorder   | K                      | Large group lecture                            | MCQ&<br>short answer<br>questions                        |
| Anti-psychoti    | ic drugs   | 1                      | <u>'</u>                                       |  |
| PHAR 29.1        | Classify antipsychotic drugs into first-<br>generation (typical) and second-<br>generation (atypical) antipsychotics,<br>and explain their mechanisms of<br>action, particularly their effects on<br>dopamine and serotonin receptors.                                 | K                      | Large group<br>lecture                         | MCQ&<br>short answer<br>questions                        |
| PHAR 29.2        | Describe the clinical applications, benefits, and potential side effects of antipsychotic drugs in managing conditions such as schizophrenia, bipolar disorder, and acute psychotic episodes, along with their long-term use considerations                            | K                      | Large group lecture                            | MCQ&<br>short answer<br>questions                        |
| Anti-epilep      | tics drugs   |                        |  |  |
| PHAR 30.1        | Understand the Mechanisms of Action of Anti-Epileptic Drugs (AEDs):  Explain how different AEDs work, including sodium channel blockers, GABA enhancers, and calcium channel modulators.  Clinical Benefit: Helps in selecting the most appropriate drug for different | K                      | Large group lecture                            | MCQ&<br>short answer<br>questions                        |

|                    |  |         | m 1:                |                        |
|--------------------|--|---------|---------------------|------------------------|
| Number             | Learning Objective   | Domain  | Teaching            | Assessment             |
| Nullibei           | Learning Objective   | K/S/A/C | Learning<br>Methods | Methods                |
|                    |  |         | Wichiods            |                        |
|                    | seizure types and minimizing side  |         |                     |                        |
|                    | effects.   |         |                     |                        |
| PAHR 30.2          | Demonstrate Knowledge of AED   | K       | Large group         | MCQ &                  |
|                    | Selection and Management in Patients:  |         | lecture             | short answer           |
|                    | Identify the first-line and alternative                                      |         |                     | questions              |
|                    | AEDs for focal and generalized   |         |                     |                        |
|                    | seizures.  |         |                     |                        |
|                    | Understand dose adjustments, side  |         |                     |                        |
|                    | effect management, and drug  |         |                     |                        |
|                    | interactions.  |         |                     |                        |
|                    | Clinical Benefit: Enhances patient   |         |                     |                        |
|                    | safety, improves seizure control, and  |         |                     |                        |
|                    | reduces adverse drug reactions.  |         |                     |                        |
| Anxiolytic an      | d hypnotic drugs part 1  |         |                     |                        |
| PHAR 31.1          | Classify anniabytic and hymnotic days  | V       | I and a success     | MCO                    |
| РПАК 31.1          | Classify anxiolytic and hypnotic drugs, including benzodiazepines, non-      | K       | Large group lecture | MCQ& short answer      |
|                    | benzodiazepine sedatives, and  |         | lecture             | questions              |
|                    | barbiturates, and explain their  |         |                     |                        |
|                    | mechanisms of action on GABA   |         |                     |                        |
|                    | receptors in the central nervous system.                                     |         |                     |                        |
| PHAR 31.2          | Describe the clinical applications of  | K       | Large group         | MCQ&                   |
|                    | anxiolytic and hypnotic drugs in   |         | lecture             | short answer           |
|                    | treating anxiety disorders, insomnia,  |         |                     | questions              |
|                    | and acute stress, including their onset                                      |         |                     |                        |
|                    | of action, duration, and potential side effects                              |         |                     |                        |
| A maria lautia a m |  |         |                     |                        |
| Anxiolytic an      | d hypnotic drugs part 2  |         |                     |                        |
| PHAR 32.1          | Explain the pharmacokinetics and   | K       | Large group         | MCQ&                   |
|                    | adverse effects of anxiolytic and  |         | lecture             | short answer           |
|                    | hypnotic drugs, focusing on tolerance,                                       |         |                     | questions              |
|                    | dependence, and withdrawal symptoms associated with long-term use.           |         |                     |                        |
|                    |  |         |                     |                        |
| PHAR 32.2          | Discuss alternative therapies to   | K       | Large group         | MCQ&                   |
|                    | traditional anxiolytic and hypnotic  |         | lecture             | short answer questions |
|                    | drugs, including selective serotonin reuptake inhibitors (SSRIs) for anxiety |         |                     | questions              |
|                    | and melatonin agonists for insomnia,   |         |                     |                        |
|                    | and their clinical applications.   |         |                     |                        |
| Epilepsy           |  |         |                     |                        |
| r ·r~J             |  |         |                     |                        |
|                    |  |         |                     |                        |

| Number        | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|---------------|---|-------------------|---------------------------------|-----------------------------------|
| PHAR 33.1     | Classify the different types of seizures (e.g., generalized, focal) and explain the underlying pathophysiology of epilepsy, focusing on the role of abnormal neuronal excitability.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 33.2     | Describe the pharmacological treatments for epilepsy, including antiepileptic drugs (AEDs) such as sodium channel blockers, GABA enhancers, and glutamate inhibitors, along with their mechanisms of action, clinical uses, and potential side effects                        | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| General anest | hetics  |                   |                                 |                                   |
| PHAR 34.1     | Understand the Mechanisms of General Anesthetics  Act on GABA and NMDA receptors to induce anesthesia. Clinical Benefit: Helps in selecting appropriate anesthetic agents for patient safety.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 34.2     | Demonstrate Safe Use of General Anesthetics Recognize indications, contraindications, and complications (e.g., hypotension, malignant hyperthermia). Clinical Benefit: Enhances perioperative safety and reduces adverse effects.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Local Anesth  | netic Drugs   |                   |                                 |                                   |
| PHAR 35.1     | Understand the Mechanism of Action and Classification of Local Anesthetics.  Explain how local anesthetics block sodium channels to prevent nerve conduction.  Differentiate between amide (e.g., lidocaine, bupivacaine) and ester (e.g., procaine, tetracaine) anesthetics. | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |

| Number      | Learning Objective  Clinical Benefit: Helps in selecting the  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|-------------|---|-------------------|---------------------------------|-----------------------------------|
|             | appropriate anesthetic for different procedures, ensuring effective pain control.   |                   |                                 |                                   |
| PHAR 35.2   | Recognize and Manage Local Anesthetic Toxicity.  Identify signs of Local Anesthetic Systemic Toxicity (LAST) (e.g., CNS symptoms, cardiac toxicity).  Understand management strategies, including lipid emulsion therapy for severe toxicity.  Clinical Benefit: Enhances patient safety by preventing and managing adverse effects effectively | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Opioids     |   |                   |                                 |                                   |
| PHAR 36.1   | Classify opioid drugs based on their receptor binding properties (e.g., mu, kappa, delta receptors) and explain their mechanisms of action in pain modulation and their effects on the central nervous system.  | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 36.2   | Describe the clinical applications of opioids in managing acute and chronic pain, including their potential side effects such as tolerance, dependence, and respiratory depression, and the strategies to mitigate these risks  | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Antiemetics |   |                   |                                 |                                   |
| PHAR 37.1   | Classify antiemetic drugs based on their mechanisms of action, including dopamine antagonists, serotonin (5-HT3) antagonists, antihistamines, and corticosteroids, and explain how they prevent nausea and vomiting.  | K                 | Large group<br>lecture          | MCQ&<br>short answer<br>questions |
| PHAR 37.2   | Describe the clinical applications of antiemetic drugs in managing nausea and vomiting associated with conditions such as chemotherapy, motion sickness, and post-operative   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |

| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|--------------|--|-------------------|---------------------------------|-----------------------------------|
|              | recovery, along with their potential side effects.   |                   |                                 |                                   |
| Peptic ulcer |  |                   |                                 |                                   |
| PHAR 38.1    | Explain the pathophysiology of peptic ulcers, including the role of Helicobacter pylori infection, gastric acid hypersecretion, and mucosal protection in ulcer formation.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 38.2    | Describe the pharmacological treatments for peptic ulcers, including proton pump inhibitors (PPIs), H2 receptor antagonists, antibiotics (for H. pylori), and antacids, and discuss their mechanisms of action, clinical applications, and potential side effects. | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Constipation |  |                   |                                 |                                   |
| PHAR39.1     | Classify the different causes of constipation, including primary (functional) and secondary (due to underlying diseases or medications), and explain the pathophysiology of each type.   | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| PHAR 39.2    | Describe the pharmacological treatments for constipation, including bulk-forming agents, stool softeners, osmotic laxatives, stimulant laxatives, and prokinetic drugs, and discuss their mechanisms of action, clinical applications, and potential side effects  | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |
| Diarrhea     |  |                   |                                 |                                   |
| PHAR 40.1    | Classify the different types of diarrhea, including acute, chronic, and infectious diarrhea, and explain their underlying causes and pathophysiology.  | K                 | Large group lecture             | MCQ&<br>short answer<br>questions |

| Number PHAR 40.2 | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods<br>& short  |
|------------------|---|-------------------|---------------------------------|-----------------------------------|
| FIAR 40.2        | Describe the pharmacological treatments for diarrhea, including antimotility agents (e.g., loperamide), adsorbents, antibiotics (for infectious causes), and oral rehydration solutions (ORS), and discuss their mechanisms of action, clinical applications, and potential side effects.   | K                 | Large group lecture             | answer questions MCQ              |
| Pharmacology     | y-osteoporosis  |                   |                                 |                                   |
| PHAR 41.1        | Explain the pathophysiology of osteoporosis, including the role of bone resorption and formation, and the impact of hormonal changes (e.g., estrogen deficiency) on bone density.   | K/S/A             | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 41.2        | Describe the pharmacological treatments for osteoporosis.  discuss their mechanisms of action, clinical applications, and potential side effects.   | K/S/A             | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Anti-rheumat     | ic and DMARD  |                   |                                 |                                   |
| PHAR 42.1        | Classify anti-rheumatic drugs into non-biologic DMARDs (e.g., methotrexate, sulfasalazine) and biologic DMARDs (e.g., TNF inhibitors, IL-6 inhibitors).  explain their mechanisms of action in modulating the immune system to reduce inflammation in conditions like rheumatoid arthritis. | K/S/A             | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 42.2        | Describe the clinical applications of DMARDs in managing autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and lupus discuss their potential side effects, including immunosuppression and increased infection risk.   | K/S/A             | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Pharmacology     | y gout  |                   |                                 |                                   |

| Number                                | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|---------------------------------------|---|-------------------|---------------------------------|-----------------------------------|
| PHAR 43.1                             | Explain the pathophysiology of gout, focusing on the accumulation of uric acid crystals in joints and the role of hyperuricemia in the development of acute gout attacks.   | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 43.2                             | Describe the pharmacological treatments for gout, including drugs that reduce uric acid production (e.g., allopurinol, febuxostat), drugs that increase uric acid excretion (e.g., probenecid), and anti-inflammatory agents (e.g., colchicine, NSAIDs) discuss their mechanisms of action, clinical applications, and potential side effects | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Pharmacolog                           | y-obesity   |                   |                                 |                                   |
| PHAR 44.1                             | Explain the pathophysiology of obesity, including the role of energy balance, genetic factors, and hormonal regulation (e.g., leptin, ghrelin) in the development of obesity.   | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 44.2                             | Describe the pharmacological treatments for obesity, including appetite suppressants (e.g., phentermine, liraglutide), lipase inhibitors (e.g., orlistat), and other weight loss agents (e.g., GLP-1 receptor agonists), discuss their mechanisms of action, clinical applications, and potential side effects.                               | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Non-steroidal-anti-inflammatory drugs |   |                   |                                 |                                   |
| PHAR 45.1                             | Classify NSAIDs based on their mechanisms of action, including COX-1 and COX-2 inhibition, and explain how they reduce inflammation, pain, and fever.   | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |

| Number          | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|-----------------|---|-------------------|---------------------------------|-----------------------------------|
| PHAR 45.2       | Describe the clinical applications of NSAIDs in managing conditions such as arthritis, pain, and dysmenorrhea, and discuss their potential side effects, including gastrointestinal bleeding, renal impairment, and cardiovascular risks.                           | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Introduction t  | to Antimicrobial drugs  |                   |                                 |                                   |
| PHAR 46.1       | Classify antimicrobial drugs into their major classes, including antibiotics, antifungals, antivirals, and antiprotozoals, and explain their mechanisms of action in inhibiting microbial growth or replication.  | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 46.2       | Describe the clinical applications of antimicrobial drugs in treating bacterial, viral, fungal, and parasitic infections, and discuss their spectrum of activity, potential side effects, and the importance of antibiotic stewardship to prevent resistance.       | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Beta-lactam d   | lrugs   |                   |                                 |                                   |
| PHAR 47.1       | Classify beta-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems, and explain their mechanisms of action in inhibiting bacterial cell wall synthesis.  | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 47.2       | Describe the clinical applications of beta-lactam drugs in treating a variety of bacterial infections, including respiratory, urinary, and skin infections, and discuss their potential side effects, such as allergic reactions and the development of resistance. | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Inhibitors of J | protein synthesis   |                   |                                 |                                   |
| PHAR 48.1       | Classify the major classes of protein synthesis inhibitors, including macrolides, tetracyclines, aminoglycosides, and chloramphenicol, and explain their  | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |

| Number  PHAR 48.2 | Learning Objective  mechanisms of action in inhibiting bacterial ribosomal function and protein production.  Describe the clinical applications of   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment Methods  MCQ& short    |
|-------------------|--|-------------------|---------------------------------|-----------------------------------|
| FIIAR 40.2        | protein synthesis inhibitors in treating bacterial infections, their spectrum of activity, and their potential side effects, such as gastrointestinal disturbances, ototoxicity, and nephrotoxicity.   | K                 | group<br>lecture                | answer questions                  |
| Quinolones        |  |                   |                                 |                                   |
| PHAR 49.1         | Explain the mechanism of action of quinolones, focusing on their inhibition of bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication and transcription.   | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 49.2         | Describe the clinical applications of quinolones in treating a variety of bacterial infections, including urinary tract infections, respiratory infections, and gastrointestinal infections, as well as their potential side effects such as tendonitis, QT prolongation, and gastrointestinal disturbances. | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Anti mycobac      | cterial drugs  |                   |                                 |                                   |
| PHAR 50.1         | Classify the main anti-mycobacterial drugs used in the treatment of tuberculosis (TB), including first-line drugs (e.g., isoniazid, rifampin, pyrazinamide, ethambutol) and second-line drugs (e.g., fluoroquinolones, aminoglycosides), and explain their mechanisms of action.                             | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |

| Number         | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|----------------|--|-------------------|---------------------------------|-----------------------------------|
| PHAR 50.2      | Describe the clinical applications of anti-mycobacterial drugs in treating tuberculosis, including the importance of combination therapy for drug-resistant TB.  discuss their potential side effects, such as hepatotoxicity, neuropathy,                     | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
|                | and visual disturbances.   |                   |                                 |                                   |
| Antiviral drug | gs   |                   |                                 |                                   |
| PHAR 51.1      | Classify antiviral drugs based on their mechanisms of action, including inhibitors of viral entry, replication, and release, such as nucleoside analogs, protease inhibitors, and neuraminidase inhibitors.  | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 51.2      | Describe the clinical applications of antiviral drugs in treating viral infections like influenza, HIV, herpes simplex virus (HSV), and hepatitis, and discuss their potential side effects and the challenges of antiviral resistance.                        | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Antifungal dr  | ugs  |                   |                                 |                                   |
| PHAR 52.1      | Classify antifungal drugs into major classes, including azoles, polyenes, echinocandins, and allylamines, and explain their mechanisms of action in inhibiting fungal cell membrane synthesis or cell wall formation.  | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 52.2      | Describe the clinical applications of antifungal drugs in treating common fungal infections, such as candidiasis, aspergillosis, and dermatophytosis, and discuss their potential side effects, such as hepatotoxicity, nephrotoxicity, and drug interactions. | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |

| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |  |  |
|--------------|--|-------------------|---------------------------------|-----------------------------------|--|--|
| Antiprotozoa | Antiprotozoal drugs  |                   |                                 |                                   |  |  |
| PHAR 53.1    | Classify antiprotozoal drugs into their major classes, including antimalarials (e.g., chloroquine, artemisinin), antileishmanial (e.g., miltefosine), and antiamoebic agents (e.g., metronidazole), and explain their mechanisms of action in inhibiting protozoan growth and replication. | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |  |  |
| PHAR 53.2    | Describe the clinical applications of antiprotozoal drugs in treating diseases caused by protozoan infections, such as malaria, leishmaniasis, and giardiasis, and discuss their potential side effects, such as gastrointestinal disturbances, neurotoxicity, and drug resistance.        | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |  |  |
| Anthelmintic | drugs  |                   |                                 |                                   |  |  |
| PHAR 54.1    | Understand the Mechanism of Action and Classification of Anthelmintic Drug  Learn how different classes of anthelmintic drugs work, their targets, and their pharmacological effects on parasitic worms.   | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |  |  |
| PHAR 54.2    | Apply Knowledge of Anthelmintic Drugs in Clinical Practice(Clinical Benefit)  identify appropriate anthelmintic treatment for specific helminth infections, ensuring effective parasite elimination while minimizing side effects and drug resistance.                                     | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |  |  |
| Antidiabetic | drugs  |                   |                                 |                                   |  |  |
| PHAR 54.1    | Understand the Classification and Mechanisms of Action of Antidiabetic Drugs  Learn how different classes of antidiabetic drugs work, their  | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |  |  |

| Number        | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|---------------|--|-------------------|---------------------------------|-----------------------------------|
|               | pharmacological effects, and their role in diabetes management.  |                   |                                 |                                   |
| PHAR 54.2     | Apply Evidence-Based Drug Selection in Clinical Practice (Clinical Benefit) Identify and prescribe appropriate antidiabetic therapy based on patient-specific factors such as blood glucose levels, comorbidities, risk of hypoglycemia, and cardiovascular or renal benefits                  | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Thyroid horm  | nones  |                   |                                 |                                   |
| PHAR 55.1     | Understand the Mechanism of Action, Pharmacokinetics, and Functions of Thyroid Hormone Drugs.  Learn how thyroid hormone drugs (e.g., levothyroxine, liothyronine)   | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
|               | work, their metabolism.  |                   |                                 |                                   |
| PHAR 55.2     | Apply Thyroid Hormone Therapy in Clinical Practice (Clinical Benefit)  Select and adjust appropriate thyroid hormone replacement therapy based on patient-specific factors (e.g., TSH levels, comorbidities, age) to ensure effective treatment of hypothyroidism and other thyroid disorders. | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| Adrenocortico | osteroids  |                   |                                 |                                   |
| PHAR 56.1     | Understand the Classification, Mechanism of Action, and Physiological Effects of Adrenocorticosteroids  Learn about glucocorticoids and mineralocorticoids, their roles in metabolism, immune response, and electrolyte balance.   | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |
| PHAR 56.2     | Apply Adrenocorticosteroid Therapy in Clinical Practice (Clinical Benefit)  Appropriately prescribe and manage corticosteroid therapy for conditions like adrenal insufficiency,   | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |

| Number      | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods             |
|-------------|--|-------------------|---------------------------------|-----------------------------------|
|             | inflammation, and autoimmune<br>diseases while minimizing side<br>effects such as adrenal suppression<br>and osteoporosis.   |                   |                                 |                                   |
| Complementa | ary medicine: Drug – Drug, Herb-drug int   | eraction          |                                 |                                   |
| PHAR 57.1   | 1.Remembering: Define complementary medicine and herbdrug interaction.  2.Explain Explain the common mechanisms of herbdrug interactions (e.g., CYP450 enzyme induction/inhibition, absorption changes).  3.Identify potential herbdrug interactions in given clinical case scenarios (e.g., warfarin + ginseng, St. John's wort + oral contraceptives).  4.Analyzing: Differentiate between beneficial and harmful herbdrug interactions in patient management.  5- Evaluate Propose safe strategies for pharmacists to counsel patients on preventing dangerous herbdrug | K                 | Large<br>group<br>lecture       | MCQ& short<br>answer<br>questions |

## Practical

| Number         | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |  |  |  |
|----------------|---|-------------------|---------------------------------|-----------------------|--|--|--|
| Pharmaceutica  | Pharmaceutical dosage forms   |                   |                                 |                       |  |  |  |
| PHAR1.1        | Understand the Types, Characteristics, and Functions of Pharmaceutical Dosage Forms.  Learn about various dosage forms (e.g., tablets, capsules, injections, topical formulations), their design, and how they affect drug absorption, distribution, and efficacy.  | k/S/C             | small groups<br>lab             | MCQ                   |  |  |  |
| PHAR1.2        | Apply Knowledge of Dosage Forms in Clinical Practice (Clinical Benefit)  Select the appropriate dosage form based on patient needs, drug properties, and the therapeutic goals, considering factors like patient compliance, onset of action, and side effects.   | K/S/C             | small groups<br>lab             | MCQ                   |  |  |  |
| Routes of drug | g administration  |                   |                                 |                       |  |  |  |
| PHAR2.1        | Understand the Different Routes of Drug Administration and Their Characteristics.  Learn about the various routes of drug administration (e.g., oral, intravenous, intramuscular, subcutaneous, topical), their absorption mechanisms, advantages, and disadvantages.                                     | k/S/C             | Small groups<br>lab             | MCQ                   |  |  |  |
| PHAR 2.2       | Apply the Appropriate Route of Administration in Clinical Practice (Clinical Benefit)  Select the most effective and appropriate route of drug administration based on the drug's properties, the patient's condition, and therapeutic goals to ensure optimal drug delivery and minimize adverse effects | K/S/C             | Small groups<br>lab             | MCQ                   |  |  |  |

| Number         | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|----------------|--|-------------------|---------------------------------|-----------------------|
| Calculation of | pharmacokinetic parameters   |                   |                                 |                       |
| PHAR 3.1       | Understand the Key Pharmacokinetic Parameters and Their Calculation.  Learn about the key pharmacokinetic parameters (e.g., half-life, clearance, volume of distribution, and bioavailability) and how to calculate them using drug concentration-time data.               | k/S/C             | Small groups<br>lab             | MCQ                   |
| PHAR 3.2       | Apply Pharmacokinetic Calculations in Clinical Practice (Clinical Benefit)  Use pharmacokinetic parameters to optimize drug dosing, adjust for patient-specific factors (e.g., renal or hepatic impairment), and ensure therapeutic drug levels while minimizing toxicity. | K/S/C             | Small groups<br>lab             | MCQ                   |
| Prescription-o | order writing  |                   | <u> </u>                        |                       |
| PHAR 4.1       | Understand the Components and Legal Requirements of a Prescription.  Learn about the essential components of a prescription (e.g., patient information, drug name, dosage, frequency, duration) and  | k/S/C             | Small groups<br>lab             | MCQ                   |
|                | the legal requirements to ensure safe and accurate prescribing.  |                   |                                 |                       |

| PHAR 4.2     | Apply Proper Prescription Writing in Clinical Practice (Clinical Benefit)  Write clear, accurate prescriptions that follow legal and clinical guidelines, considering factors like drug interactions, patient conditions, and cost-effectiveness to ensure patient safety and optimal therapeutic outcomes   | K/S/C             | Small groups lab                | MCQ                   |
|--------------|--|-------------------|---------------------------------|-----------------------|
| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
| Drug-induced | discoloration of urine   |                   |                                 |                       |
| PHAR 5.1     | Understand the Mechanisms and Causes of Drug-Induced Urine Discoloration.  Learn about the various drugs (e.g., rifampin, phenazopyridine, levodopa) that can cause changes in urine color, and understand the underlying pharmacological mechanisms behind these effects.   | k/S/C             | Small groups<br>lab             | MCQ                   |
| PHAR 5.2     | Identify and Manage Drug- Induced Urine Discoloration in Clinical Practice (Clinical Benefit) Recognize the clinical significance of drug-induced urine discoloration, differentiate it from pathological causes, and provide patient education to alleviate concerns while managing the underlying condition or adjusting treatment if necessary. | K/S/C             | Small groups lab                | MCQ                   |
|              | d clinical trials  |                   |                                 |                       |

| PHAR 6.1       | Understand the Drug Discovery and Development Process  Learn the stages of drug discovery and development, from preclinical research, lead compound identification, and optimization, to clinical trials and regulatory approval.                                  | K/S/C             | Small groups<br>lab             | MCQ                   |
|----------------|--|-------------------|---------------------------------|-----------------------|
| PHAR 6.2       | Apply Knowledge of Toxicity Evaluation and Clinical Trials in Drug Development (Clinical Benefit)  | K/S/C             | Small groups<br>lab             | MCQ                   |
|                | Understand the importance of toxicity evaluation and preclinical studies to ensure drug safety, and learn how clinical trials are designed and conducted to assess drug efficacy and safety, ultimately benefiting patient care and regulatory compliance.         |                   |                                 |                       |
| Number         | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
| Pharmaceutica  | al dosage forms  |                   |                                 |                       |
| PHAR1.1        | Understand the Types, Characteristics, and Functions of Pharmaceutical Dosage Forms.  Learn about various dosage forms (e.g., tablets, capsules, injections, topical formulations), their design, and how they affect drug absorption, distribution, and efficacy. | k/S/C             | small groups<br>lab             | MCQ                   |
| PHAR1.2        | Apply Knowledge of Dosage Forms in Clinical Practice (Clinical Benefit) Select the appropriate dosage form based on patient needs, drug properties, and the therapeutic goals, considering factors like patient compliance, onset of action, and side effects.     | K/S/C             | small groups<br>lab             | MCQ                   |
| Routes of drug | g administration   |                   |                                 |                       |

| PHAR2.1        | Understand the Different Routes of Drug Administration and Their Characteristics.  Learn about the various routes of drug administration (e.g., oral, intravenous, intramuscular, subcutaneous, topical), their absorption mechanisms, advantages, and disadvantages.                                     | k/S/C             | Small groups<br>lab             | MCQ                   |
|----------------|---|-------------------|---------------------------------|-----------------------|
| PHAR 2.2       | Apply the Appropriate Route of Administration in Clinical Practice (Clinical Benefit)  Select the most effective and appropriate route of drug administration based on the drug's properties, the patient's condition, and therapeutic goals to ensure optimal drug delivery and minimize adverse effects | K/S/C             | Small groups<br>lab             | MCQ                   |
| Number         | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
| Calculation of | f pharmacokinetic parameters  |                   |                                 |                       |
| PHAR 3.1       | Understand the Key Pharmacokinetic Parameters and Their Calculation.  Learn about the key pharmacokinetic parameters (e.g., half-life, clearance, volume of distribution, and bioavailability) and how to calculate them using drug concentration-time data.  | k/S/C             | Small groups<br>lab             | MCQ                   |
| PHAR 3.2       | Apply Pharmacokinetic Calculations in Clinical Practice (Clinical Benefit) Use pharmacokinetic parameters to optimize drug dosing, adjust for patient-specific factors (e.g., renal or hepatic impairment), and ensure therapeutic drug levels while minimizing toxicity.                                 | K/S/C             | Small groups<br>lab             | MCQ                   |

| Prescription-o | Prescription-order writing  |                   |                                 |                       |  |
|----------------|---|-------------------|---------------------------------|-----------------------|--|
| PHAR 4.1       | Understand the Components and Legal Requirements of a Prescription.  Learn about the essential components of a prescription (e.g., patient information, drug name, dosage, frequency, duration) and the legal requirements to ensure  | k/S/C             | Small groups<br>lab             | MCQ                   |  |
| PHAR 4.2       | safe and accurate prescribing.  Apply Proper Prescription Writing in Clinical Practice (Clinical Benefit)  Write clear, accurate prescriptions that follow legal and clinical guidelines, considering factors like drug interactions, patient conditions, and costeffectiveness to ensure patient safety and optimal therapeutic outcomes | K/S/C             | Small groups lab                | MCQ                   |  |
| Number         | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |  |
| Drug-induced   | discoloration of urine  |                   |                                 |                       |  |
| PHAR 5.1       | Understand the Mechanisms and Causes of Drug-Induced Urine Discoloration.  Learn about the various drugs (e.g., rifampin, phenazopyridine, levodopa) that can cause changes in urine color, and understand the underlying pharmacological mechanisms behind these effects.  | k/S/C             | Small groups<br>lab             | MCQ                   |  |

| PHAR 5.2 | Identify and Manage Drug-Induced Urine Discoloration in Clinical Practice (Clinical Benefit) Recognize the clinical significance of drug-induced urine discoloration, differentiate it from pathological causes, and provide patient education to alleviate concerns while managing the underlying condition or adjusting treatment if necessary.            | K/S/C | Small groups lab    | MCQ |
|----------|--|-------|---------------------|-----|
| •        | y and development; toxicity<br>d clinical trials   |       |                     |     |
| PHAR 6.1 | Understand the Drug Discovery and Development Process  Learn the stages of drug discovery and development, from preclinical research, lead compound identification, and optimization, to clinical trials and regulatory approval.  | K/S/C | Small groups<br>lab | MCQ |
| PHAR 6.2 | Apply Knowledge of Toxicity Evaluation and Clinical Trials in Drug Development (Clinical Benefit) Understand the importance of toxicity evaluation and preclinical studies to ensure drug safety, and learn how clinical trials are designed and conducted to assess drug efficacy and safety, ultimately benefiting patient care and regulatory compliance. | K/S/C | Small groups<br>lab | MCQ |

| Number         | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|----------------|--|-------------------|---------------------------------|-----------------------|
| Pharmaceutica  | al dosage forms  |                   |                                 |                       |
| PHAR1.1        | Understand the Types, Characteristics, and Functions of Pharmaceutical Dosage Forms.  Learn about various dosage forms (e.g., tablets, capsules, injections, topical formulations), their design, and how they affect drug absorption, distribution, and | k/S/C             | small groups<br>lab             | MCQ                   |
|                | efficacy.  |                   |                                 |                       |
| PHAR1.2        | Apply Knowledge of Dosage Forms in Clinical Practice (Clinical Benefit)  | K/S/C             | small groups<br>lab             | MCQ                   |
|                | Select the appropriate dosage form based on patient needs, drug properties, and the therapeutic goals, considering factors like patient compliance, onset of action, and side effects.   |                   |                                 |                       |
| Routes of drug | g administration   |                   |                                 |                       |
| PHAR2.1        | Understand the Different Routes of Drug Administration and Their Characteristics.  | k/S/C             | Small groups<br>lab             | MCQ                   |
|                | Learn about the various routes of drug administration (e.g., oral, intravenous, intramuscular, subcutaneous, topical), their absorption mechanisms, advantages, and disadvantages.   |                   |                                 |                       |
| PHAR 2.2       | Apply the Appropriate Route of<br>Administration in Clinical Practice<br>(Clinical Benefit)<br>Select the most effective and   | K/S/C             | Small groups<br>lab             | MCQ                   |
|                | appropriate route of drug administration based on the drug's properties, the patient's condition, and therapeutic goals to ensure  |                   |                                 |                       |

|                | optimal drug delivery and minimize adverse effects  |                   |                                 |                       |  |  |
|----------------|---|-------------------|---------------------------------|-----------------------|--|--|
| Number         | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |  |  |
| Calculation of | Calculation of pharmacokinetic parameters   |                   |                                 |                       |  |  |
| PHAR 3.1       | Understand the Key Pharmacokinetic Parameters and Their Calculation.  | k/S/C             | Small groups<br>lab             | MCQ                   |  |  |
|                | Learn about the key pharmacokinetic parameters (e.g., half-life, clearance, volume of distribution, and bioavailability) and how to calculate them using drug concentration-time data.  |                   |                                 |                       |  |  |
| PHAR 3.2       | Apply Pharmacokinetic Calculations in Clinical Practice (Clinical Benefit)  | K/S/C             | Small groups<br>lab             | MCQ                   |  |  |
|                | Use pharmacokinetic parameters to optimize drug dosing, adjust for patient-specific factors (e.g., renal or hepatic impairment), and ensure therapeutic drug levels while minimizing toxicity.  |                   |                                 |                       |  |  |
| Prescription-o | order writing   |                   |                                 |                       |  |  |
| PHAR 4.1       | Understand the Components and Legal Requirements of a Prescription.  Learn about the essential components of a prescription (e.g., patient information, drug name, dosage, frequency, duration) and the legal requirements to ensure safe and accurate prescribing. | k/S/C             | Small groups<br>lab             | MCQ                   |  |  |
| PHAR 4.2       | Apply Proper Prescription Writing in Clinical Practice (Clinical Benefit)   | K/S/C             | Small groups<br>lab             | MCQ                   |  |  |
|                | Write clear, accurate prescriptions that follow legal and clinical guidelines, considering factors like   |                   |                                 |                       |  |  |

|                              | drug interactions, patient conditions, and cost- effectiveness to ensure patient safety and optimal therapeutic outcomes  | Domain  | Teaching            | Assessment |
|------------------------------|---|---------|---------------------|------------|
| Number                       | Learning Objective  | K/S/A/C | Learning<br>Methods | Methods    |
| Drug-induced                 | discoloration of urine  |         |                     |            |
| PHAR 5.1                     | Understand the Mechanisms and<br>Causes of Drug-Induced Urine<br>Discoloration.   | k/S/C   | Small groups<br>lab | MCQ        |
|                              | Learn about the various drugs (e.g., rifampin, phenazopyridine, levodopa) that can cause changes in urine color, and understand the underlying pharmacological mechanisms behind these effects.   |         |                     |            |
| PHAR                         | Identify and Manage Drug-<br>Induced Urine Discoloration in   | K/S/C   | Small groups lab    | MCQ        |
| 5.2                          | Clinical Practice (Clinical Benefit) Recognize the clinical significance of drug-induced urine discoloration, differentiate it from pathological causes, and provide patient education to alleviate concerns while managing the underlying condition or adjusting treatment if necessary. |         |                     |            |
| Drug discover evaluation and | y and development; toxicity<br>I clinical trials  | l       |                     |            |
| PHAR 6.1                     | Understand the Drug Discovery and Development Process   | K/S/C   | Small groups<br>lab | MCQ        |
|                              | Learn the stages of drug discovery<br>and development, from preclinical<br>research, lead compound<br>identification, and optimization, to<br>clinical trials and regulatory<br>approval.   |         |                     |            |
| PHAR 6.2                     | Apply Knowledge of Toxicity Evaluation and Clinical Trials in Drug Development (Clinical Benefit)   | K/S/C   | Small groups<br>lab | MCQ        |

|                | Understand the importance of toxicity evaluation and preclinical studies to ensure drug safety, and learn how clinical trials are designed and conducted to assess drug efficacy and safety, ultimately benefiting patient care and regulatory compliance.            | Domain  | Teaching            | Assessment |
|----------------|---|---------|---------------------|------------|
| Number         | Learning Objective  | K/S/A/C | Learning<br>Methods | Methods    |
| Pharmaceutica  | al dosage forms   |         |                     |            |
| PHAR1.1        | Understand the Types, Characteristics, and Functions of Pharmaceutical Dosage Forms.  Learn about various dosage forms (e.g., tablets, capsules, injections, topical formulations), their design, and how they affect drug absorption, distribution, and efficacy.    | k/S/C   | small groups<br>lab | MCQ        |
| PHAR1.2        | Apply Knowledge of Dosage Forms in Clinical Practice (Clinical Benefit)  Select the appropriate dosage form based on patient needs, drug properties, and the therapeutic goals, considering factors like patient compliance, onset of action, and side effects.       | K/S/C   | small groups<br>lab | MCQ        |
| Routes of drug | g administration  |         |                     |            |
| PHAR2.1        | Understand the Different Routes of Drug Administration and Their Characteristics.  Learn about the various routes of drug administration (e.g., oral, intravenous, intramuscular, subcutaneous, topical), their absorption mechanisms, advantages, and disadvantages. | k/S/C   | Small groups<br>lab | MCQ        |
| PHAR 2.2       | Apply the Appropriate Route of<br>Administration in Clinical Practice<br>(Clinical Benefit)   | K/S/C   | Small groups<br>lab | MCQ        |

|                | Select the most effective and appropriate route of drug administration based on the drug's properties, the patient's condition, and therapeutic goals to ensure optimal drug delivery and minimize adverse effects  |                   |                           |                       |
|----------------|---|-------------------|---------------------------|-----------------------|
| Number         | Learning Objective  | Domain<br>K/S/A/C | Teaching Learning Methods | Assessment<br>Methods |
| Calculation of | pharmacokinetic parameters  |                   |                           |                       |
| PHAR 3.1       | Understand the Key Pharmacokinetic Parameters and Their Calculation.  Learn about the key pharmacokinetic parameters (e.g., half-life, clearance, volume of distribution, and bioavailability) and how to calculate them using                                      | k/S/C             | Small groups<br>lab       | MCQ                   |
| PHAR 3.2       | Apply Pharmacokinetic   | K/S/C             | Small groups              | MCQ                   |
|                | Calculations in Clinical Practice (Clinical Benefit)  Use pharmacokinetic parameters to optimize drug dosing, adjust for patient-specific factors (e.g., renal or hepatic impairment), and ensure therapeutic drug levels while minimizing toxicity.                |                   | lab                       |                       |
| Prescription-o | rder writing  |                   |                           |                       |
| PHAR 4.1       | Understand the Components and Legal Requirements of a Prescription.  Learn about the essential components of a prescription (e.g., patient information, drug name, dosage, frequency, duration) and the legal requirements to ensure safe and accurate prescribing. | k/S/C             | Small groups<br>lab       | MCQ                   |

| PHAR 4.2       | Apply Proper Prescription Writing in Clinical Practice (Clinical Benefit)  Write clear, accurate prescriptions that follow legal and clinical guidelines, considering factors like drug interactions, patient conditions, and cost-effectiveness to ensure patient safety and optimal therapeutic outcomes  | K/S/C             | Small groups<br>lab             | MCQ                   |
|----------------|---|-------------------|---------------------------------|-----------------------|
| Number         | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
| Drug-induced   | discoloration of urine  |                   |                                 |                       |
| PHAR 5.1       | Understand the Mechanisms and Causes of Drug-Induced Urine Discoloration.  Learn about the various drugs (e.g., rifampin, phenazopyridine, levodopa) that can cause changes   | k/S/C             | Small groups<br>lab             | MCQ                   |
|                | in urine color, and understand the underlying pharmacological mechanisms behind these effects.  |                   |                                 |                       |
| PHAR<br>5.2    | Identify and Manage Drug-Induced Urine Discoloration in Clinical Practice (Clinical Benefit) Recognize the clinical significance of drug-induced urine discoloration, differentiate it from pathological causes, and provide patient education to alleviate concerns while managing the underlying condition or adjusting treatment if necessary. | K/S/C             | Small groups<br>lab             | MCQ                   |
| evaluation and | y and development; toxicity<br>d clinical trials  |                   |                                 |                       |
| PHAR 6.1       | Understand the Drug Discovery and Development Process  Learn the stages of drug discovery and development, from preclinical research, lead compound identification, and optimization, to  | K/S/C             | Small groups<br>lab             | MCQ                   |

|          | clinical trials and regulatory approval.  |       |                  |     |
|----------|---|-------|------------------|-----|
| PHAR 6.2 | Apply Knowledge of Toxicity Evaluation and Clinical Trials in Drug Development (Clinical Benefit)  Understand the importance of toxicity evaluation and preclinical studies to ensure drug safety, and learn how clinical trials are designed and conducted to assess drug efficacy and safety, ultimately benefiting patient care and regulatory compliance. | K/S/C | Small groups lab | MCQ |

# **Pathology**



**Third Grade** 

#### **Academic Program Description**

This academic program description **summarizes** the course's most essential qualities and the learning objectives that the student is expected to attain, indicating whether he or she made advantage of all of the resources that are accessible. It includes a description of each course in the program of study.

| 1) Educational Establishment                  | University of AL-Ameed  |
|---|---|
| 2) Scientific Department                      | College of medicine   |
| 3) Name of the Professional Academic Program. | Modified Traditional Curriculum   |
| 4) Final Graduation Certificate               | M.B.ChB   |
|   | Availability of relevant scientific research in<br>the field of specialization          |
|   | Access to global electronic networks  |
|   | Access to traditional and digital libraries   |
| 5) Educational system: Annual/courses/other   | Teaching aids such as data show and<br>PowerPoint presentations                         |
|   | Availability of equipped classrooms   |
|   | • Use of free online communication platforms (e.g., Free Conference Call)               |
| 6) Approved accreditation program             | Iraqi National Guideline on Standards for<br>Established and Accrediting Medical School |
| 7) Other external factors                     | Weather Conditions, National or Religious<br>Holidays, Public Health Emergencies        |
| 8) Date the description was written           | 15\9\2024   |

#### 9) Objectives of the academic program:

- 1. To provide students with an in-depth understanding of the pathological basis of diseases affecting the major body systems including respiratory, gastrointestinal, hepatobiliary, renal, endocrine, musculoskeletal, nervous, and reproductive systems.
- 2. To enable students to recognize and describe the gross and microscopic features of common pathological conditions within these systems.
- 3. To integrate systemic pathology knowledge with prior foundational concepts learned in general and cardiovascular pathology.

- 4. To enhance students' clinical reasoning by correlating pathological findings with signs, symptoms, and diagnostic tools.
- 5. To prepare students for clinical rotations by strengthening their diagnostic mindset and medical terminology through exposure to real-world case discussions.
- 6. To support the development of lifelong learning and ethical medical practice aligned with the mission of the College of Medicine at the University of Al-Ameed.
- 10. The most reliable resources for program information are:

Robbins basic pathology

Muris textbook of pathology

Rosai and Ackerman's Surgical Pathology

USMLE step1 lecture notes 2021: pathology

Pathology out lines .com

## Pathology \ Grade 3

Code: PATH 303 5 Credits

| Number              | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods              |  |  |  |  |
|---------------------|--|-------------------|---------------------------------|------------------------------------|--|--|--|--|
| Introduction        | Introduction and cell injury   |                   |                                 |                                    |  |  |  |  |
| PATH<br>1.1<br>PATH | By the end of this lecture, students will be able to define pathology, explain its goals, and differentiate between various branches of pathology with accurate examples  Students will demonstrate the ability to match | K                 | Large group lecture             | MCQ & short answer Questions MCQ & |  |  |  |  |
| 1.2                 | appropriate pathological techniques (e.g., light microscopy, immunohistochemistry) with relevant diagnostic applications during labbased scenarios   |                   | group<br>lecture                | short<br>answer<br>Questions       |  |  |  |  |
| PATH<br>1.3         | Given histopathological data, students will<br>analyze patterns of reversible and irreversible<br>cell injury, identifying key features such as<br>cellular swelling and nuclear changes                                 | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions       |  |  |  |  |
| PATH<br>1.4         | Students will evaluate multiple causes of cell injury—including hypoxia, toxins, and immune reactions—by comparing their pathophysiological mechanisms and clinical impact.  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions       |  |  |  |  |
| PATH<br>1.5         | Students will construct a complete summary table distinguishing between types of necrosis (e.g., coagulative, liquefactive, caseous), including morphology, causes, and affected tissues                                 | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions       |  |  |  |  |
| Cell injury         |  |                   |                                 |                                    |  |  |  |  |
| PATH<br>2.1         | By the end of this lecture, students will be able to describe the mechanisms and morphological features of apoptosis and explain how it differs from necrosis.   | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions       |  |  |  |  |
| PATH<br>2.2         | Students will identify histological evidence of apoptosis, fatty change, and calcification in tissue sections using specific visual and cellular criteria  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions       |  |  |  |  |
| PATH 2.3            | Students will analyze the types of cellular adaptation—hypertrophy, hyperplasia, atrophy, and metaplasia—by comparing their causes, mechanisms, and examples.  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions       |  |  |  |  |
| PATH<br>2.4         | Students will evaluate the clinical significance of intracellular accumulations (e.g., lipofuscin, hemosiderin, bilirubin) in liver and cardiac pathology contexts.  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions       |  |  |  |  |

| Number      | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|-------------|--|-------------------|---------------------------------|---------------------------------------|
| PATH 2.5    | Students will construct a concept map summarizing subcellular responses to injury (autophagy, mitochondrial changes, cytoskeletal abnormalities) and their pathological relevance        | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| Inflammati  | on part I  |                   |                                 |                                       |
| PATH<br>3.1 | By the end of this lecture, students will be able to recall the key cardinal signs of inflammation and list at least four causes of acute inflammation.                                  |                   | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH<br>3.2 | Students will be able to explain the stepwise vascular and cellular responses involved in acute inflammation, including changes in flow, permeability, and leukocyte migration.          | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| PATH<br>3.3 | Given a case scenario, students will identify whether inflammation is acute or chronic based on clinical signs, cellular components, and histologic features.                            | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH<br>3.4 | Students will analyze the phases of leukocyte recruitment and identify specific molecules involved in rolling, adhesion, and transmigration processes.                                   | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 3.5    | Students will evaluate the roles of various chemical mediators (e.g., histamine, prostaglandins, cytokines) in modulating vascular reactions and leukocyte behavior in inflammation.     | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| Inflammati  | on part II   |                   |                                 |                                       |
| PATH<br>4.1 | By the end of this lecture, students will be able to list four morphologic patterns of acute inflammation and describe at least one example of each.                                     | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| PATH<br>4.2 | Students will explain the beneficial and harmful effects of acute inflammation, and summarize the three possible outcomes following an inflammatory episode.                             | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| PATH 4.3    | Given histological images, students will identify key cellular features that distinguish acute from chronic inflammation, such as the presence of mononuclear infiltrates and fibrosis.  |                   | Large group<br>ecture           | MCQ &<br>short<br>answer<br>Questions |
| PATH<br>4.4 | Students will analyze the roles of macrophages, lymphocytes, plasma cells, and eosinophils in chronic inflammation and describe how their interactions sustain the inflammatory process. |                   | Large group<br>ecture           | MCQ & short answer Questions          |

| Number      | Learning Objective   |   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|-------------|--|---|-------------------|---------------------------------|------------------------------|
| PATH<br>4.5 | Students will evaluate the clinical relevance of chronic inflammation in diseases such as tuberculosis, atherosclerosis, and rheumatoid arthritis based on pathologic findings.    | K |                   | Large group<br>lecture          | MCQ & short answer Questions |
| Chronic in  | flammation and tissue repair   |   |                   |                                 |                              |
| PATH<br>5.1 | By the end of this lecture, students will recall at least five diseases associated with granulomatous inflammation and define the term "granuloma" with its cellular composition.  | K |                   | Large group<br>lecture          | MCQ & short answer Questions |
| PATH<br>5.2 | Students will explain the differences between foreign body and immune granulomas and describe the role of cytokines like IFN- $\gamma$ and IL-2 in their formation.                | K |                   | Large group<br>lecture          | MCQ & short answer Questions |
| PATH<br>5.3 | students will identify granulomas,<br>differentiate caseating from non-caseating<br>forms, and relate findings to diseases like<br>TB or sarcoidosis.                              | K |                   | Large group<br>lecture          | MCQ & short answer Questions |
| PATH<br>5.4 | Students will analyze systemic effects of inflammation, such as fever, leukocytosis, and acute phase protein elevation, and explain their underlying cytokine-mediated mechanisms. | K |                   | Large group<br>lecture          | MCQ & short answer Questions |
| PATH<br>5.5 | Students will evaluate the differences<br>between regeneration and scar formation in<br>tissue repair, including conditions favoring<br>primary vs. secondary intention healing.   | K |                   | Large group<br>lecture          | MCQ & short answer Questions |
| Hemodyna    | mic disorders I  |   |                   |                                 |                              |
| PATH<br>6.1 | By the end of this lecture, students will list<br>the seven major hemodynamic disorders<br>and recall the core definitions of hyperemia,<br>congestion, edema, and thrombosis.     | K |                   | Large group<br>ecture           | MCQ & short answer Questions |
| PATH<br>6.2 | Students will describe the mechanisms underlying edema formation and explain the differences between transudate and exudate in the context of fluid dynamics.                      | K |                   | Large group<br>ecture           | MCQ & short answer Questions |
| PATH 6.3    | Given clinical vignettes, students will distinguish between causes and morphologic findings of acute vs chronic pulmonary and hepatic congestion.                                  | K | 1                 | Large group<br>ecture           | MCQ & short answer Questions |
| PATH<br>6.4 | Students will analyze Virchow's triad and explain how endothelial injury, abnormal blood flow, and hypercoagulability contribute to thrombogenesis.                                | K |                   | Large group<br>ecture           | MCQ & short answer Questions |

| Number      | Learning Objective   |   | Domain<br>K/S/A/O | 7 | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|-------------|--|---|-------------------|---|---------------------------------|---------------------------------------|
| PATH<br>6.5 | Students will evaluate the differences between arterial and venous thrombi, including morphology, clinical significance, and treatment approaches.                             | K |                   |   | ge group<br>ture                | MCQ &<br>short<br>answer<br>Questions |
| Hemodyna    | amic disorders 2   |   |                   |   |                                 |                                       |
| PATH 7.1    | By the end of this lecture, students will be able to define hemorrhage, embolism, infarction, and shock, and classify at least two subtypes or causes for each.                | K |                   |   | ge group<br>ture                | MCQ & short answer Questions          |
| PATH<br>7.2 | Students will explain the differences between red and white infarcts, including underlying mechanisms and typical affected organs.   | K |                   |   | ge group<br>ture                | MCQ & short answer Questions          |
| PATH 7.3    | Given clinical symptoms and images, students will identify the type of shock (e.g., cardiogenic, hypovolemic, septic) and suggest the most likely underlying cause.            | K |                   |   | ge group<br>ture                | MCQ & short answer Questions          |
| PATH<br>7.4 | Students will analyze the pathophysiological cascade of septic shock, tracing the role of microbial products, cytokine release, and endothelial activation.                    | K |                   |   | ge group<br>ture                | MCQ & short answer Questions          |
| PATH<br>7.5 | Students will evaluate the factors that influence infarct development—such as rate of occlusion, vascular anatomy, and tissue susceptibility—and assess clinical implications. | K |                   |   | ge group<br>ture                | MCQ & short answer Questions          |
| Genetic Di  | sorders I  |   |                   |   |                                 |                                       |
| PATH<br>8.1 | By the end of this lecture, students will be able to list the major types of genetic mutations and define basic terms such as allele, genotype, phenotype, and locus.          | K |                   |   | ge group<br>ture                | MCQ & short answer Questions          |
| PATH<br>8.2 | Students will explain the differences between autosomal dominant, autosomal recessive, and X-linked inheritance patterns with appropriate clinical examples.                   | K |                   |   | ge group<br>ture                | MCQ &<br>short<br>answer<br>Questions |
| PATH<br>8.3 | Students will classify selected genetic diseases such as Marfan syndrome, cystic fibrosis, and thalassemia according to their inheritance patterns and molecular mechanisms.   | K |                   |   | ge group<br>ture                | MCQ & short answer Questions          |
| PATH<br>8.4 | Students will analyze the pathogenesis of diseases caused by frame-shift mutations, trinucleotide repeat expansions, and genomic imprinting effects.                           | K |                   |   | ge group<br>ture                | MCQ & short answer Questions          |

| Number       | Learning Objective  |   | Domai<br>K/S/A | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|--------------|---|---|----------------|---------------------------------|---------------------------------------|
| PATH<br>8.5  | Students will analyze the pathogenesis of diseases caused by frame-shift mutations, trinucleotide repeat expansions, and genomic imprinting effects.  | K |                | arge group                      | MCQ & short answer Questions          |
| Genetic Di   | sorders 2   |   |                |                                 |                                       |
| PATH<br>9.1  | By the end of this lecture, students will list major chromosomal abnormalities (e.g., trisomies, deletions, inversions) and identify related syndromes such as Down, Turner, and Klinefelter. | K |                | arge group<br>cture             | MCQ &<br>short<br>answer<br>Questions |
| PATH<br>9.2  | Students will explain the mechanisms of nondisjunction and anaphase lag and how they contribute to aneuploidy and mosaicism.  | K |                | arge group<br>cture             | MCQ &<br>short<br>answer<br>Questions |
| PATH<br>9.3  | students will classify the disorder and link it to the correct chromosomal change (e.g., 47,XXY → Klinefelter syndrome).  | K |                | arge group<br>cture             | MCQ & short answer Questions          |
| PATH 9.4     | Students will analyze differences between se chromosome disorders and autosomal abnormalities, focusing on clinical features, inheritance patterns, and hormonal impact.                      | X | K              | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 9.5     | Students will evaluate the impact of genomic imprinting disorders (e.g., Angelman vs Prader-Willi) based on parental origin, gene silencing, and clinical manifestations.                     | С | K              | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| Immunopa     | thology I   |   |                |                                 |                                       |
| PATH<br>10.1 | By the end of this lecture, students will be all to list the main components of innate and adaptive immunity and define the four types hypersensitivity reactions.                            |   | K              | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 10.2    | Students will explain the mechanisms of Typ I–IV hypersensitivity reactions, including immune cells, mediators, and timelines involved in each type   | e | K              | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH<br>10.3 | Given clinical case scenarios, students will identify the type of hypersensitivity reaction based on symptoms, timing, and laboratory findings.   |   | K              | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH<br>10.4 | Students will analyze the pathogenesis and tissue responses in diseases like SLE, myasthenia gravis, and contact dermatitis, linking them to hypersensitivity types.                          |   | K              | Large<br>group<br>lecture       | MCQ & short answer Questions          |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|--------------|---|-------------------|---------------------------------|---------------------------------------|
| PATH<br>10.5 | Students will evaluate the role of cytokines and immune mediators in both protective immunity and immune-mediated tissue damage.  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| Immunopatl   | hology II   |                   |                                 |                                       |
| PATH<br>11.1 | By the end of this lecture, students will recall<br>the classification of immune deficiencies and<br>list examples of primary and secondary<br>immunodeficiency syndromes.            | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH<br>11.2 | Students will explain the immunologic mechanisms involved in transplant rejection (hyperacute, acute, chronic, GVHD) and relate them to hypersensitivity types.                       | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| PATH 11.3    | Given a clinical case, students will identify<br>the type of autoimmune disease (organ-<br>specific vs systemic) and match it with the<br>underlying immune response mechanism.       | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 11.4    | Students will analyze the pathogenesis and immune features of AIDS-related neoplasms (Kaposi sarcoma, Non-Hodgkin lymphoma, cervical cancer) based on viral associations              | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| PATH 11.5    | Students will evaluate histological techniques used in diagnosing amyloidosis, including Congo red staining and birefringence under polarized light.                                  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| Neoplasia1   |   |                   |                                 |                                       |
| PATH 12.1    | By the end of this lecture, students will be able to list the major categories of tumors (benign, malignant, mixed) and correctly apply the terminology used in tumor classification. | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| PATH 12.2    | Students will describe the key histological and gross differences between benign and malignant neoplasms, including criteria such as differentiation, invasion, and metastasis        | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 12.3    | Given clinical cases and microscopic slides,<br>students will identify tumor types (e.g.,<br>adenoma vs. carcinoma) and assign<br>appropriate benign or malignant classification      | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 12.4    | Students will analyze tumor morphology including features like anaplasia, nuclear atypia, pleomorphism, and abnormal mitoses to differentiate grades of malignancy                    | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |

| Number      | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|-------------|---|-------------------|---------------------------------|------------------------------|
| PATH 12.5   | Students will evaluate patterns of tumor spread—local invasion, lymphatic, hematogenous, and seeding—to predict potential behavior and prognosis  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| Neoplasia2  |   |                   |                                 |                              |
| PATH 13.1   | By the end of this lecture, students will be able to list major categories of carcinogenic agents, including chemical, physical, microbial, and viral causes of cancer                                | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| PATH 13.2   | Students will explain the roles of environmental factors (e.g., smoking, alcohol, infections) and inherited conditions in cancer development, using key examples like HPV, H. pylori, and aflatoxins. | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| PATH 13.3   | Given clinical scenarios, students will associate specific carcinogens with their corresponding cancers (e.g., EBV with Burkitt lymphoma, UV light with melanoma).                                    | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| PATH 13.4   | Students will analyze the molecular pathways of carcinogenesis by identifying mutations in oncogenes (e.g., RAS, MYC), tumor suppressor genes, and genes regulating apoptosis or DNA repair           | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| PATH 13.5   | Students will evaluate the impact of epigenetic alterations and tumor heterogeneity on cancer progression, prognosis, and response to therapy   | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| Neoplasia 3 |   |                   |                                 |                              |
| PATH 14.1   | By the end of this lecture, students will list key tumor suppressor genes (e.g., RB, TP53, APC) and describe their normal roles in regulating cell cycle and apoptosis.                               | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| PATH 14.2   | Students will explain molecular mechanisms of cancer progression, including evasion of apoptosis, telomere maintenance, angiogenesis, invasion, and metastasis.                                       | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| PATH 14.3   | Given tumor characteristics, students will apply TNM staging and tumor grading criteria to classify the neoplasm's clinical severity and treatment implication  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |
| Neoplasia 4 |   |                   |                                 |                              |
| PATH 15.1   | By the end of this lecture, students will be able to define cachexia, list common paraneoplastic syndromes, and identify examples of associated tumor types.  | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|--------------|---|-------------------|---------------------------------|---------------------------------------|
| PATH 15.2    | Students will describe the pathophysiologic mechanisms behind paraneoplastic endocrine syndromes and differentiate them from normal hormone-producing tumors.                       | К                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 15.3    | Students will match diagnostic biopsy techniques (FNA, core, endoscopic) to clinical scenarios, and determine their appropriate usage and limitations.                              | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 15.4    | Students will analyze diagnostic challenges using cytology, histochemistry, and immunohistochemistry in distinguishing poorly differentiated tumors.                                | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| Environment  | al and Nutritional Diseases   |                   |                                 |                                       |
| PATH 16.1    | By the end of this lecture, students will list major environmental toxins (e.g., lead, mercury, CO), their sources, and outline associated clinical syndromes.                      | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 16.2    | Students will explain the systemic health effects of air pollution, tobacco, alcohol, and radiation, emphasizing their mechanisms of toxicity and disease outcomes.                 | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| PATH 16.3    | Given a clinical scenario, students will identify the most likely environmental or occupational exposure causing the patient's symptoms (e.g., anemia, neuropathy, fibrosis).       | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 16.4    | Students will analyze the differences between<br>marasmus and kwashiorkor based on<br>pathophysiology, clinical signs, and laboratory<br>features                                   | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| PATH 16.5    | Students will evaluate the mechanisms and public health importance of vitamin deficiencies (A, D) and their systemic and disease-specific consequences.                             | K                 | Large<br>group<br>lecture       | MCQ &<br>short<br>answer<br>Questions |
| Cardiovascul | lar System Pathology1   |                   |                                 |                                       |
| PATH 17.1    | By the end of this lecture, students will list major vascular pathologies such as atherosclerosis, aneurysms, arteriolosclerosis, and common types of vasculitis with key examples. | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |
| PATH 17.2    | Students will explain the pathogenesis, risk factors, and complications of atherosclerosis, including how it contributes to myocardial infarction and stroke                        | K                 | Large<br>group<br>lecture       | MCQ & short answer Questions          |

| Number                     | Learning Objective   |   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|----------------------------|--|---|-------------------|---------------------------------|------------------------------|
| PATH 17.3                  | Given histological or clinical data, students will differentiate between types of arteriosclerosis (hyaline vs hyperplastic) and identify associated conditions like hypertension and diabetes.                      | K | gr                | arge<br>coup<br>cture           | MCQ & short answer Questions |
| PATH<br>17.4               | Students will analyze features distinguishing stable from vulnerable atherosclerotic plaques and assess their potential for rupture and thrombosis.  | K | gr                | arge<br>coup<br>cture           | MCQ & short answer Questions |
| PATH<br>17.5               | Students will evaluate clinical presentations and imaging to differentiate between true and false aneurysms and between types of aortic dissection (type A vs type B).   | K | gr                | arge<br>coup<br>cture           | MCQ & short answer Questions |
| Cardiovascu<br>Pathology 2 |  |   |                   |                                 |                              |
| PATH 18.1                  | By the end of this lecture, students will list major venous disorders (e.g., varicose veins, thrombophlebitis), lymphatic conditions (e.g., lymphedema), and congenital heart defects (e.g., VSD, ASD, TOF).         | K | gr                | arge<br>oup<br>cture            | MCQ & short answer Questions |
| PATH<br>18.2               | Students will explain the pathophysiology of left-sided and right-sided heart failure, including morphological and clinical consequences in lungs, liver, and peripheral tissues.                                    | K | gr                | arge<br>oup<br>cture            | MCQ & short answer Questions |
| PATH<br>18.3               | Given clinical symptoms or gross pathology images, students will classify congenital heart defects based on shunt direction (L→R, R→L) and predict associated complications like cyanosis or pulmonary hypertension. | K | gr                | arge<br>coup<br>cture           | MCQ & short answer Questions |
| PATH<br>18.4               | Students will analyze differences between benign, intermediate, and malignant vascular tumors (e.g., hemangioma vs Kaposi sarcoma vs angiosarcoma) using histological and clinical criteria.                         | K | gr                | arge<br>coup<br>cture           | MCQ & short answer Questions |
| PATH<br>18.5               | Students will evaluate the risk factors and consequences of varicose veins, esophageal varices, and hemorrhoids in the context of venous stasis and portal hypertension.   | K | gr                | arge<br>coup<br>cture           | MCQ & short answer Questions |

### **Practical**

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |  |  |  |  |
|--------------|---|-------------------|---------------------------------|-----------------------|--|--|--|--|
| Introduction | Introduction to pathology   |                   |                                 |                       |  |  |  |  |
| PATH 1.1     | A-Define the scope of pathology and its role in diagnosing disease through the examination of tissues, organs, and bodily fluids  B- Identify the gross anatomical features of the stomach  | K/S               | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| PATH 1.2     | A-Describe the tissue processing steps for histological examination B-Compare chemical fixation and frozen section techniques   | K/S               | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| Cell injury  |   |                   |                                 |                       |  |  |  |  |
| PATH 2.1     | A-Differentiate between reversible and irreversible cell injury by identifying key microscopic changes.  B-Compare the morphological features of necrosis and apoptosis  C-Classify the five major types of necrosis                    | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| PATH 2.2     | A-Describe the gross and microscopic progression of myocardial infarction, B-Recognize the pathologic hallmarks of gangrenous necrosis C-Explain the mechanisms and diagnostic features of fat necrosis                                 | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| Cell injury  |   |                   |                                 |                       |  |  |  |  |
| PATH 3.1     | A-Differentiate between apoptosis and necrosis B-Classify and describe the four major cellular adaptations C-Identify intracellular accumulations and their pathologic implications   | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| PATH 3.2     | A-Explain the mechanisms and consequences of pathologic calcification B-Correlate gross and microscopic findings in common diseases Liver steatosis Aortic stenosis Bronchial metaplasia C- Recognize the role of pigments in diagnosis | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |  |  |  |  |
|--------------|---|-------------------|---------------------------------|-----------------------|--|--|--|--|
| Inflammation |   |                   |                                 |                       |  |  |  |  |
| PATH 4.1     | A-Define acute and chronic inflammation B-Describe the vascular and cellular events in acute inflammation, C-Identify the cardinal signs of inflammation  | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| PATH 4.2     | A- Analyze acute appendicitis as a model of acute inflammation, focusing on: Gross findings, Microscopic features B-Differentiate suppurative vs. fibrinous exudates in acute inflammation C-Explain the transition to chronic inflammation | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| ACUTE INF    | FLAMMATION  |                   |                                 |                       |  |  |  |  |
| PATH 5.1     | A-Differentiate the morphologic patterns of acute inflammation B-Describe the gross and microscopic features of acute appendicitis, C-Explain the cellular and tissue changes in chronic inflammation,                                      | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| PATH 5.1     | A-Identify the role of immune cells in chronic inflammation B-Correlate chronic inflammation with systemic diseases, such as:   | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| Chronic infl | ammation and tissue repair  |                   |                                 |                       |  |  |  |  |
| PATH 6.1     | A-Define granulomatous inflammation and describe its key microscopic features B-Differentiate immune vs. foreign body granulomas by etiology and histology C-Explain the stages of tissue repair, comparing                                 | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| PATH 6.2     | A- Analyze acute appendicitis as a model of acute inflammation, focusing on: Gross findings, Microscopic features B-Differentiate suppurative vs. fibrinous exudates in acute inflammation C-Explain the transition to chronic inflammation | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |
| Hemodynam    | nic disorders   |                   |                                 |                       |  |  |  |  |
| PATH 7.1     | A-Differentiate between hyperemia (active) and congestion (passive), identifying Gross appearance, Microscopic features B-Describe the pathologic changes in chronic venous congestion C-Explain Virchow's triad and its role in thrombosis | K                 | Small<br>group<br>lecture       | CIVA                  |  |  |  |  |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|---|-------------------|---------------------------------|-----------------------|
| PATH 7.2     | A-Identify thrombus vs. postmortem clot using: Lines of Zahn Gross/microscopic: B-Classify thrombi by location and associated diseases: C-Correlate edema types with underlying pathology   | K                 | Small<br>group<br>lecture       | CIVA                  |
| Hemodynam    | nic disorders   |                   |                                 |                       |
| PATH 8.1     | A-classify hemorrhagic manifestations based on their clinical and pathological features:  B-Explain the pathogenesis and consequences of embolism, including:  C-Differentiate red vs. white infarcts by etiology and morphology:                 | K                 | Small<br>group<br>lecture       | CIVA                  |
| PATH 8.1     | A-Describe the gross and microscopic features of common infarcts B-Identify the types and mechanisms of shock, correlating with clinical examples C-Recognize microvascular bleeding disorders (e.g., thrombocytopenia) by their pathologic signs | K                 | Small<br>group<br>lecture       | CIVA                  |
| Genetics     |   |                   |                                 |                       |
| PATH 9.1     | A-Interpret pedigree charts to identify inheritance patterns of genetic disorders: B-Describe chromosomal abnormalities and their nomenclature: -C-Recognize common genetic syndromes by karyotype and clinical features:                         | K                 | Small<br>group<br>lecture       | CIVA                  |
| PATH 9.2     | A-Explain meiotic errors leading to chromosomal disorders B-Differentiate types of structural chromosomal rearrangements: C-Apply karyotyping skills to diagnose genetic conditions:  | K                 | Small<br>group<br>lecture       | CIVA                  |
| Neoplasia    |   |                   |                                 |                       |
| PATH<br>10.1 | -A-Differentiate between benign and malignant neoplasms based on: Gross features: Microscopic characteristics, B-Classify benign tumors by tissue origin and morphology: C-Identify malignant tumors by nomenclature and histologic patterns:     | K                 | Small<br>group<br>lecture       | CIVA                  |

| Number                  | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|-------------------------|--|-------------------|---------------------------------|-----------------------|
| PATH<br>10.2            | - A-Describe the gross and microscopic features of common neoplasms: B-Explain the concept of teratomas and their pathologic features: C-Recognize key diagnostic criteria for malignancy                          | K                 | Small<br>group<br>lecture       | CIVA                  |
| Neoplasia               |  |                   |                                 |                       |
| PATH 11.1               | A-Differentiate between benign and malignant neoplasms based on: B-Classify tumors by degree of differentiation C- Identify microscopic features of malignancy   | K                 | Small<br>group<br>lecture       | CIVA                  |
| PATH 11.2               | A-Describe gross and microscopic patterns of invasion: B-Explain the pathways of metastasis: -Correlate histologic grading with prognosis  | K                 | Small<br>group<br>lecture       | CIVA                  |
| Neoplasia               |  |                   |                                 |                       |
| PATH 12.1               | A-Define tumor grading and staging, emphasizing their clinical significance: -B-Compare grading systems for common cancers: - C- Identify microscopic features used in grading                                     | K                 | Small<br>group<br>lecture       | CIVA                  |
| PATH 12.2               | A-Describe the TNM staging system and its components:  -B-Correlate histologic grade with prognosis and treatment:  - C-Explain the clinical importance of stagin  | K                 | Small<br>group<br>lecture       | CIVA                  |
|                         | DRY.DIAGNOSIS  |                   |                                 |                       |
| OF CANCEL<br>PATH 13.1  | A- Describe the methods of cancer sample collection, B-Explain the role of histochemistry and immunohistochemistry (IHC) in cancer diagnosis: C- Evaluate the utility of serum tumor markers in cancer management: | K                 | Small<br>group<br>lecture       | CIVA                  |
| PATH 13.2               | -A- Apply molecular diagnostic techniques for tumor analysis: B- Correlate diagnostic findings with therapeutic decisions:   | K                 | Small<br>group<br>lecture       | CIVA                  |
| Environment<br>Diseases | tal and Nutritional  |                   |                                 |                       |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|---|-------------------|---------------------------------|-----------------------|
| PATH<br>14.1 | A-Identify the pathologic effects of air pollution on the lungs - B-Describe the toxic effects of heavy metals -Compare protein-energy malnutrition (PEM) syndromes Marasmus: Kwashiorkor Cachexia:   | K                 | Small<br>group<br>lecture       | CIVA                  |
| PATH<br>14.2 | A-Explain the pathology of vitamin deficiencies: -B-Recognize occupational diseases: C-Correlate hepatic steatosis with etiology Gross 'Microscopic   | K                 | Small<br>group<br>lecture       | CIVA                  |
| Cardiovascu  | lar System Pathology 1  |                   |                                 |                       |
| PATH<br>15.1 | A-Compare normal arterial/venous histology -B-Identify the 3 vascular layers (tunica intima/media/adventitia) and their structural differences in arteries vs. veins, - C-Explain atherosclerosis pathogenesis -D-Analyze atherosclerotic plaque morphology | K                 | Small<br>group<br>lecture       | CIVA                  |
| PATH<br>15.2 | A-Differentiate aneurysm types - B-Correlate plaque complications -C-Identify vascular aging changes  | K                 | Small<br>group<br>lecture       | CIVA                  |
| Cardiovascu  | lar System Pathology 2  |                   |                                 |                       |
| PATH<br>16.1 | -A-Differentiate hypertensive vascular changes in arterioles: -B-Classify vasculitides by vessel size and histopathology: - C-Identify microscopic features of vasculitis:  | K                 | Small<br>group<br>lecture       | CIVA                  |
| PATH<br>16.2 | -A-Describe Buerger's disease (thromboangiitis obliterans): Gross, Microscopic - B-Explain Raynaud's phenomenon: -Correlate clinical and pathologic findings:   | K                 | Small<br>group<br>lecture       | CIVA                  |

# parasitology



# **Third Grade**

#### Academic program discretion

This academic program description provides a brief overview of the key features of the program and the expected learning outcomes for the student, demonstrating whether the student has made the most of the available opportunities. It is accompanied by a description of each course within the program.

| Educational Establishment                  | University of Al-Ameed   |
|--|--|
| Scientific Department                      | College of Medicine  |
| Name of the Professional Academic Program. | Modified traditional curriculum  |
| Final Graduation Certificate               | M.B.Ch.B   |
| Educational system: Annual/courses/other   | Annual   |
| Approved accreditation program             | Iraqi National Guidelines on Standards for<br>Established and Accrediting Medical<br>Schools |
| Other external factors                     | WHO  |
| Date the description was written           | 2025/4/1   |

Objectives of the academic program:

Key Objectives of the PARSobiology Program for Third-Year Medical Students at Al-Ameed University College:

Understanding Parasitic Characteristics: Study the biological properties of various parasites, including protozoa, helminths, and ectoparasites, and their mechanisms of impact on the human body.

Immunology and Its Relation to Parasitology: Understand the interaction between parasites and the immune system, and how the body defends itself against parasitic infections.

Parasitic Infection Diagnosis: Learn the methods of diagnosing parasitic diseases through laboratory testing and clinical examination.

Treatment and Prevention of Parasitic Infections: Understand the appropriate treatment methods for parasitic infections, including antiparasitic medications, vaccines, and immunotherapy.

Environmental Impact on Parasites: Study the effect of environmental factors such as temperature, humidity, and sanitation on the growth and reproduction of parasites.

Ethical Aspects of Parasitological Research: Apply ethical principles in scientific and medical research, including the handling of biological samples and patient privacy.

| Albassam text of medical mycology          |
|--|
| Paniker's Textbook of Medical Parasitology |
| Mycology:                                  |
| The Medical Mycology Handbook              |
|  |
|  |

Г

## Parasitology \ Grade 3

Code: PARS 304 5Credits

| Number                 | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------------------|--|-------------------|---------------------------------|---------------------------------------|
| Classifica<br>Protozoa | ation of Medical Parasites and Morphology of   |                   |                                 |                                       |
| PARS 1                 | Identify and classify various medical protozoan parasites based on their morphological characteristics.  Analyze the differences in structure and function among protozoal species.  Compare the life cycles of different protozoa and their implications in disease transmission.  Enhance the ability to identify protozoal parasites in clinical samples, aiding in accurate diagnosis. Support the development of differential diagnosis skills when encountering protozoal infections.  Contribute to effective disease prevention strategies through a deeper understanding of protozoal morphology and lifecycle. | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Intestinal             | Protozoal Disease (Dysenteric Amoebiasis)  |                   |                                 |                                       |
| PARS 2                 | Understand the pathophysiology of dysenteric amoebiasis and its clinical manifestations.  Analyze laboratory diagnostic methods for detecting Entamoeba histolytica.  Evaluate the therapeutic options for treating amoebiasis.  Clinical Benefits:  Improve diagnostic accuracy in identifying dysenteric amoebiasis in patients with gastrointestinal symptoms.  Provide effective treatment strategies to reduce morbidity and prevent complications such as liver abscess.  Enhance understanding of public health measures to control amoebiasis transmission.  | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Intestinal             | Protozoal Disease (Giardiasis, Balantidiasis)  |                   |                                 |                                       |
| PARS 3                 | Identify the causative agents of giardiasis and balantidiasis, understanding their lifecycle and transmission.  Explore clinical symptoms and diagnostic methods for both diseases.  Discuss treatment options and the prevention strategies for giardiasis and balantidiasis.  Clinical Benefits:  Aid in the differential diagnosis of gastrointestinal diseases, specifically in endemic areas.   | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |

| Number    | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods        |
|-----------|---|-------------------|---------------------------------|------------------------------|
|           | Support effective treatment choices for parasitic intestinal infections, reducing patient discomfort and recovery time.  Improve awareness of preventive measures, including hygiene and sanitation, to curb transmission.  |                   |                                 |                              |
| Urogenita | al Protozoal Disease (Trichomoniasis)   |                   |                                 |                              |
| PARS 4    | Explain the lifecycle of Trichomonas vaginalis and its clinical significance.  Identify diagnostic techniques for detecting trichomoniasis.  Understand the pharmacological treatment and prevention of trichomoniasis.  Clinical Benefits:  Enhance diagnostic capabilities for urogenital infections, particularly in sexually active populations.  Provide effective treatments to reduce complications like infertility and pelvic inflammatory disease.  Promote awareness of sexually transmitted infections and preventive practices.  | K                 | Large group lecture             | MCQ & Short answer questions |
| Sporozoa  | l Diseases (Toxoplasmosis)  |                   |                                 |                              |
| PARS 5    | Understand the lifecycle and transmission of Toxoplasma gondii. Recognize the clinical manifestations of toxoplasmosis in both immunocompetent and immunocompromised individuals. Evaluate the diagnostic techniques and treatment protocols for toxoplasmosis. Clinical Benefits: Improve early detection and treatment in immunocompromised patients, particularly in HIV/AIDS and pregnant women. Minimize complications such as congenital defects and encephalitis through effective diagnosis and intervention. Support public health initiatives aimed at controlling zoonotic transmission from cats. | K                 | Large group lecture             | MCQ & Short answer questions |
| Sporozoa  | l Diseases (Malaria)  |                   |                                 |                              |

| Number   | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|----------|---|-------------------|---------------------------------|---------------------------------------|
| PARS 6   | Analyze the lifecycle of Plasmodium species and their role in malaria transmission.  Recognize clinical symptoms and diagnostic methods for malaria.  Discuss the latest treatment protocols and preventive measures for malaria.  Clinical Benefits:  Contribute to accurate diagnosis and timely treatment to reduce mortality and morbidity in malaria-endemic regions.  Equip healthcare providers with knowledge of anti-malarial drugs and strategies for resistance management.  Support malaria control programs by understanding environmental factors influencing transmission. | K                 | Large group lecture             | MCQ & Short answer questions          |
| Haemofla | agellates (Leishmania)  |                   |                                 |                                       |
| PARS 7   | Understand the biology and lifecycle of Leishmania parasites. Identify clinical signs of cutaneous, mucocutaneous, and visceral leishmaniasis. Analyze diagnostic and treatment options for leishmaniasis. Clinical Benefits: Enhance diagnostic skills in identifying leishmaniasis, particularly in endemic areas. Provide appropriate treatment regimens to manage different forms of leishmaniasis and prevent complications. Support global health initiatives to control vector- borne diseases.  | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Haemofla | agellates (Trypanosomiasis)   |                   |                                 |                                       |
| PARS 8   | Study the lifecycle and pathogenicity of Trypanosoma species. Identify clinical signs and diagnostic methods for both African and American trypanosomiasis. Evaluate the available therapeutic treatments and challenges in managing trypanosomiasis. Clinical Benefits: Aid in diagnosing trypanosomiasis, especially in endemic regions, improving patient outcomes. Support effective treatment approaches to prevent disease progression and severe complications. Contribute to control programs targeting vector control and treatment access.                                      | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |  |
|------------|---|-------------------|---------------------------------|---------------------------------------|--|
| Medical A  | Medical Arthropods & Scabies / Myiasis  |                   |                                 |                                       |  |
| PARS 9     | Classify and identify various medical arthropods and their role in disease transmission. Understand the lifecycle and clinical presentation of scabies and myiasis. Evaluate treatment strategies and preventive measures for arthropod-borne diseases. Clinical Benefits: Enhance diagnostic skills in identifying arthropod-related infections, including scabies and myiasis. Provide effective treatment and control measures to reduce morbidity in affected individuals. Educate patients on prevention and hygiene practices to reduce arthropod-related diseases. | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |  |
| General N  | Medical Mycology  |                   |                                 |                                       |  |
| PARS<br>10 | Understand the classification and characteristics of medically significant fungi.  Analyze the mechanisms of fungal pathogenesis and host interactions.  Study the laboratory techniques used for diagnosing fungal infections.  Clinical Benefits:  Improve diagnostic accuracy for fungal infections, including skin, systemic, and opportunistic mycoses.  Provide effective treatment regimens for fungal diseases, improving patient care.  Enhance awareness of fungal infection risks, particularly in immunocompromised individuals.                              | K                 | Large group lecture             |                                       |  |
| Mycotic 1  | Diseases (Systemic Candidiasis)   |                   |                                 |                                       |  |
| PARS<br>11 | Understand the pathophysiology and clinical presentation of systemic candidiasis. Discuss diagnostic methods and treatment strategies for systemic Candida infections. Explore preventive measures for at-risk populations. Clinical Benefits: Improve diagnosis and management of systemic candidiasis, reducing morbidity in hospitalized and immunocompromised patients. Provide insights into antifungal therapy and resistance patterns. Support infection control measures in healthcare settings to prevent outbreaks.   | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |  |

| Number               | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|----------------------|---|-------------------|---------------------------------|---------------------------------------|
| Skin Myc<br>Mycosis) | cosis (Superficial, Dermato, Subcutaneous   |                   |                                 |                                       |
| PARS<br>12           | Classify and describe the clinical manifestations of skin mycoses. Understand the diagnostic methods used to identify superficial, dermato, and subcutaneous fungal infections. Evaluate treatment options for managing various types of skin mycoses. Clinical Benefits: Enhance diagnosis and treatment of common dermatophyte infections, including athlete's foot and ringworm. Reduce the spread of fungal infections through proper treatment and preventive education. Improve patient care for chronic or resistant fungal infections.  | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Pulmona              | ry and Neuro Mycosis  |                   |                                 |                                       |
| PARS<br>13           | Analyze the pathogenesis of pulmonary and neuro mycoses caused by invasive fungi.  Identify the diagnostic techniques used for detecting pulmonary and central nervous system fungal infections.  Understand treatment options and the role of antifungal drugs in managing severe mycoses.  Clinical Benefits:  Aid in diagnosing and managing life-threatening pulmonary and neuro mycoses in immunocompromised patients.  Promote early intervention to prevent complications such as fungal meningitis or respiratory failure.  Contribute to improving patient outcomes in severe fungal infections. | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Mucor M              | ycosis  |                   |                                 |                                       |
| PARS<br>14           | Identify the causative agents of mucormycosis and their risk factors.  Discuss the clinical features and diagnostic methods for mucormycosis.  Understand treatment approaches, including surgical interventions and antifungal therapy.  Clinical Benefits:  Enhance diagnostic accuracy for mucormycosis, especially in diabetic or immunocompromised patients.  Provide insights into aggressive management strategies, including early diagnosis and debridement.   | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |

| Number                 | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------------------|---|-------------------|---------------------------------|---------------------------------------|
|                        | Reduce morbidity and mortality in patients at risk for mucormycosis.  |                   |                                 |                                       |
| Mycotoxi               | icosis  |                   |                                 |                                       |
| PARS<br>15             | Understand the sources and types of mycotoxins produced by fungi.  Analyze the clinical symptoms and effects of mycotoxin exposure.  Discuss the preventive and treatment measures for mycotoxicosis.  Clinical Benefits:  Educate healthcare professionals on the risks of mycotoxicosis and its diagnostic features.  Improve patient management by recognizing and addressing mycotoxin-related illnesses.  Support public health initiatives to reduce mycotoxin exposure.  | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Introduct              | ion to General Helminths  |                   |                                 |                                       |
| PARS<br>16             | Understand the general characteristics, classification, and lifecycle of helminths. Discuss the clinical significance of helminth infections in human health. Identify the major diagnostic methods used to detect helminth infections. Clinical Benefits: Improve diagnostic skills for helminth infections, especially in endemic regions. Support accurate and timely treatment decisions for helminth-related diseases. Enhance awareness of public health measures to control helminth infections.                 | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Classifica<br>Helminth | ation of Medical Parasites and Morphology of  |                   |                                 |                                       |
| PARS<br>17             | Classify and describe the morphology of major helminths affecting human health.  Compare and contrast the different types of helminths (nematodes, cestodes, trematodes).  Analyze the impact of helminth infections on human health.  Clinical Benefits:  Enhance diagnostic accuracy in identifying helminths from clinical specimens.  Provide guidance for treatment strategies based on the type and lifecycle of the helminth.  Contribute to the development of better control measures for helminth infections. | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Intestinal             | Nematodes (Enterobiasis, Ascariasis)  |                   |                                 |                                       |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|---|-------------------|---------------------------------|---------------------------------------|
| PARS<br>18 | Identify the causative agents of enterobiasis and ascariasis and understand their lifecycle. Recognize the clinical features and diagnostic techniques for these infections. Discuss treatment options for intestinal nematode infections. Clinical Benefits: Improve the diagnosis and management of common parasitic infections in the gastrointestinal tract. Prevent complications such as malnutrition and intestinal obstruction. Provide public health strategies to control the transmission of intestinal nematodes.   | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Intestinal | Nematodes (Trichuriasis/Trichinosis)  |                   |                                 |                                       |
| PARS<br>19 | Identify the causative agents of trichuriasis and trichinosis, and describe their life cycle and clinical impact.  Understand diagnostic methods and therapeutic approaches for these infections.  Discuss the epidemiology and preventive measures for trichuriasis and trichinosis.  Clinical Benefits:  Enhance diagnosis and treatment of less common intestinal nematodes.  Prevent complications such as rectal prolapse in trichuriasis and muscle damage in trichinosis.  Raise awareness about preventive measures, including proper cooking practices.        | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
|            | Nematodes, Hookworm (Ancylostoma duodenale, americanus)   |                   |                                 |                                       |
| PARS 20    | Describe the lifecycle of hookworms and their method of transmission.  Understand the clinical manifestations of hookworm infections, including anemia and malnutrition.  Analyze diagnostic methods and treatment options for hookworm infections.  Clinical Benefits:  Improve diagnostic accuracy for hookworm infections, particularly in endemic areas.  Provide treatment options to address anemia and nutritional deficiencies caused by hookworm.  Support health education programs focusing on prevention, particularly regarding soil-transmitted helminths | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Intestinal | Nematodes (Strongyloidiasis, Trichostrongyliosis)   |                   |                                 |                                       |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|---|-------------------|---------------------------------|---------------------------------------|
| PARS<br>21 | Identify the causative agents of strongyloidiasis and trichostrongyliosis. Understand the clinical signs, symptoms, and diagnostic approaches for these infections. Discuss treatment regimens and prevention strategies for strongyloidiasis and trichostrongyliosis. Clinical Benefits: Enhance diagnosis of strongyloidiasis, particularly in immunocompromised patients. Prevent complications such as hyperinfection syndrome in strongyloidiasis. Promote public health strategies to control transmission in areas with poor sanitation.   | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
|            | d Tissue Nematodes (Filariasis, Trichinella spiralis,   |                   |                                 |                                       |
| PARS<br>22 | Understand the lifecycle and pathophysiology of filarial infections, including Wuchereria bancrofti. Identify clinical manifestations of filariasis, including lymphatic filariasis and elephantiasis. Discuss diagnostic methods and available treatments for filarial infections. Clinical Benefits: Improve the ability to diagnose and treat lymphatic filariasis, reducing morbidity from elephantiasis. Understand the epidemiology of filarial diseases and how to manage mass drug administration programs. Reduce complications in endemic areas through early diagnosis and effective treatment d Tissue Nematodes, Onchocerca volvulus, Loa- | K                 | Large group lecture             | MCQ & Short answer questions          |
| PARS<br>23 | Describe the lifecycle and pathogenesis of Onchocerca volvulus and Loa loa. Recognize the clinical signs of onchocerciasis (river blindness) and loiasis. Discuss diagnostic techniques and treatment options for these infections. Clinical Benefits: Enhance early detection and treatment of onchocerciasis, preventing blindness. Provide effective treatment strategies to manage loiasis and reduce its long-term effects. Improve public health strategies in endemic areas to reduce vector transmission.   | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Blood an   | d Tissue Nematodes, Dracunculus medinensis  |                   |                                 |                                       |
| PARS<br>24 | Study the lifecycle of Dracunculus medinensis and its impact on human health.   | K                 | Large group lecture             | MCQ &<br>Short                        |

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                 |
|------------|---|-------------------|---------------------------------|---------------------------------------|
|            | Identify the clinical features of dracunculiasis (Guinea worm disease).  Discuss current diagnostic techniques and eradication efforts for dracunculiasis.  Clinical Benefits:  Support eradication efforts for Guinea worm disease through early identification and case management.  Promote preventive strategies such as water filtration to prevent transmission in endemic regions.  Raise awareness about the global efforts to eliminate dracunculiasis.  |                   |                                 | answer<br>questions                   |
| Intestinal | Cestodes (Taeniasis)  |                   |                                 |                                       |
| PARS<br>25 | Identify the lifecycle of Taenia solium and Taenia saginata and understand the clinical impact of taeniasis.  Discuss diagnostic methods for detecting taeniasis, including stool examination and serology.  Explore treatment options for taeniasis and associated complications such as cysticercosis.  Clinical Benefits:  Improve diagnosis and management of taeniasis, reducing morbidity.  Prevent complications such as neurocysticercosis, especially in regions where pork consumption is common.  Support public health measures to reduce transmission through proper food handling and sanitation. | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Intestinal | Cestodes (Hymenolepiasis, Diphylobothriasis)  |                   |                                 |                                       |
| PARS<br>26 | Understand the lifecycle and pathogenicity of Hymenolepis nana and Diphyllobothrium latum. Identify the clinical features and diagnostic techniques for these infections.  Discuss the treatment options for both hymenolepiasis and diphyllobothriasis.  Clinical Benefits:  Enhance the ability to diagnose and treat hymenolepiasis and diphyllobothriasis.  Reduce complications such as vitamin B12 deficiency in diphyllobothriasis.  Promote improved diagnostic accuracy and treatment in regions with high prevalence.   | K                 | Large group lecture             | MCQ &<br>Short<br>answer<br>questions |
| Tissue Co  | estodes (Echinococcosis, Hydatidosis)   |                   |                                 |                                       |

| Analyze the lifecycle of Echinococcus granulosus and its clinical presentation.  Discuss the diagnostic methods for hydatid disease  | K   | Large group   | MCO 0   |
|--|---|---|---|
| and the role of imaging in diagnosis.  Explore treatment options for hydatid cysts, including surgery and drug therapy.  Clinical Benefits:  Improve diagnosis and management of echinococcosis, reducing complications such as cyst rupture and secondary infections.  Support preventive measures, including health education on animal hygiene and safe practices in endemic regions.  Promote public health initiatives to control hydatid disease transmission.   |   | lecture   | MCQ &<br>Short<br>answer<br>questions   |
| es, Blood Flukes (Schistosomiasis/Bilharziasis)  |   |   |   |
| Understand the lifecycle of Schistosoma species and their clinical manifestations.  Recognize diagnostic methods for schistosomiasis, including serological tests and stool examination.  Discuss the available treatments for schistosomiasis and its long-term effects on organ systems.  Clinical Benefits:  Improve diagnosis and treatment of schistosomiasis, particularly in endemic regions.  Reduce morbidity associated with chronic schistosomiasis, such as liver fibrosis and bladder cancer.  Enhance control strategies to reduce transmission, including snail control and mass drug administration.  es, Liver Flukes (Fasciola hepatica), Intestinal | K   | Large group lecture   | MCQ & Short answer questions  |
| asciolopsis buski)   |   | <u>,                                      </u>  |   |
| Study the lifecycle and clinical impact of Fasciola hepatica and Fasciolopsis buski.  Identify the clinical features of fascioliasis and fasciolopsiasis, including liver inflammation and intestinal obstruction.  Discuss diagnostic techniques and treatment options for liver and intestinal flukes.  Clinical Benefits:  Improve diagnosis and treatment of fascioliasis and fasciolopsiasis in endemic regions.  Prevent complications such as cholangitis and liver cirrhosis in fascioliasis.  Promote public health education on avoiding contaminated water sources and snails   | K   | Large group lecture   | MCQ &<br>Short<br>answer<br>questions   |
|  | echinococcosis, reducing complications such as cyst rupture and secondary infections.  Support preventive measures, including health education on animal hygiene and safe practices in endemic regions.  Promote public health initiatives to control hydatid disease transmission.  es, Blood Flukes (Schistosomiasis/Bilharziasis)  Understand the lifecycle of Schistosoma species and their clinical manifestations.  Recognize diagnostic methods for schistosomiasis, including serological tests and stool examination.  Discuss the available treatments for schistosomiasis and its long-term effects on organ systems.  Clinical Benefits:  Improve diagnosis and treatment of schistosomiasis, particularly in endemic regions.  Reduce morbidity associated with chronic schistosomiasis, such as liver fibrosis and bladder cancer.  Enhance control strategies to reduce transmission, including snail control and mass drug administration.  es, Liver Flukes (Fasciola hepatica), Intestinal asciolopsis buski)  Study the lifecycle and clinical impact of Fasciola hepatica and Fasciolopsis buski.  Identify the clinical features of fascioliasis and fasciolopsiasis, including liver inflammation and intestinal obstruction.  Discuss diagnostic techniques and treatment options for liver and intestinal flukes.  Clinical Benefits:  Improve diagnosis and treatment of fascioliasis and fasciolopsiasis in endemic regions.  Prevent complications such as cholangitis and liver cirrhosis in fascioliasis.  Promote public health education on avoiding | echinococcosis, reducing complications such as cyst rupture and secondary infections.  Support preventive measures, including health education on animal hygiene and safe practices in endemic regions.  Promote public health initiatives to control hydatid disease transmission.  es, Blood Flukes (Schistosomiasis/Bilharziasis)  Understand the lifecycle of Schistosoma species and their clinical manifestations.  Recognize diagnostic methods for schistosomiasis, including serological tests and stool examination.  Discuss the available treatments for schistosomiasis and its long-term effects on organ systems.  Clinical Benefits:  Improve diagnosis and treatment of schistosomiasis, particularly in endemic regions.  Reduce morbidity associated with chronic schistosomiasis, such as liver fibrosis and bladder cancer.  Enhance control strategies to reduce transmission, including snail control and mass drug administration.  es, Liver Flukes (Fasciola hepatica), Intestinal asciolopsis buski)  Study the lifecycle and clinical impact of Fasciola hepatica and Fasciolopsis buski.  Identify the clinical features of fascioliasis and fasciolopsiasis, including liver inflammation and intestinal obstruction.  Discuss diagnostic techniques and treatment options for liver and intestinal flukes.  Clinical Benefits:  Improve diagnosis and treatment of fascioliasis and fasciolopsiasis in endemic regions.  Prevent complications such as cholangitis and liver cirrhosis in fascioliasis.  Promote public health education on avoiding contaminated water sources and snails | echinococcosis, reducing complications such as cyst rupture and secondary infections.  Support preventive measures, including health education on animal hygiene and safe practices in endemic regions.  Promote public health initiatives to control hydatid disease transmission.  es, Blood Flukes (Schistosomiasis/Bilharziasis)  Understand the lifecycle of Schistosoma species and their clinical manifestations.  Recognize diagnostic methods for schistosomiasis, including serological tests and stool examination.  Discuss the available treatments for schistosomiasis and its long-term effects on organ systems.  Clinical Benefits:  Improve diagnosis and treatment of schistosomiasis, such as liver fibrosis and bladder cancer.  Enhance control strategies to reduce transmission, including snail control and mass drug administration.  es, Liver Flukes (Fasciola hepatica), Intestinal asciolopsis buski)  Study the lifecycle and clinical impact of Fasciola hepatica and Fasciolopsis buski.  Identify the clinical features of fascioliasis and fasciolopsiasis, including liver inflammation and intestinal obstruction.  Discuss diagnostic techniques and treatment options for liver and intestinal flukes.  Clinical Benefits:  Improve diagnosis and treatment of fascioliasis and fasciolopsiasis in endemic regions.  Prevent complications such as cholangitis and liver cirrhosis in fascioliasis.  Promote public health education on avoiding contaminated water sources and snails |

| Number | Learning Objective                                | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------|---|-------------------|---------------------------------|-----------------------|
| PARS   | Understand the lifecycle and pathogenesis of      | K                 | Large group                     | MCQ &                 |
| 30     | Paragonimus westermani.                           |                   | lecture                         | Short                 |
|        | Recognize the clinical symptoms of pulmonary      |                   |                                 | answer                |
|        | paragonimiasis and its diagnostic challenges.     |                   |                                 | questions             |
|        | Discuss the available treatments and preventive   |                   |                                 |                       |
|        | measures for lung fluke infections.               |                   |                                 |                       |
|        | Clinical Benefits:                                |                   |                                 |                       |
|        | Improve diagnosis and treatment of                |                   |                                 |                       |
|        | paragonimiasis, particularly in endemic regions.  |                   |                                 |                       |
|        | Prevent complications such as chronic respiratory |                   |                                 |                       |
|        | symptoms and lung fibrosis.                       |                   |                                 |                       |
|        | Raise awareness of parasitic lung infections,     |                   |                                 |                       |
|        | especially in individuals with exposure to raw or |                   |                                 |                       |
|        | undercooked crustaceans.                          |                   |                                 |                       |

#### Practical

| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|--|-------------------|---------------------------------|-----------------------|
| Introduction | on - Parasitology  |                   |                                 |                       |
| PARS 1       | Understand the fundamental concepts of parasitology and the significance of parasitic infections in human health.  Identify different types of parasites and understand their life cycles.  Apply the principles of parasitology to realworld clinical scenarios.  Clinical Benefits:  Recognize the importance of early diagnosis and management of parasitic infections.  Develop a foundational understanding that aids in clinical decision-making when encountering parasitic diseases.  Gain insights into the epidemiology of parasitic infections and their impact on public health. | K/S/C             | Small group<br>Lab              | MCQ                   |
| Sterilizatio | n  |                   |                                 |                       |

| Number | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------|--|-------------------|---------------------------------|-----------------------|
| PARS 2 | Learn the different methods of sterilization used in PARSobiology and parasitology laboratories.  Understand the principles behind physical and chemical sterilization techniques.  Apply appropriate sterilization methods to prevent contamination in laboratory settings.  Clinical Benefits:  Ensure the safety and reliability of diagnostic tests through proper sterilization techniques.  Minimize the risk of cross-contamination in clinical laboratories, which enhances diagnostic accuracy.  Develop habits for maintaining aseptic techniques in clinical and research environments. | K/S/C             | Small group<br>Lab              | MCQ                   |
|        | pic examination / stool examination -  |                   |                                 |                       |
| _      | rotozoa (Entamoeba histolytica, Giardia<br>ılantidium coli)  |                   |                                 |                       |
| PARS 3 | Learn the PARSoscopic techniques for examining stool samples for intestinal protozoa.  Identify and differentiate between the key intestinal protozoa based on their morphology.  Understand the clinical significance of these protozoa and their diagnostic criteria.  Clinical Benefits:  Enhance diagnostic capabilities for detecting intestinal protozoal infections in patients.  Understand the clinical manifestation and management of diseases caused by these protozoa.  Develop skills in identifying common protozoal pathogens through laboratory methods.                          | K/S/C             | Small group<br>Lab              | MCQ                   |
|        | ratory diagnosis of vagina, oral, skin,<br>nas vaginalis)  |                   |                                 |                       |
| PARS 4 | Learn how to collect and examine swab samples from different body sites for parasitic infections.  Identify Trichomonas vaginalis in swab samples using PARSoscopic techniques.  Understand the diagnostic criteria for detecting Trichomonas vaginalis in clinical settings.  Clinical Benefits:  | K/S/C             | Small group<br>Lab              | MCQ                   |


| Learning Objective  | Domain<br>K/S/A/C   | Teaching<br>Learning<br>Methods  | Assessment<br>Methods   |
|---|---|--|---|
| Improve the accuracy of diagnosing Trichomonas vaginalis infections. Develop competence in handling and processing samples from various anatomical sites. Understand the clinical presentation and management of Trichomonas vaginalis infections.  |   |  |   |
| oratory diagnosis of blood and examination<br>a, filaria  |   | 1  | <u>'</u>  |
| Learn the techniques for blood sample collection and examination for blood-borne parasitic diseases.  Understand how to identify Plasmodium spp. (malaria) and Wuchereria bancrofti (filariasis) under the PARSoscope.  Interpret blood film results for the diagnosis of malaria and filaria.  Clinical Benefits:  Improve diagnostic skills for detecting malaria and filariasis in clinical settings.  Understand the clinical implications of diagnosing malaria and filariasis early.  Enhance decision-making skills regarding the treatment and management of these diseases.  | K/S/C   | Small group<br>Lab   | MCQ   |
| ratory diagnosis of CSF and examination   |   |  |   |
| Learn the process for collecting cerebrospinal fluid (CSF) and its examination for parasitic infections.  Understand the clinical relevance of CSF examination in diagnosing central nervous system infections caused by parasites.  Identify parasitic pathogens in CSF samples using appropriate diagnostic techniques.  Clinical Benefits:  Improve the ability to diagnose parasitic infections affecting the central nervous system, such as Toxoplasma gondii and Naegleria fowleri.  Gain skills in performing lumbar punctures and handling CSF samples safely and effectively.  Contribute to accurate diagnosis and early treatment of parasitic meningoencephalitis. | K/S/C   | Small group<br>Lab   | MCQ   |
|   | Improve the accuracy of diagnosing Trichomonas vaginalis infections. Develop competence in handling and processing samples from various anatomical sites. Understand the clinical presentation and management of Trichomonas vaginalis infections.  Devalory diagnosis of blood and examination of filaria  Learn the techniques for blood sample collection and examination for blood-borne parasitic diseases. Understand how to identify Plasmodium spp. (malaria) and Wuchereria bancrofti (filariasis) under the PARSoscope. Interpret blood film results for the diagnosis of malaria and filaria. Clinical Benefits: Improve diagnostic skills for detecting malaria and filariasis in clinical settings. Understand the clinical implications of diagnosing malaria and filariasis early. Enhance decision-making skills regarding the treatment and management of these diseases.  atory diagnosis of CSF and examination  Learn the process for collecting cerebrospinal fluid (CSF) and its examination for parasitic infections. Understand the clinical relevance of CSF examination in diagnosing central nervous system infections caused by parasites. Identify parasitic pathogens in CSF samples using appropriate diagnostic techniques. Clinical Benefits: Improve the ability to diagnose parasitic infections affecting the central nervous system, such as Toxoplasma gondii and Naegleria fowleri. Gain skills in performing lumbar punctures and handling CSF samples safely and effectively. Contribute to accurate diagnosis and early | Improve the accuracy of diagnosing Trichomonas vaginalis infections. Develop competence in handling and processing samples from various anatomical sites. Understand the clinical presentation and management of Trichomonas vaginalis infections.  Trichomonas vaginalis infections  Trichomonas vaginalis infections  Trichomonas vaginalis infections and examination  Trichomonas vaginalis infection and examination  Trichomonas vaginalis infections ample collection and examination for blood-borne parasitic diseases.  Trichomonas vaginalis infections and examination for blood-borne parasitic diseases.  Trichomonas vaginalis  Trichomonas vaginalis infections and examination  Trichomonas vaginalis infections and examination  Trichomonas vaginalis infections affectis improve diagnostic skills for blood-borne parasitic pathogens in trichomonasitic infections. Understand the clinical implications of diagnosing malaria and filariasis early.  Enhance decision-making skills regarding the treatment and management of these diseases.  Trichomonas vaginalis  Trichomonas vaginalis  Trichomonas vaginalis infections of blood and examination  Trichomonas vaginalis  Trichomonas vaginali | Improve the accuracy of diagnosing Trichomonas vaginalis infections. Develop competence in handling and processing samples from various anatomical sites.  Understand the clinical presentation and management of Trichomonas vaginalis infections.  Pratory diagnosis of blood and examination filaria  Learn the techniques for blood sample collection and examination for blood-borne parasitic diseases.  Understand how to identify Plasmodium spp. (malaria) and Wuchereria bancrofti (filariasis) under the PARSoscope. Interpret blood film results for the diagnosis of malaria and filarias. Clinical Benefits:  Improve diagnostic skills for detecting malaria and filariasis in clinical settings. Understand the clinical implications of diagnosing malaria and filariasis early. Enhance decision-making skills regarding the treatment and management of these diseases.  atory diagnosis of CSF and examination  Learn the process for collecting cerebrospinal fluid (CSF) and its examination for parasitic infections. Understand the clinical relevance of CSF examination in diagnosing central nervous system infections caused by parasites. Identify parasitic pathogens in CSF samples using appropriate diagnostic techniques. Clinical Benefits:  Improve the ability to diagnose parasitic infections affecting the central nervous system, such as Toxoplasma gondii and Naegleria fowleri.  Gain skills in performing lumbar punctures and handling CSF samples safely and effectively. Contribute to accurate diagnosis and early |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|---|-------------------|---------------------------------|-----------------------|
| PARS 7       | Understand the basic principles of medical mycology, including fungal classifications and their clinical significance.  Learn the methods for collecting fungal specimens from clinical samples.  Recognize the difference between superficial and systemic fungal infections.  Clinical Benefits:  Recognize the growing importance of fungal infections in immunocompromised patients.  Understand the clinical implications of diagnosing and treating fungal diseases.  Enhance diagnostic accuracy for fungal pathogens through proper specimen collection and examination techniques. | K/S/C             | Small group<br>Lab              | MCQ                   |
| Scraping fr  | om skin, nail, and hair   |                   |                                 |                       |
| PARS 8       | Learn the techniques for collecting skin, nail, and hair samples for fungal infections. Understand how to examine these samples PARSoscopically for fungal elements. Identify and differentiate fungal pathogens responsible for dermatophyte infections. Clinical Benefits: Gain proficiency in diagnosing dermatophyte infections, such as Tinea corporis and Tinea pedis. Understand the significance of proper sample collection to avoid misdiagnosis. Improve patient care by identifying fungal infections early for effective treatment.  | K/S/C             | Small group<br>Lab              | MCQ                   |
| Stain and so | olutions with Biopsy stain  |                   |                                 |                       |
| PARSosco     | Learn the different types of stains and their application in fungal identification. Understand the importance of biopsy stains in diagnosing fungal infections. Apply various staining techniques to identify fungal structures in biopsy samples. Clinical Benefits: Enhance diagnostic accuracy for fungal infections through the use of specific staining techniques. Improve the ability to diagnose deep and invasive fungal infections. Contribute to the successful treatment of patients with fungal diseases by ensuring accurate diagnosis.                                       | K/S/C             | Small group<br>Lab              | MCQ                   |
|              | invasive fungal infections. Contribute to the successful treatment of patients with fungal diseases by ensuring   |                   |                                 |                       |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------------|---|-------------------|---------------------------------|-----------------------|
| PARS 10      | Learn how to examine various clinical samples (sputum, stool, urine, CSF) for parasitic and fungal pathogens. Understand the PARSoscopic features of common parasites and fungi in different body fluids. Develop competency in identifying a broad range of parasitic and fungal pathogens in clinical specimens. Clinical Benefits: Enhance diagnostic skills for identifying parasitic and fungal infections across different anatomical sites. Improve understanding of how to interpret laboratory results and make accurate diagnoses. Contribute to effective treatment plans for patients with parasitic and fungal infections. | K/S/C             | Small group<br>Lab              | MCQ                   |
| Culture and  | d sensitivity for fungal diseases   |                   |                                 |                       |
| PARS 11      | Learn the techniques for culturing fungal pathogens from clinical samples. Understand the principles of antiPARSobial sensitivity testing for fungal infections. Interpret culture results and susceptibility patterns to guide treatment decisions. Clinical Benefits: Improve diagnostic accuracy and treatment of fungal infections based on culture and sensitivity results. Understand how to manage antifungal therapy effectively, including resistance patterns. Enhance patient outcomes by using appropriate antifungal agents tailored to the infection.   | K/S/C             | Small group<br>Lab              | MCQ                   |
| Introduction | on / Intestinal nematodes   |                   |                                 |                       |
| PARS 12      | Learn the classification and morphological characteristics of intestinal nematodes. Understand the life cycles and transmission methods of common intestinal nematodes. Identify key diagnostic features of intestinal nematodes. Clinical Benefits: Improve diagnostic skills for identifying intestinal nematode infections. Understand the clinical impact of intestinal nematodes on gastrointestinal health.   | K/S/C             | Small group<br>Lab              | MCQ                   |

| Number     | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|------------|--|-------------------|---------------------------------|-----------------------|
|            | Contribute to effective patient management by diagnosing intestinal nematode infections.   |                   |                                 |                       |
| Blood film |  |                   |                                 |                       |
| PARS 13    | Learn how to prepare and examine blood films for detecting parasitic infections.  Identify blood-borne parasites using blood smear techniques.  Understand the significance of blood film examination in diagnosing diseases like malaria and filariasis.  Clinical Benefits:  Enhance diagnostic capabilities for bloodborne parasitic infections, particularly malaria.  Develop skills in blood smear preparation and parasite identification.  Improve patient care by enabling early detection and treatment of blood-borne parasitic diseases. | K/S/C             | Small group<br>Lab              | MCQ                   |

## **Internal Medicine**



# **Third Grade**

### Academic program discretion

This academic program description provides a brief overview of the key features of the program and the expected learning outcomes for the student, demonstrating whether the student has made the most of the available opportunities. It is accompanied by a description of each course within the program.

| Educational Establishment                    | University of al-ameed   |  |  |  |
|--|--|--|--|--|
| 2-Scientific Department                      | College of medicine  |  |  |  |
| 3-Name of the Professional Academic Program. | Modified traditional curriculum  |  |  |  |
| 4-Final Graduation Certificate               | M.B.Ch.B   |  |  |  |
| 5- Educational system: Annual/courses/other  | Annual   |  |  |  |
| 6-Approved accreditation program             | Applied for Iraqi National Guideline on Standards for Established and Accrediting Medical School   |  |  |  |
| 7-Other external factors                     | Availability of relevant scientific research in the field of specialization  Access to global electronic networks  Access to traditional and digital libraries  Teaching aids such as data show and PowerPoint presentations  Availability of equipped classrooms  Use of free online communication platforms (e.g., Free Conference Call) |  |  |  |
| 8-Date the description was written           | 2024/9/15  |  |  |  |
| 9- objectives of academic program            |  |  |  |  |

To provide students with a strong foundational knowledge in internal medicine, focusing on the understanding of pathophysiology, clinical presentation, differential diagnosis, and management of common medical disorders encountered in adult patients.

To develop students' clinical reasoning and problem-solving skills, enabling them to perform accurate history taking, systematic physical examination, and formulation of appropriate diagnostic and management plans in inpatient and outpatient settings.

To train students in evidence-based medical practice, encouraging the integration of current clinical guidelines, scientific literature, and critical appraisal skills into patient care decisions across various internal medicine subspecialties (e.g., cardiology, pulmonology, gastroenterology, nephrology, endocrinology).

To enhance students' communication and professional skills, including empathy, ethical reasoning, and teamwork, especially when interacting with patients, families, and healthcare professionals in internal medicine wards and clinics.

To expose students to real-life clinical scenarios through bedside teaching, ward rounds, case-based discussions, and simulation exercises to prepare them for future clinical responsibilities.

To promote community awareness and preventive medicine, by educating students about chronic diseases such as hypertension, diabetes mellitus, and heart disease, and encouraging their participation in health campaigns and screening programs.

To cultivate a spirit of inquiry and clinical research, by encouraging students to participate in internal medicine research projects, case reports, and quality improvement initiatives relevant to local and national health needs.

10) The most reliabl resources for program information are:

Hutchison's clinical methods

Macleod's clinical examination

Systematic guide to physical diagnosis

Moby's guide to physical examination

The common symptom guide

Skills for communicating with patient

Davidson's principles and practice of medicine

Kumar and Clark's clinical medicine

Harrison's principles of internal medicine

Oxford textbook of medicine

|                | Internal Medicine\ Grade 3 |           |
|----------------|----------------------------|-----------|
| Code: MEDI 305 |                            | 5 Credits |

| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods                            | Assessment<br>Methods              |
|--------------|--|-------------------|--|------------------------------------|
| Cardiovascu  | lar System   |                   |  |                                    |
| MEDI.1.1     | Describe the anatomy and physiology of the cardiovascular system, including heart chambers and vessels.    | K                 | Large group lecture  | MCQs, Short<br>Answer<br>Questions |
| MEDI.1.2     | Perform a comprehensive cardiovascular examination.  | S                 | Clinical skills lab, bedside teaching                      | OSCE                               |
| MEDI.1.3     | Interpret common cardiovascular diagnostic tests (e.g., ECG, echocardiography).                            | С                 | Clinical skills lab, bedside teaching                      | CIVA                               |
| MEDI.1.4     | Demonstrate empathy and professionalism when communicating with patients about cardiovascular health.      | A                 | Clinical skills<br>lab, bedside<br>teaching                | OSCE                               |
| Respiratory  | System   |                   |  |                                    |
| MEDI.2.1     | Explain the structure and function of the respiratory system, including gas exchange mechanisms.           | K                 | Large group lecture  | MCQs, Short<br>Answer<br>Questions |
| MEDI.2.2     | Conduct a thorough respiratory examination, including inspection, palpation, percussion, and auscultation. | S                 | Clinical skills lab  | OSCE                               |
| MEDI.2.3     | Analyze pulmonary function tests and imaging to diagnose respiratory conditions.                           | С                 | Clinical skills lab  | CIVA                               |
| MEDI.2.4     | Educate patients on smoking cessation and respiratory health maintenance.                                  | A                 | Large group lecture  | OSCE                               |
| Gastrointest | inal System  |                   |  |                                    |
| MEDI.3.1     | Describe the anatomy and physiology of the gastrointestinal tract and accessory organs.                    | K                 | Large group lecture  | MCQs, Short<br>Answer<br>Questions |
| MEDI.3.2     | Perform abdominal examinations to assess gastrointestinal health.  | S                 | Clinical skills lab, bedside teaching                      | OSCE                               |
| MEDI.3.3     | Interpret laboratory and imaging studies related to gastrointestinal disorders.                            | С                 | Case-based<br>learning,<br>problem-<br>solving<br>sessions | CIVA                               |
| MEDI.3.4     | Counsel patients on dietary modifications for gastrointestinal health.                                     | A                 | Clinical skills lab, bedside teaching                      | OSCE                               |
| Urinary Syst | em   |                   |  |                                    |

| Number      | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods             | Assessment<br>Methods              |
|-------------|--|-------------------|---|------------------------------------|
| MEDI.4.1    | Explain the structure and function of the urinary system, including nephron physiology.            | K                 | Large group lecture                         | MCQs, Short<br>Answer<br>Questions |
| MEDI.4.2    | Conduct physical examinations focusing on the urinary system.                                      | S                 | Clinical skills lab                         | OSCE                               |
| MEDI.4.3    | Analyze urinalysis and imaging results to diagnose urinary disorders.                              | С                 | Large group lecture                         | CIVA                               |
| MEDI.4.4    | Discuss preventive measures for urinary tract infections with patients.                            | A                 | Large group lecture                         | OSCE,                              |
| Endocrine S | ystem  |                   |   |                                    |
| MEDI.5.1    | Describe the hormonal regulation and feedback mechanisms of the endocrine system.                  | K                 | Large group lecture                         | MCQs, Short<br>Answer<br>Questions |
| MEDI.5.2    | Perform clinical assessments for endocrine disorders (e.g., thyroid examination).                  | S                 | Clinical skills<br>lab, bedside<br>teaching | OSCE                               |
| MEDI.5.3    | Interpret laboratory tests for endocrine function (e.g., blood glucose, hormone levels).           | С                 | Large group lecture                         | CIVA                               |
| MEDI.5.4    | Address lifestyle modifications with patients managing endocrine disorders.                        | A                 | Large group lecture                         | OSCE                               |
| Immunity &  | Immune Deficiency  |                   |   |                                    |
| MEDI.6.1    | Explain the components and functions of the immune system, including innate and adaptive immunity. | K                 | Large group lecture                         | MCQs, Short<br>Answer<br>Questions |
| MEDI.6.2    | Identify clinical signs of immune deficiencies through patient history and examination.            | S                 | Clinical skills lab, case simulations       | OSCE                               |
| MEDI.6.3    | Develop management plans for patients with immune deficiencies.                                    | С                 | Large group lecture                         | CIVA                               |
| MEDI.6.4    | Educate patients on infection prevention strategies.   | A                 | Large group lecture                         | OSCE                               |
| Body Weigh  | nt Disorders   |                   |   |                                    |
| MEDI.7.1    | Define various body weight disorders, including underweight and overweight classifications.        | K                 | Large group lecture                         | MCQs, Short<br>Answer<br>Questions |
| MEDI.7.2    | Assess nutritional status and body composition in patients.  | S                 | Clinical skills lab                         | OSCE                               |
| MEDI.7.3    | Formulate individualized management plans for patients with body weight disorders.                 | С                 | Large group lecture                         | CIVA                               |
| MEDI.7.4    | Address psychosocial aspects related to body weight with sensitivity.                              | A                 | Large group lecture                         | OSCE                               |
| Obesity and | Appetite   |                   |   |                                    |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods              |
|--------------|---|-------------------|---------------------------------|------------------------------------|
| MEDI.8.1     | Explain the physiological and psychological factors influencing appetite and obesity.           | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.8.2     | Evaluate patients for obesity-related health risks.   | S                 | Clinical skills lab             | OSCE                               |
| MEDI.8.3     | Develop comprehensive weight management plans, including lifestyle interventions.               | С                 | Large group lecture             | CIVA                               |
| MEDI.8.4     | Counsel patients on sustainable dietary and physical activity changes.                          | A                 | Large group lecture             | OSCE                               |
| Disorders of | Nutrition   |                   |                                 |                                    |
| MEDI.9.1     | Identify common nutritional disorders and their clinical manifestations.                        | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.9.2     | Perform nutritional assessments, including dietary history and physical examination.            | S                 | Clinical skills lab             | OSCE                               |
| MEDI.9.3     | Create nutrition care plans tailored to individual patient needs.                               | С                 | Large group lecture             | CIVA                               |
| MEDI.9.4     | Promote healthy eating habits through patient education.  | A                 | Large group lecture             | OSCE                               |
| Vitamin Dis  | orders  |                   |                                 |                                    |
| MEDI.10.1    | Describe the role of essential vitamins and the consequences of their deficiencies or excesses. | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.10.2    | Recognize clinical signs of vitamin deficiencies through patient assessment.                    | S                 | Clinical skills lab             | OSCE                               |
| MEDI.10.3    | Develop treatment plans for correcting vitamin imbalances.                                      | С                 | Large group lecture             | CIVA                               |
| MEDI.10.4    | Educate patients on dietary sources of essential vitamins.                                      | A                 | Large group lecture             | OSCE                               |
| History Taki | ing   |                   |                                 |                                    |
| MEDI.11.1    | Understand the components of a comprehensive medical history.                                   | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.11.2    | Elicit accurate and relevant information from patients during history taking.                   | S                 | Large group lecture             | OSCE                               |
| MEDI.11.3    | Integrate patient history into clinical reasoning and decision-making.                          | С                 | Large group lecture             | CIVA                               |
| MEDI.11.4    | Demonstrate active listening and empathy during patient interviews.                             | A                 | Large group lecture             | OSCE                               |
| General Exa  | mination  |                   |                                 |                                    |
| MEDI.12.1    | Define the components of general examination and list the steps systematically.                 | K                 | Lectures,<br>clinical skill lab | MCQs, Short<br>Answer<br>Questions |

|  |   | ъ .               | Teaching                |                       |
|--|---|-------------------|-------------------------|-----------------------|
| Number                                 | Learning Objective  | Domain<br>K/S/A/C | Learning                | Assessment<br>Methods |
|  |   | N/S/A/C           | Methods                 | Methods               |
| MEDI.12.2                              | Demonstrate correct techniques in                                 |                   | Bedside                 |                       |
|  | general physical examination on                                   | S                 | teaching,               | OSCE                  |
| 1 (55) 10 0                            | simulated patients.   |                   | clinical skill lab      |                       |
| MEDI.12.3                              | Interpret abnormal general findings                               |                   | Case-based              |                       |
|  | (e.g., pallor, cyanosis, lymphadenopathy) in relation to          | C                 | discussions,<br>bedside | CIVA, OSCE            |
|  | common diseases.  |                   | teaching                |                       |
| MEDI.12.4                              | Show professionalism and respectful                               |                   | Role-playing,           |                       |
| 141201.12.1                            | communication when examining                                      | A                 | bedside                 | OSCE                  |
|  | patients.   |                   | teaching                |                       |
| Behavioral S                           | Sciences: Communication Skills                                    |                   |                         |                       |
|  | T   |                   | T                       | 1400 gt .             |
| MEDI.13.1                              | Describe the principles of effective                              | 17                | Large group             | MCQs, Short<br>Answer |
|  | communication in clinical settings.                               | K                 | lecture                 | Questions             |
| MEDI.13.2                              | Demonstrate active listening and                                  |                   | Large group             | _                     |
| WIED1.13.2                             | empathy during patient interactions.                              | S                 | lecture                 | OSCE                  |
| MEDI.13.3                              | Apply communication strategies to                                 |                   |                         |                       |
|  | convey complex medical information                                | C                 | Large group             | CIVA                  |
|  | clearly.  |                   | lecture                 |                       |
| MEDI.13.4                              | Reflect on personal communication                                 |                   | Large group             | MCQs, Short           |
|  | styles and their impact on patient                                | A                 | lecture                 | Answer                |
|  | care.   |                   | lecture                 | Questions             |
| Behavioral S                           | Sciences: Learning  |                   |                         |                       |
| MEDI.14.1                              | Explain various learning theories and                             |                   | I and a second          | MCQs, Short           |
|  | their applications in medical                                     | K                 | Large group lecture     | Answer                |
|  | education.  |                   | lecture                 | Questions             |
| MEDI.14.2                              | Identify personal learning styles and                             | _                 | Large group             | MCQs, Short           |
|  | strategies for effective study.                                   | S                 | lecture                 | Answer                |
| MEDIALO                                |   |                   |                         | Questions             |
| MEDI.14.3                              | Develop a personalized learning plan incorporating evidence-based | C                 | Large group             | MCQs, Short<br>Answer |
|  | strategy.   | C                 | lecture                 | Questions             |
| MEDI.14.4                              | Demonstrate a commitment to                                       |                   |                         | MCQs, Short           |
| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | lifelong learning and continuous                                  | A                 | Large group             | Answer                |
|  | professional development.   |                   | lecture                 | Questions             |
| Behavioral S                           | Sciences: Memory  | •                 |                         |                       |
| MEDI.15.1                              | Describe the types of memory and                                  |                   |                         | MCQs, Short           |
| 1411-171.13.1                          | their roles in learning and clinical                              | K                 | Large group             | Answer                |
|  | practice.   | 17                | lecture                 | Questions             |
| MEDI.15.2                              | Apply memory enhancement  |                   | ,                       | MCQs, Short           |
|  | techniques to improve information                                 | S                 | Large group             | Answer                |
|  | retention.  |                   | lecture                 | Questions             |
| MEDI.15.3                              | Analyze factors affecting memory                                  |                   | Large group             | MCQs, Short           |
|  | performance in clinical settings.                                 | C                 | lecture                 | Answer                |
|  | performance in clinical settings.                                 |                   | 1001010                 | Questions             |
| MEDI.15.4                              | Reflect on personal memory strengths                              |                   | Large group             | MCQs, Short           |
|  | and areas for improvement.  | A                 | lecture                 | Answer                |
|  |   |                   |                         | Questions             |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods              |
|--------------|---|-------------------|---------------------------------|------------------------------------|
| Behavioral S | Sciences: Perception  |                   |                                 |                                    |
| MEDI.16.1    | Explain the processes involved in human perception and their relevance to clinical practice.              | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.16.2    | Identify perceptual biases and their potential impact on clinical decision-making.                        | S                 | Large group lecture             | OSCE                               |
| MEDI.16.3    | Evaluate the role of perception in patient-provider interactions.   | С                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.16.4    | Demonstrate awareness of personal perceptual biases and strategies to mitigate them.                      | A                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| Behavioral S | Sciences: Emotion and thinking  |                   |                                 |                                    |
| MEDI.17.1    | Describe the interplay between emotion and cognitive processes in clinical settings.                      | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.17.2    | Apply emotional regulation strategies during patient care.  | S                 | Large group lecture             | OSCE                               |
| MEDI.17.3    | Analyze how emotions influence clinical reasoning and decision-making.                                    | С                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.17.4    | Demonstrate empathy and emotional intelligence in patient interactions.                                   | A                 | Large group lecture             | OSCE                               |
| Behavioral S | Sciences: Sick Role   |                   |                                 |                                    |
| MEDI.18.1    | Explain Talcott Parsons' concept of the sick role and its implications in healthcare.                     | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.18.2    | Identify the rights and obligations associated with the sick role in various cultural contexts.           | S                 | Large group lecture             | OSCE                               |
| MEDI.18.3    | Analyze the impact of the sick role on patient behavior and healthcare delivery.                          | С                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.18.4    | Demonstrate sensitivity to patients' experiences and societal expectations related to illness.            | A                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| Behavioral S | Sciences: Aggression  |                   |                                 |                                    |
| MEDI.19.1    | Describe the psychological and physiological factors contributing to aggressive behavior in patients.     | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.19.2    | Apply de-escalation techniques effectively in simulated clinical scenarios involving aggressive patients. | S                 | Large group lecture             | OSCE                               |

| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods              |
|--------------|--|-------------------|---------------------------------|------------------------------------|
| MEDI.19.3    | Evaluate the effectiveness of different aggression management strategies in healthcare settings.                     | С                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.19.4    | Exhibit self-awareness and control over personal responses when confronted with aggression in clinical environments. | A                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| Behavioral S | Sciences: Communication Skills, Patient  | Safety, and       | Medical Ethics                  |                                    |
| MEDI.20.1    | Integrate effective communication strategies to enhance patient safety and uphold medical ethics.                    | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.20.2    | Demonstrate the ability to communicate adverse events and medical errors transparently and empathetically.           | S                 | Large group lecture             | OSCE                               |
| MEDI.20.3    | Analyze ethical dilemmas in clinical practice and apply ethical decision-making frameworks.                          | С                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.20.4    | Reflect on personal values and their influence on ethical clinical practice and patient safety.                      | A                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| Fever and P  | yrexia of Unknown Origin (PUO)   |                   |                                 |                                    |
| MEDI.21.1    | Define PUO and list its common etiologies, including infections, malignancies, and autoimmune disorders.             | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.21.2    | Perform a systematic clinical evaluation to identify potential causes of PUO.  | S                 | Large group lecture             | OSCE, CIVA                         |
| MEDI.21.3    | Interpret diagnostic tests to differentiate between various causes of PUO.   | С                 | Large group lecture             | CIVA                               |
| MEDI.21.4    | Demonstrate empathy and effective communication when managing patients with PUO.                                     | A                 | Large group lecture             | OSCE                               |
| Viral Diseas | es: Herpes Family  |                   |                                 |                                    |
| MEDI.22.1    | Describe the virology, transmission, and clinical manifestations of Herpesviridae infections.                        | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.22.2    | Identify and diagnose common herpesvirus infections based on clinical features and laboratory findings.              | S                 | Large group lecture             | OSCE, CIVA                         |
| MEDI.22.3    | Develop management plans for patients with herpesvirus infections, considering antiviral therapies.                  | С                 | Large group lecture             | CIVA                               |

| Number        | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods              |
|---------------|--|-------------------|---------------------------------|------------------------------------|
| MEDI.22.4     | Counsel patients on prevention strategies and address psychosocial aspects of herpesvirus infections.                | A                 | Large group lecture             | OSCE                               |
| Viral Diseas  | es: Herpes Family and Vaccine-Preventa   | ble Diseases      | 3                               |                                    |
| MEDI.23.1     | List vaccine-preventable diseases within the Herpesviridae family and their respective vaccines.                     | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.24.2     | Administer vaccines appropriately and manage potential adverse reactions.  | S                 | Large group lecture             | OSCE, CIVA                         |
| MEDI.24.3     | Evaluate vaccination schedules and implement immunization programs effectively.                                      | С                 | Large group lecture             | CIVA                               |
| MEDI.24.4     | Advocate for vaccination and address vaccine hesitancy in diverse populations.                                       | A                 | Large group lecture             | OSCE                               |
| Viral Diseas  | es: Influenza and COVID-19   |                   |                                 |                                    |
| MEDI.25.1     | Compare the pathophysiology, transmission, and clinical features of influenza and COVID-19.                          | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.25.2     | Conduct appropriate testing and interpret results for respiratory viral infections.                                  | S                 | Large group lecture             | OSCE, CIVA                         |
| MEDI.25.3     | Formulate management plans for patients with influenza or COVID-19, including antiviral use and isolation protocols. | С                 | Large group lecture             | CIVA                               |
| MEDI.25.4     | Communicate public health measures and educate patients on prevention strategies for respiratory viruses.            | A                 | Large group lecture             | OSCE                               |
| Viral Diseas  | es: HIV  |                   |                                 |                                    |
| MEDI.26.1     | Explain the virology, transmission routes, and stages of HIV infection.  | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.26.2     | Perform HIV testing and counseling in accordance with current guidelines.  | S                 | Large group lecture             | OSCE, CIVA                         |
| MEDI.26.3     | Develop comprehensive care plans for individuals living with HIV, including antiretroviral therapy management.       | С                 | Large group lecture             | CIVA                               |
| MEDI.26.4     | Address stigma and ethical considerations in the care of patients with HIV.  | A                 | Large group lecture             | OSCE                               |
| Bacterial Dis | seases: Gram-Positive  |                   |                                 |                                    |
| MEDI.27.1     | Identify common gram-positive bacteria and the diseases they cause.  | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |

| Number        | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods              |
|---------------|--|-------------------|---------------------------------|------------------------------------|
| MEDI.27.2     | Perform and interpret gram staining and culture techniques for grampositive organisms.                       | S                 | Large group lecture             | OSCE                               |
| MEDI.27.3     | Choose appropriate antibiotic therapies for gram-positive bacterial infections.                              | С                 | Large group lecture             | CIVA                               |
| MEDI.27.4     | Promote infection control practices to prevent the spread of gram-positive bacteria.                         | A                 | Large group lecture             | OSCE                               |
| Bacterial Dis | seases: Gram-Negative  |                   |                                 |                                    |
| MEDI.28.1     | Describe the characteristics and pathogenic mechanisms of gramnegative bacteria.                             | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.28.2     | Identify gram-negative organisms using laboratory diagnostic techniques.                                     | S                 | Large group lecture             | OSCE                               |
| MEDI.28.3     | Develop treatment plans for infections caused by gram-negative bacteria, considering resistance patterns.    | С                 | Large group lecture             | CIVA                               |
| MEDI.28.4     | Advocate for prudent antibiotic use to combat antimicrobial resistance.                                      | A                 | Large group lecture             | OSCE                               |
| Bacterial Dis | seases: Anaerobic  |                   |                                 |                                    |
| MEDI.29.1     | Explain the growth requirements and pathogenicity of anaerobic bacteria.                                     | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.29.2     | Collect and process clinical specimens appropriately for anaerobic culture.                                  | S                 | Large group lecture             | OSCE                               |
| MEDI.29.3     | Manage infections caused by anaerobic bacteria, including appropriate antimicrobial therapy.                 | С                 | Large group lecture             | CIVA                               |
| MEDI.29.4     | Emphasize the importance of timely diagnosis and treatment of anaerobic infections to prevent complications. | A                 | Large group lecture             | OSCE                               |
| Bacterial Dis | seases: Tuberculosis (TB)  |                   |                                 |                                    |
| MEDI.30.1     | Describe the epidemiology, transmission, and pathogenesis of TB.   | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.30.2     | Perform and interpret diagnostic tests for TB, including skin tests and imaging.                             | S                 | Clinical skill labs             | OSCE, CIVA                         |
| MEDI.30.3     | Develop treatment regimens for latent and active TB, considering drug resistance.                            | С                 | Large group lecture             | CIVA                               |
| MEDI.30.4     | Address public health strategies for TB control and prevention.  | A                 | Large group lecture             | OSCE                               |

| Number         | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods              |
|----------------|---|-------------------|---------------------------------|------------------------------------|
| Parasitic Info | estations   |                   |                                 |                                    |
| MEDI.31.1      | Identify common human parasites and their life cycles.  | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.31.2      | Diagnose parasitic infections using appropriate laboratory techniques.  | S                 | Large group lecture             | OSCE                               |
| MEDI.31.3      | Formulate treatment plans for various parasitic infections.   | С                 | Large group lecture             | CIVA                               |
| MEDI.31.4      | Educate patients and communities on prevention and control of parasitic diseases.   | A                 | Large group lecture             | OSCE                               |
| Helminthic l   | Infestations  |                   |                                 |                                    |
| MEDI.32.1      | Describe the classification,<br>morphology, and life cycles of<br>medically important helminths (e.g.,<br>nematodes, cestodes, trematodes). | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.32.2      | Perform diagnostic procedures for helminthic infections, including stool examination and serological tests.                                 | S                 | Large group lecture             | OSCE                               |
| MEDI.32.3      | Develop treatment plans for helminthic infections, considering drug choices and resistance patterns.  | С                 | Large group lecture             | CIVA                               |
| MEDI.32.4      | Educate patients and communities on prevention and control measures for helminthic infections.  | A                 | Large group lecture             | OSCE                               |
| Fungal Infec   | etions  |                   |                                 |                                    |
| MEDI.33.1      | Identify common fungal pathogens and the diseases they cause, including superficial and systemic mycoses.                                   | K                 | Large group lecture             | MCQs, Short<br>Answer<br>Questions |
| MEDI.33.2      | Perform and interpret laboratory tests for fungal infections, such as KOH preparation and fungal cultures.                                  | S                 | Large group lecture             | OSCE                               |
| MEDI.33.3      | Formulate management strategies for various fungal infections, considering antifungal therapies and patient factors.                        | С                 | Large group lecture             | CIVA                               |
| MEDI.33.4      | Counsel patients on adherence to antifungal treatments and preventive measures to avoid recurrence.   | A                 | Large group lecture             | OSCE                               |

#### **Practical**

| Number     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods               | Assessment<br>Methods   |  |
|------------|---|-------------------|---|-------------------------|--|
| Week 1: Hi | story Taking  |                   |   |                         |  |
| MEDI.1.1   | Describe the essential components of a comprehensive medical history, including chief complaint, HPI, PMH.      | K                 | Bedside<br>teaching,<br>Clinical skill<br>lab | CIVA,<br>OSCE,<br>OSLER |  |
| MEDI.1.2   | Demonstrate effective communication skills while obtaining a patient's history in a clinical setting.           | S                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSCE,<br>OSLER          |  |
| MEDI.1.3   | Analyze patient information to formulate a relevant differential diagnosis based on history alone.              | С                 | Bedside<br>teaching,<br>Clinical skill<br>lab | CIVA, OSCE              |  |
| MEDI.1.4   | Show professionalism and empathy during patient interviews, respecting confidentiality and cultural values.     | A                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSLER,<br>OSCE          |  |
| Week 2: Ge | neral Examination   |                   |   |                         |  |
| MEDI.2.1   | Describe the steps and techniques of a systematic general physical examination.                                 | K                 | Bedside<br>teaching,<br>Clinical skill<br>lab | CIVA,<br>OSCE,<br>OSLER |  |
| MEDI.2.2   | Perform a complete general examination including assessment of consciousness, posture, gait, and vital signs.   | S                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSCE,<br>OSLER          |  |
| MEDI.2.3   | Differentiate between normal and abnormal general physical signs and relate them to common clinical conditions. | С                 | Bedside<br>teaching,<br>Clinical skill<br>lab | CIVA, OSCE              |  |
| MEDI.2.4   | Display a professional attitude, maintain patient dignity, and ensure effective communication during the exam.  | A                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSCE,<br>OSLER          |  |
| Week 3: Co | Week 3: Communication Skills  |                   |   |                         |  |
| MEDI.3.1   | Identify the key elements of effective verbal and non-verbal communication in a healthcare setting.             | K                 | Bedside<br>teaching,<br>Clinical skill<br>lab | CIVA,<br>OSCE,<br>OSLER |  |

| Number   | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods               | Assessment<br>Methods   |
|--|---|-------------------|---|-------------------------|
| MEDI.3.2   | Explain the importance of active listening and empathy in building rapport with patients.   | S                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSCE,<br>OSLER          |
| MEDI.3.3   | Demonstrate the ability to ask openended questions to gather comprehensive patient information.   | С                 | Bedside<br>teaching,<br>Clinical skill<br>lab | CIVA, OSCE              |
| MEDI.3.4   | Differentiate between appropriate and inappropriate communication techniques in various patient scenarios (e.g., delivering difficult news, communicating with anxious patients). | A                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSLER,<br>OSCE          |
| Week 4: Vit  | al Signs  |                   |   |                         |
| MEDI.4.1   | Describe the normal ranges of temperature, pulse, respiration, and blood pressure.  | K                 | Bedside<br>teaching,<br>Clinical skill<br>lab | CIVA,<br>OSCE,<br>OSLER |
| MEDI.4.2   | Accurately measure and record a patient's vital signs using standard techniques.  | S                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSCE,<br>OSLER          |
| MEDI.4.3   | Interpret abnormal vital signs and correlate with potential clinical conditions.  | С                 | Bedside<br>teaching,<br>Clinical skill<br>lab | CIVA, OSCE              |
| MEDI.4.4   | Demonstrate respect and reassurance to patients during the measurement process.   | A                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSLER,<br>OSCE          |
| Week 5: Rev  | view of History Taking  |                   |   |                         |
| MEDI.5.1   | Recall the structure of a complete medical history, including chief complaint and history of present illness.   | k                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSLER,<br>OSCE, CIVA    |
| MEDI.5.2   | Elicit a focused and relevant medical history in a logical and patient-centered manner.   | k                 | Bedside<br>teaching,<br>Clinical skill<br>lab | OSCE, CIVA              |
| MEDI.5.3   | Identify inconsistencies or red flags in a patient's history.   | С                 | Bedside teaching                              | OSLER,<br>CIVA          |
| MEDI.5.4   | Show empathy and professionalism while reviewing sensitive aspects of history.  | A                 | Bedside teaching                              | OSCE                    |
| Week 6: General Examination Related to CVS (Cardiovascular System) |   |                   |   |                         |

| Number      | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods            | Assessment<br>Methods |  |  |
|-------------|---|-------------------|--|-----------------------|--|--|
| MEDI.6.1    | List the key signs and symptoms of common cardiovascular diseases (e.g., heart failure, valvular disease).  | K                 | Bedside<br>teaching                        | CIVA                  |  |  |
| MEDI.6.2    | Perform a general physical exam to identify signs of cardiovascular dysfunction (e.g., cyanosis, edema).  | S                 | Clinical skill lab                         | OSCE,<br>OSLER        |  |  |
| MEDI.6.3    | Correlate general physical findings with specific cardiovascular pathologies.   | С                 | Bedside<br>teaching                        | CIVA                  |  |  |
| MEDI.6.4    | Maintain patient dignity and explain the procedure clearly during the examination.  | A                 | Bedside teaching                           | OSCE                  |  |  |
| Week 7: Ge  | neral Examination Related to Respiratory  | System            |  |                       |  |  |
| MEDI.7.1    | Describe common respiratory signs seen on general examination (e.g., dyspnea, cyanosis).  | K                 | Clinical skill lab                         | CIVA                  |  |  |
| MEDI.7.2    | Perform general observations relevant to respiratory illness (e.g., respiratory rate, accessory muscle use).  | S                 | Bedside teaching                           | OSCE                  |  |  |
| MEDI.7.3    | Interpret general signs in the context of underlying respiratory diseases like COPD or pneumonia.   | С                 | Bedside teaching                           | OSLER,<br>CIVA        |  |  |
| MEDI.7.4    | Ensure patient comfort and communicate findings with clarity and care.  | A                 | Bedside<br>teaching                        | OSCE                  |  |  |
| Week 8: Ge  | eneral Examination Related to GIT   |                   |  |                       |  |  |
| MEDI.8.1    | Describe the normal inspection findings of the abdomen and key anatomical landmarks.  | K                 | Bedside<br>teaching,<br>clinical skill lab | OSCE, CIVA            |  |  |
| MEDI.8.2    | Perform a full abdominal examination, including inspection, palpation, percussion, and auscultation.  | S                 | Bedside<br>teaching,<br>clinical skill lab | OSCE, OSPE            |  |  |
| MEDI.8.3    | Analyze abnormal abdominal signs (e.g., tenderness, guarding, shifting dullness) and relate them to common GIT conditions such as ascites, appendicitis, or hepatomegaly. | С                 | Bedside<br>teaching,<br>clinical skill lab | CIVA, OSCE            |  |  |
| MEDI.8.4    | Demonstrate professional behavior and appropriate communication while examining a patient with abdominal complaints.  | A                 | Bedside<br>teaching,<br>clinical skill lab | OSCE                  |  |  |
| Week 9: Pul | Week 9: Pulmonary Function Test   |                   |  |                       |  |  |
| MEDI.9.1    | Describe the principles of pulmonary function testing and the significance  | K                 | Work shop                                  | OSCE, CIVA            |  |  |

|             |  |                   | Teaching                                   |                       |
|-------------|--|-------------------|--|-----------------------|
| Number      | Learning Objective   | Domain<br>K/S/A/C | Learning Methods                           | Assessment<br>Methods |
|             | of key measurements (e.g., FVC, FEV1).   |                   | Wictiods                                   |                       |
| MEDI.9.2    | Perform spirometry correctly, ensuring proper patient instruction and reproducibility of results.          | S                 |  | OSPE, OSCE            |
| MEDI.9.3    | Interpret basic PFT results and differentiate between obstructive and restrictive lung diseases.           | С                 |  | CIVA, OSCE            |
| MEDI.9.4    | Communicate findings to patients in a clear, empathetic manner, especially in chronic disease follow-ups.  | A                 |  | OSCE                  |
| Week 10: Su | nrface Anatomy   |                   |  |                       |
| MEDI.10.1   | Describe the principles and steps of<br>Basic Life Support (BLS) including<br>indications for CPR and AED. | K                 | Clinical skill lab, bedside teaching       | CIVA, OSCE            |
| MEDI.10.2   | Demonstrate correct technique for performing high-quality CPR on adult and pediatric mannequins.           | S                 | Clinical skill lab                         | OSPE, OSCE            |
| MEDI.10.3   | Apply the steps of using an Automated External Defibrillator (AED) in a simulated emergency scenario.      | С                 | Clinical skill<br>lab                      | OSCE, CIVA            |
| MEDI.10.4   | Show calm, effective communication and teamwork during resuscitation drills.                               | A                 | Clinical skill lab                         | OSCE                  |
| Week 11: E0 | CG   |                   |  |                       |
| MEDI.11.1   | Describe the components of a normal ECG trace and the physiological basis of each wave and interval.       | K                 | Clinical skill<br>lab, bedside<br>teaching | CIVA, OSCE            |
| MEDI.11.2   | Perform correct placement of ECG leads and record a 12-lead ECG accurately.                                | S                 | Clinical skill lab                         | OSPE, OSCE            |
| MEDI.11.3   | Interpret common ECG abnormalities such as myocardial infarction, arrhythmias, and electrolyte imbalance.  | С                 | Clinical skill<br>lab                      | OSCE, CIVA            |
| MEDI.11.4   | Demonstrate professional communication when explaining ECG findings to patients or colleagues.             | A                 | Clinical skill<br>lab                      | OSCE                  |
| Week12: CF  | PR and AED   |                   |  |                       |
| MEDI.12.1   | Describe the basic steps of CPR and the indications for using an AED in adult and pediatric patients.      | K                 | Bedside<br>teaching,<br>clinical skill lab | CIVA, OSCE            |
| MEDI.12.2   | Demonstrate proper technique for chest compressions, rescue breathing, and AED application.                | S                 | Bedside<br>teaching,<br>clinical skill lab | OSCE, OSPE            |

| Number    | Learning Objective  | Domain<br>K/S/A/C | Teaching Learning Methods                  | Assessment<br>Methods |
|-----------|---|-------------------|--|-----------------------|
| MEDI.12.3 | Analyze different emergency scenarios and decide when and how to initiate CPR and apply AED.      | С                 | Bedside<br>teaching,<br>clinical skill lab | OSCE, CIVA            |
| MEDI.12.4 | Show teamwork, composure, and effective communication during simulated cardiac arrest situations. | A                 | Bedside<br>teaching,<br>clinical skill lab | OSCE                  |

## **Surgery**



# **Third Grade**

### Academic program discretion

This academic program description summarizes the course's most essential qualities and the learning objectives that the student is expected to attain, indicating whether he or she made advantage of all of the resources that are accessible.

| Educational Establishment                  | University of Al-Ameed  |
|--|---|
| Scientific Department                      | Surgical department   |
| Name of the Professional Academic Program. | Modified traditional curriculum   |
| Final Graduation Certificate               | M.B.Ch.B  |
| Educational system. Annual/courses/other   | Annual  |
| Approved accreditation program             | Approved accreditation program  Iraqi National Guideline on Standards for Established and Accrediting Medical School  |
| Other external factors                     | Availability of relevant scientific research in the field of specialization  Access to global electronic networks  Access to traditional and digital libraries  Teaching aids such as data show and  PowerPoint presentations  Availability of equipped classrooms  Use of free online communication  platforms (e.g., Free Conference Call |
| Date the description was written           | 1/4/2025  |

#### Academic program objective

- 1-Graduate doctors with a strong foundation in surgery, enabling them to understand, diagnose, and treat surgical cases in emergency departments, surgical wards, and outpatient clinics. Strengthen students' clinical skills through theoretical and practical discussions, clinical patient examinations in hospitals, and hands-on training in skills laboratories. Additionally, conduct surgical workshops at the college to discuss surgical cases and explore their management.
- 2-Provide training and skills to practice surgery safely by diagnosing and treating common and urgent surgical cases, as well as managing trauma and emergency situations.
- 3-Integrate modern educational techniques and advanced technology into teaching methods and surgical programs, while utilizing information and communication technologies to share knowledge, conduct research, and develop surgical curricula.
- 4-Promote cultural exchange and establish bilateral partnerships with medical schools and professional surgical organizations at the Arab and international levels to expand academic and scientific collaboration in the field of surgery.
- 5-Strengthen collaboration between the college and the community by organizing seminars, conferences, and workshops that address national surgical and health issues.
- 6-Support the preparation of future leaders in the field of surgery, empowering them to achieve excellence and leadership in their medical specialties.
- 7-Regarding health understand global health and public health strategies related to surgical care access, safe surgery initiatives, and trauma system development.
- 8- Discussing the importance of patient education Explain the importance of early screening programs and understand the role of lifestyle modification ,Identify risk factors

Promote trauma prevention.

The most reliable resources for program information are:

Bailey and love

Short practice of surgery

Code: SURG 306 2 Credits

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|--------------|---|-------------------|---------------------------------|--------------------------------------|
| Introduction | to surgery  |                   |                                 |                                      |
| SURG1.1      | Define surgery and discuss its historical evolution, including key milestones and advancements in surgical techniques and technology.  Explain the principles of asepsis, antisepsis, and surgical ethics in modern surgical practice.  Discuss the role of surgery in managing various diseases, including trauma, cancer, infections, and congenital abnormalities.  Describe the different types of surgical procedures (elective, emergency, minimally invasive, and robotic surgery) and their indications.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION/<br>MCQ  |
| SURG1.2      | Recognize the preoperative, intraoperative, and postoperative phases of surgery and the importance of multidisciplinary collaboration.  Explain the common complications associated with surgery, including infection, bleeding, thrombosis, and anesthesia-related risks.  Discuss patient safety principles in surgery, including the use of checklists, consent processes, and surgical site infection prevention.  Recognize the impact of surgical innovations, including laparoscopic and robotic-assisted surgery, on patient outcomes and recovery. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Wounds, hea  | ling & tissue repair  |                   |                                 |                                      |
| SURG2.1      | Define different types of wounds (incised, lacerated, contused, puncture, and avulsion) and classify them based on depth and severity.  Explain the phases of wound healing (inflammatory, proliferative, and remodeling) and factors that influence wound healing.  Discuss the role of fibroblasts, collagen synthesis, and angiogenesis in tissue repair and wound contraction.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|--------------|--|-------------------|---------------------------------|--------------------------------------|
| SURG2.2      | Identify systemic and local factors affecting wound healing, including diabetes, infection, ischemia, and nutritional deficiencies.  Explain the difference between primary, secondary, and tertiary intention healing and their clinical relevance.  Discuss the complications of wound healing, including hypertrophic scars, keloids, dehiscence, and chronic nonhealing ulcers.  Recognize the importance of infection control in wound management, including the role of antiseptics, dressings, and negative pressure wound therapy. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Wounds, heal | ling & tissue repair   |                   |                                 |                                      |
| SURG3.1      | Define chronic wounds and differentiate them from acute wounds in terms of pathophysiology and management.  . Discuss the pathophysiology of pressure ulcers, venous ulcers, and diabetic foot ulcers, including risk factors and staging.  . Explain the role of hyperbaric oxygen therapy, bioengineered skin substitutes, and skin grafts in chronic wound management.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG3.2      | Explain the role of prophylactic antibiotics in surgical wound infection prevention and their appropriate use.  Describe the role of vacuum-assisted closure (VAC) therapy and its indications in wound management.  Recognize the importance of multidisciplinary care (e.g., plastic surgeons, vascular surgeons, and endocrinologists) in managing complex wounds.  Discuss the prevention of wound healing complications, including patient education, lifestyle modifications, and early intervention strategies.                     | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number        | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|---------------|--|-------------------|---------------------------------|--------------------------------------|
| Fluid and Ele | ctrolyte Balance   |                   |                                 |                                      |
| SURG4.1       | Explain the distribution of body fluids, including intracellular, extracellular, and transcellular compartments, and their clinical significance.  . Discuss the physiological mechanisms regulating fluid balance, including osmoregulation, hormonal control (ADH, aldosterone), and renal function.  . Recognize the clinical features, causes, and management of common fluid imbalances, including dehydration, hypovolemia, and hypervolemia.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG4.2       | Discuss the causes, clinical presentation, and management of electrolyte imbalances, including hyponatremia, hyperkalemia, and hypocalcemia.  . Describe the indications for intravenous fluid therapy, including types of fluids  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Acid Base Ba  | lance  |                   |                                 |                                      |
| SURG5.1       | Define acid-base balance and explain its physiological regulation through the respiratory and renal systems.  . Discuss the concepts of pH, bicarbonate (HCO <sub>3</sub> <sup>-</sup> ), and partial pressure of carbon dioxide (PaCO <sub>2</sub> ) in arterial blood gas (ABG) analysis.  . Explain the causes, clinical manifestations, and management of metabolic acidosis, including diabetic ketoacidosis and lactic acidosis.  . Discuss the pathophysiology and treatment of metabolic alkalosis, including vomiting-induced alkalosis and diuretic use. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|--------------|---|-------------------|---------------------------------|--------------------------------------|
| SURG5.2      | Explain the causes, diagnosis, and management of respiratory acidosis and respiratory alkalosis in surgical patients.  Recognize the role of buffer systems (bicarbonate, phosphate, and protein buffers) i maintaining acid-base homeostasis.  Discuss the importance of arterial blood gas (ABG) interpretation in diagnosing acid-base disorders and guiding treatment.  Describe the principles of acid-base correction, including the use of intravenous bicarbonate therapy | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Skin & Subcu | itaneous Tissue   |                   |                                 |                                      |
| SURG6.1      | Describe the structure and function of the skin, including its layers (epidermis, dermis, and subcutaneous tissue) and their clinical significance.  Explain the pathophysiology of common skin infections, including cellulitis, abscesses, necrotizing fasciitis, and their management.  Discuss the principles of wound assessment, including classification of burns, ulcers, and traumatic skin injuries.  Describe the clinical presentation and management of pressure     | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG6.2      | Explain the role of surgical debridement, dressings, and skin grafting in wound management.  . Discuss the diagnosis and treatment of benign skin lesions, including lipomas, epidermoid cysts, and dermatofibromas.  . Recognize the importance of histopathological examination in differentiating benign from malignant skin lesions.  . Discuss the role of reconstructive surgery, including flap techniques, in managing complex skin defects.                              | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number        | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|---------------|---|-------------------|---------------------------------|--------------------------------------|
| Skin & Subcu  | utaneous Tissue   |                   |                                 |                                      |
| SURG7.1       | Explain the etiology and clinical presentation of soft tissue infections, including erysipelas, cellulitis, and necrotizing soft tissue infections.  Describe the principles of antibiotic selection for bacterial skin infections based on culture results and antimicrobial susceptibility.  Discuss the pathophysiology and management of necrotizing fasciitis, including early recognition, surgical debridement, and intensive care support.  Explain the risk factors, diagnosis, and treatment of hidradenitis suppurativa, including medical and surgical options. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG7.2       | Discuss the classification, diagnosis, and management of chronic nonhealing wounds, including venous and arterial ulcers.  Recognize the clinical features and management of cutaneous manifestations of systemic diseases, such as vasculitis and autoimmune skin conditions.  Explain the role of biologic and immunosuppressive therapies in treating inflammatory skin conditions like psoriasis and pemphigus vulgaris.  Discuss the principles of reconstructive plastic surgery in skin defect management, including grafting and local flap techniques.             | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Metabolic res | sponse to injury  |                   |                                 |                                      |
| SURG8.1       | Explain the physiological changes following injury, including the systemic inflammatory response and hormonal adaptations.  Discuss the phases of metabolic response to injury: the ebb phase, flow phase, and recovery phase.  Recognize the effects of trauma, burns, and major surgery on metabolism, including hypermetabolism and protein catabolism.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number        | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |  |
|---------------|--|-------------------|---------------------------------|--------------------------------------|--|
|               | . Explain the role of cytokines, stress hormones (cortisol, catecholamines), and inflammatory mediators in the metabolic response.   |                   |                                 |                                      |  |
| SURG8.2       | Discuss the pathophysiology and management of sepsis-induced metabolic derangements.  Describe the nutritional implications of hypermetabolism and catabolism in critically ill patients.  Explain the role of early enteral and parenteral nutrition in reducing morbidity and mortality in surgical patients.  Discuss the importance of monitoring metabolic parameters (e.g., glucose, lactate, nitrogen balance) in post-injury patient care.                         | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |  |
| Nutrition and | fluid therapy  |                   |                                 |                                      |  |
| SURG9.1       | Explain the principles of perioperative nutrition and its impact on surgical outcomes.  . Discuss the indications, benefits, and limitations of enteral versus parenteral nutrition in surgical patients.  . Recognize the clinical manifestations and management of protein-energy malnutrition and its impact on wound healing.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |  |
| SURG9.2       | Describe the components of a balanced nutritional plan for surgical patients, including macronutrients, micronutrients, and fluid requirements.  Explain the importance of early nutrition in critically ill patients, including immune-enhancing diets.  Discuss the role of specialized nutrition in specific surgical conditions, such as short bowel syndrome and burns.  Explain the principles of refeeding syndrome, including prevention and management strategies | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |  |
| Nutrition and | Nutrition and fluid therapy  |                   |                                 |                                      |  |
| SURG9.1       | Explain the principles of perioperative nutrition and its impact on surgical outcomes.   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |  |

| Number        | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|---------------|---|-------------------|---------------------------------|--------------------------------------|
|               | Discuss the indications, benefits, and limitations of enteral versus parenteral nutrition in surgical patients. Recognize the clinical manifestations and management of protein-energy malnutrition and its impact on wound healing.  |                   |                                 |                                      |
| SURG9.2       | Describe the components of a balanced nutritional plan for surgical patients, including macronutrients, micronutrients, and fluid requirements.  Explain the importance of early nutrition in critically ill patients, including immune-enhancing diets.  Discuss the role of specialized nutrition in specific surgical conditions, such as short bowel syndrome and burns.  Explain the principles of refeeding syndrome, including prevention and management strategies        | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Nutrition and | fluid therapy   |                   |                                 |                                      |
| SURG10.1      | Discuss the metabolic consequences of prolonged fasting and starvation in surgical patients.  Explain the role of nitrogen balance in assessing protein requirements and the need for supplementation.  Describe the indications and complications of total parenteral nutrition (TPN), including catheterrelated infections and metabolic disturbances.  Explain the role of immunonutrition in critically ill patients, including arginine, glutamine, and omega-3 fatty acids. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number       | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|--------------|--|-------------------|---------------------------------|--------------------------------------|
| SURG10.2     | Discuss the specific nutritional needs of patients undergoing major gastrointestinal surgery and bariatric surgery.  Explain the concept of enhanced recovery after surgery (ERAS) protocols and their impact on perioperative nutrition.  Describe the assessment and management of micronutrient deficiencies, including vitamin and mineral supplementation.  Discuss the importance of monitoring electrolyte and metabolic parameters in patients receiving artificial nutrition. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Introduction | to trauma  |                   |                                 |                                      |
| SURG11.1     | Define trauma and describe its epidemiology, including global burden and preventable causes.  Explain the primary survey (ABCDE approach) in trauma assessment and its clinical relevance.  Discuss the secondary survey in trauma evaluation, including systematic head-to-toe examination.  Describe the principles of damage control resuscitation, including permissive hypotension and hemostatic resuscitation.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG11.2     | Explain the pathophysiology of traumatic shock, including hypovolemic, neurogenic, and septic shock.  Discuss the role of focused assessment with sonography for trauma (FAST) and extended FAST (eFAST) in trauma evaluation.  Explain the importance of the golden hour in trauma management and strategies to improve patient outcomes.  Discuss the indications for emergency surgical intervention in trauma patients, including exploratory laparotomy and thoracotomy.          | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number  Early assessm | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|-----------------------|--|-------------------|---------------------------------|--------------------------------------|
| SURG12.1              | Describe the principles of advanced trauma life support (ATLS) in the initial assessment of trauma patients.  Explain the role of prehospital care in trauma management, including airway management and fluid resuscitation.  Discuss the indications and techniques for securing the airway in trauma patients, including endotracheal intubation and cricothyroidotomy.  Recognize the signs of lifethreatening hemorrhage and discuss immediate hemorrhage control strategies.   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Wounds, heal          | ing & tissue repair  |                   |                                 |                                      |
| SURG12.2              | Explain the role of point-of-care ultrasound in assessing trauma patients.  . Discuss the management of traumatic brain injury, including intracranial pressure monitoring and neurosurgical intervention.  . Explain the assessment and management of spinal cord injuries in trauma.  8. Discuss the role of trauma registries and quality improvement initiatives in improving trauma outcomes  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Torso and pel         | vic trauma   |                   |                                 |                                      |
| SURG13.1              | Discuss the common causes and mechanisms of blunt and penetrating torso trauma, including motor vehicle accidents and gunshot wounds.  Explain the classification and management of rib fractures, including flail chest and their complications (e.g., pneumothorax, hemothorax).  Describe the assessment and management of thoracic trauma, including tension pneumothorax, hemothorax, and cardiac tamponade.  Explain the diagnosis and management of solid organ injuries (liver, spleen, kidneys) in abdominal trauma, including non-operative management strategies. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number         | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|----------------|---|-------------------|---------------------------------|--------------------------------------|
| Disaster surge | ery   |                   |                                 |                                      |
| SURG14.1       | Define disaster surgery and describe the principles of mass casualty triage (START and SALT systems).  . Explain the role of damage control resuscitation and surgery in disaster scenarios.  . Discuss the management of blast injuries, including primary, secondary, tertiary, and quaternary effects.  . Describe the common surgical interventions in disaster settings, including amputations, fasciotomies, and debridement.                           | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG14.2       | Explain the principles of field hospitals and mobile surgical units in disaster response.  . Discuss the role of multidisciplinary teams, including surgeons, anesthetists, and emergency physicians, in disaster management.  . Recognize the challenges of resource-limited settings and ethical dilemmas in disaster surgery.  . Explain post-disaster rehabilitation strategies, including prosthetics, reconstructive surgery, and psychological support | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Conflict surge | ery   |                   |                                 |                                      |
| SURG15.1       | Define conflict surgery and discuss the unique challenges of providing surgical care in war zones.  Explain the management of gunshot wounds, including wound ballistics and debridement principles.  Discuss the pathophysiology and management of blast injuries, including lung, brain, and abdominal injuries.  Describe the role of tourniquets, hemostatic agents, and damage control surgery in combat trauma  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG15.2       | Explain the management of open fractures, amputations, and soft tissue injuries in battlefield conditions.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number               | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|----------------------|---|-------------------|---------------------------------|--------------------------------------|
|                      | . Discuss the challenges of infection control, including multidrug-resistant organisms in conflict zones Recognize the importance of humanitarian surgical missions and organizations like the ICRC and MSF Explain the principles of post-war rehabilitation, including reconstructive surgery and psychological support for war-injured patients. cisions & sutures   |                   |                                 |                                      |
| material<br>SURG16.1 | Describe the different types of   | K/S               | LADGE                           | тдоцо                                |
| SURG16.1             | Describe the different types of abdominal incisions and their indications (midline, paramedian, Kocher's, Pfannenstiel, etc.) Explain the advantages and disadvantages of each type of incision concerning wound healing and postoperative complications Discuss the classification and properties of suturing materials (absorbable vs. non-absorbable, monofilament vs. multifilament) Explain the principles of wound closure techniques, including interrupted, continuous, and subcuticular suturing | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Skin & Subcu         | taneous Tissue  |                   |                                 |                                      |
| SURG16.2             | Recognize the complications of improper wound closure, including wound dehiscence and incisional hernias.  . Discuss the role of surgical staplers and adhesives in modern surgical wound closure.  . Explain the factors influencing suture selection based on tissue type (e.g., skin, fascia, bowel).  . Describe the principles of postoperative wound care, including dressing selection and infection prevention.   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Cyst, Ulcer, Sinus   |   |                   |                                 |                                      |
| SURG17.1             | Discuss the common causes of sebaceous cysts, dermoid cysts, and pilonidal cysts, including their surgical management.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number        | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|---------------|--|-------------------|---------------------------------|--------------------------------------|
|               | . Explain the pathophysiology and classification of ulcers, including venous, arterial, and neuropathic ulcers Describe the diagnosis and management of chronic ulcers, including wound debridement, dressings, and skin grafting Discuss the causes and management of common sinuses and fistulas, including pilonidal sinuses and anal fistulas.   |                   |                                 |                                      |
| SURG17.2      | Explain the principles of chronic wound care, including the role of negative pressure wound therapy.  Recognize the risk factors and management strategies for malignant transformation in chronic ulcers (Marjolin's ulcer).  Discuss the role of biopsy and histopathological examination in diagnosing non-healing ulcers.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Surgical Infe | ction  |                   |                                 |                                      |
| SURG18.1      | Define surgical infections and classify them into superficial, deep, and organ/space infections.  . Discuss the microbiology of common surgical infections, including Staphylococcus aureus, Streptococcus, and anaerobes.  . Explain the principles of surgical site infection (SSI) prevention, including antibiotic prophylaxis and aseptic technique.  . Describe the diagnosis and management of abscesses, cellulitis, and necrotizing soft tissue infections. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG18.2      | Discuss the management of deep-seated infections, including peritonitis, mediastinitis, and necrotizing fasciitis.  Explain the role of source control in surgical infection management, including drainage and debridement.  Recognize the importance of multidrug-resistant organisms and antibiotic stewardship in surgical practice.  Discuss the complications of untreated surgical infections, including sepsis and multi-organ failure                       | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number          | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|-----------------|---|-------------------|---------------------------------|--------------------------------------|
| Surgical Infec  | ction   |                   |                                 |                                      |
| SURG19.1        | Explain the pathophysiology and risk factors for sepsis and septic shock in surgical patients.  . Discuss the criteria for diagnosing sepsis (qSOFA, SIRS criteria) and the importance of early recognition.  . Describe the principles of sepsis management, including fluid resuscitation, vasopressor therapy, and early antibiotics.  . Explain the indications for surgical intervention in sepsis, including source control strategies. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG19.2        | Discuss the role of biomarkers (e.g., procalcitonin, lactate) in sepsis diagnosis and monitoring.  Recognize the long-term complications of sepsis, including post-sepsis syndrome and organ dysfunction.  Explain the role of infection prevention strategies in surgical wards, including hand hygiene and antibiotic stewardship.  Discuss the impact of nosocomial infections and multidrug-resistant pathogens in surgical patients.     | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Sterilization a | & Disinfection  |                   |                                 |                                      |
| SURG20.1        | Define sterilization and disinfection and explain their importance in infection control.  . Discuss the different methods of sterilization, including autoclaving, ethylene oxide gas, and plasma sterilization.  . Explain the principles of high-level, intermediate-level, and low-level disinfection.  . Describe the indications and uses of chemical disinfectants, including alcohol, chlorhexidine, and formaldehyde.                 | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number                     | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|----------------------------|---|-------------------|---------------------------------|--------------------------------------|
| SURG20.1                   | Discuss the importance of sterilization in surgical instrument processing and its impact on surgical outcomes.  Explain the role of aseptic technique in preventing surgical site infections.  Recognize the challenges and solutions in maintaining sterile environments in operating rooms.  Discuss infection control policies and quality assurance measures in healthcare settings   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Tropical infedinfestations | ctions and  |                   |                                 |                                      |
| SURG21.1                   | Define tropical infections and discuss their epidemiology, including endemic regions and risk factors.  Explain the clinical presentation, diagnosis, and surgical complications of amoebic liver abscess, including drainage techniques.  Discuss the pathophysiology and management of schistosomiasis-related urological and hepatic complications.  Describe the surgical implications of hydatid disease, including cystectomy and perioperative considerations. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG21.1                   | Recognize the clinical features and management of filariasis-related lymphatic obstruction and elephantiasis.  Explain the surgical approach to necrotizing fasciitis in tropical settings, including aggressive debridement and antibiotic therapy.  Discuss the impact of tropical infections on wound healing and postoperative recovery.  Explain the principles of infection control and vaccination strategies in endemic region                                | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Hydatid Cysts              |   |                   |                                 |                                      |
| SURG22.1                   | Describe the life cycle of Echinococcus granulosus and its role in hydatid cyst formation Explain the clinical presentation and complications of hydatid cysts in the liver, lungs, and other organs Discuss the imaging modalities used for diagnosing hydatid cysts, including ultrasound and CT scans.   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number        | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|---------------|---|-------------------|---------------------------------|--------------------------------------|
|               | . Explain the surgical management of hydatid cysts, including PAIR (puncture, aspiration, injection, and reaspiration) and open surgery   |                   |                                 |                                      |
| SURG22.2      | Discuss the medical treatment of hydatid disease, including the role of albendazole and mebendazole.  Recognize the complications of untreated hydatid cysts, including rupture, secondary infection, and anaphylaxis.  Explain preventive measures to reduce the transmission of Echinococcus infection in endemic areas.  Discuss the importance of multidisciplinary management involving surgeons, infectious disease specialists, and radiologists                               | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Principles of | oncology  |                   |                                 |                                      |
| SURG23.1      | Define oncology and discuss the basic principles of cancer biology, including carcinogenesis and tumor progression.  Explain the TNM staging system and its role in guiding cancer management.  Describe the different modalities of cancer treatment, including surgery, chemotherapy, radiotherapy, and targeted therapy.  Discuss the indications and principles of oncologic surgery, including curative, palliative, and cytoreductive surgery.                                  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG23.2      | <ul> <li>Explain the role of sentinel lymph node biopsy in cancer staging and treatment.</li> <li>Recognize the principles of cancer screening programs, including colorectal, breast, and cervical cancer screening.</li> <li>Discuss the complications of cancer treatment, including chemotherapyinduced immunosuppression and radiation fibrosis.</li> <li>Explain the psychosocial aspects of cancer care, including palliative care and end-of-life decision-making.</li> </ul> | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number         | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|----------------|--|-------------------|---------------------------------|--------------------------------------|
| Tissue & Mol   | ecular Diagnosis   |                   |                                 |                                      |
| SURG24.1       | Explain the principles of tissue biopsy techniques, including excisional, incisional, core needle, and fine needle aspiration biopsy (FNAB).  . Discuss the role of histopathology and immunohistochemistry in cancer diagnosis.  . Explain the significance of tumor markers (e.g., CEA, AFP, CA-125) in cancer diagnosis and prognosis.  . Describe the principles of molecular pathology, including PCR, fluorescence in situ hybridization (FISH), and next-generation sequencing. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG24.2       | Discuss the role of genetic testing in hereditary cancer syndromes, including BRCA mutations and Lynch syndrome.  . Explain the importance of frozen section analysis in intraoperative cancer diagnosis.  . Discuss the impact of precision medicine in tailoring cancer treatment based on molecular profiling.  . Recognize the limitations and ethical considerations of molecular diagnostics in clinical practice.   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Arterial Disor | der  |                   |                                 |                                      |
| SURG25.1       | Describe the anatomy and physiology of arterial circulation and its clinical relevance.  . Discuss the pathophysiology, risk factors, and classification of peripheral arterial disease (PAD).  . Explain the clinical presentation and diagnostic evaluation of acute and chronic limb ischemia.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG25.2       | Discuss the indications for surgical and endovascular interventions in PAD, including angioplasty and bypass surgery.  Explain the management of aortic aneurysms, including surveillance, open repair, and endovascular aneurysm repair (EVAR).   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number       | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |  |
|--------------|---|-------------------|---------------------------------|--------------------------------------|--|
|              | . Recognize the complications of arterial disorders, including embolism, thrombosis, and critical limb ischemia Discuss the role of lifestyle modification and pharmacological therapy in the prevention of arterial disease Explain the principles of postoperative care and rehabilitation in vascular surgery  |                   |                                 |                                      |  |
| Venous Disor | rder  |                   |                                 |                                      |  |
| SURG26.1     | Describe the anatomy and function of the venous system, including superficial and deep veins.  Discuss the pathophysiology and risk factors of chronic venous insufficiency (CVI) and varicose veins. Explain the clinical presentation and diagnostic approach to deep vein thrombosis (DVT). Discuss the medical and surgical management of varicose veins, including sclerotherapy, vein stripping, and endovenous ablation. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |  |
| SURG26.2     | Explain the complications of untreated venous disorders, including venous ulcers and post-thrombotic syndrome.  . Discuss the indications for anticoagulation therapy in venous thromboembolism (VTE).  . Explain the role of compression therapy and lifestyle modifications in the management of venous disorders.  . Recognize the importance of thromboprophylaxis in hospitalized and post-surgical patients               | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |  |
| Lymphatic D  | Lymphatic Disorder  |                   |                                 |                                      |  |
| SURG27.1     | Explain the anatomy and physiology of the lymphatic system and its role in immune function.  . Discuss the pathophysiology and causes of lymphedema, including primary and secondary lymphedema. Recognize the clinical presentation and diagnostic evaluation of lymphatic obstruction.  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |  |

| Number      | Learning Objective  | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|-------------|---|-------------------|---------------------------------|--------------------------------------|
|             | . Discuss the conservative and surgical management of lymphedema, including compression therapy and lymphovenous anastomosis.   |                   |                                 |                                      |
| SURG27.2    | Explain the role of lymph node biopsy in the staging of malignancies.  . Discuss the diagnosis and management of lymphadenopathy, including infectious, inflammatory, and neoplastic causes.  . Recognize the complications of chronic lymphedema, including cellulitis and lymphangiosarcoma.  . Discuss the impact of lymphatic disorders on quality of life and rehabilitation strategies  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| DVT & gange | rene  |                   |                                 |                                      |
| SURG28.1    | Explain the pathophysiology and risk factors for deep vein thrombosis (DVT), including Virchow's triad.  Discuss the clinical presentation and diagnostic approach to DVT, including D-dimer testing and Doppler ultrasound.  Explain the principles of anticoagulation therapy in DVT management, including indications and complications.  Discuss the pathophysiology and classification of gangrene, including dry, wet, and gas gangrene | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG28.2    | Explain the clinical features and management of Fournier's gangrene and necrotizing fasciitis.  Recognize the indications for surgical debridement and amputation in gangrenous conditions.  Discuss the role of hyperbaric oxygen therapy in managing gas gangrene.  Explain the importance of thromboprophylaxis in preventing DVT in surgical and immobilized patients   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number        | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods                |
|---------------|--|-------------------|---------------------------------|--------------------------------------|
| Shock & hem   | orrhage  |                   |                                 |                                      |
| SURG29.1      | Define shock and classify its types, including hypovolemic, cardiogenic, distributive, and obstructive shock.  . Discuss the pathophysiology and compensatory mechanisms of shock.  . Explain the clinical presentation and diagnostic approach to shock, including hemodynamic monitoring.  . Discuss the principles of fluid resuscitation, including crystalloid and colloid solutions.   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG29.2      | Explain the management of hemorrhagic shock, including blood transfusion and damage control resuscitation.  . Discuss the indications for massive transfusion protocols in trauma and surgical patients.  . Recognize the complications of shock, including multi-organ dysfunction syndrome (MODS).  . Explain the role of vasopressors and inotropes in managing different types of shock  | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| Blood transfu | sion   |                   |                                 |                                      |
| SURG30.1      | Explain the principles of blood transfusion, including blood grouping, crossmatching, and compatibility testing.  . Discuss the indications and contraindications for blood transfusion in surgical practice.  . Describe the different blood products (whole blood, packed red blood cells, platelets, fresh frozen plasma, cryoprecipitate) and their clinical use.  . Recognize the complications of blood transfusion, including hemolytic reactions, febrile reactions, and transfusion-related infections. | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |
| SURG30.2      | Discuss the management of massive transfusion protocols in trauma and perioperative settings.  Explain the principles of autologous blood transfusion and intraoperative cell salvage.   | K/S               | LARGE<br>GROUP<br>TEACHING      | SHORT<br>ANSWER<br>QUESTION /<br>MCQ |

| Number | Learning Objective   | Domain<br>K/S/A/C | Teaching<br>Learning<br>Methods | Assessment<br>Methods |
|--------|--|-------------------|---------------------------------|-----------------------|
|        | <ul> <li>. Discuss the role of transfusion in managing anemia and coagulopathy in surgical patients.</li> <li>. Explain the ethical considerations and guidelines for safe blood donation and transfusion practices</li> </ul> |                   |                                 |                       |

## Biostatistics and public health



## **Third Grade**

| 1. Educational Institution                   | University of Al-Ameed   |
|--|--|
| 2. Scientific Department/Center              | College of Medicine / Department of Public health and family medicine (Biostatistics and family medicine)  |
| 3. Name of academic or professional program  | Modified traditional curriculum  |
| 4. Name of the final certificate             | M.B.Ch.B   |
| 5. Academic System: Annual / Courses / Other | Annual   |
| 6.Accredited Certification Program           | Iraqi National Guideline on Standards for<br>Established and Accrediting Medical School  |
| 7.Other external influences                  | Availability of relevant scientific research in the field of specialization  Access to global electronic networks  Access to traditional and digital libraries  Teaching aids such as data show and PowerPoint presentations  Availability of equipped classrooms  Use of free online communication platforms (e.g., Free Conference Call) |
| 8. Description preparation date              | 15/9/2024  |

## 9- Objectives of the academic program:

- Developing the ability to use prevention and control measures for health problems in the communities, understanding core concepts of biostatistics: descriptive statistics, inferential statistics, correlation and regression.
- Acquiring abilities and skills related to epidemiology and statistics in analyzing health indicators, understanding core concepts of public health: principles of public health.
- Understanding the basic principles of primary health care and communities medicine as a strategy and services, disease prevention and health promotion, epidemiology.
- Identifying communities' health problems, prioritizing and managing them, including communicable and non-communicable diseases, reproductive, nutritional, and injuries
- The ability to work in a team with leadership skills.

- Integration and Application: applying biostatistics to public health problems, be able to use basic statistical methods to analyze public health data.
- Apply biostatistical and public health principles to identify and analyze health problems within the local communities.
- 13. The most reliable resources for program information are:
- Richard S.Snell, Clinical Anatomy by Regions, . Lippincott Williams & Wilkins
- Moore, Keith L.; Dalley, Arthur F, Clinically Oriented Anatomy, Lippincott Williams & Wilkins
- ABC OFLEARNING AND TEACHING IN MEDICINE by PETER CANTILLON 2003 ISBN 07279 16785
- Teaching and Learning Communication Skills in Medicine by Suzanne Kurtz Professor of Communication Faculties of Education and Medicine 2004

|          | Biostatistics and public health \ Grade 3 |           |
|----------|---|-----------|
| BIPH 307 |   | 2 Credits |

| Number         | Learning Objective   | Domain<br>K/S/A/C* | I earning | Assessment<br>Methods   |
|----------------|--|--------------------|-----------|---|
| 1.Introduction | on to Biostatistics  |                    |           |   |
| BIPH1.1        | Explain how biostatistics aids in interpreting research and guiding clinical decisions, recognize the role of biostatistics in evidence-based medicine.  Connect biostatistics to evaluating diagnostic tests, treatment effectiveness, and risk assessment.                 | K                  |           | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH1.2        | . Describe hypothesis testing principles, including Type I and Type II errors, identify common statistical tests in medical research (e.g., t-tests, chi-square tests) Understand the clinical use of hypothesis testing in comparing treatments and assessing risk factors. | K                  |           | , comprising<br>multiple choice<br>questions, single<br>best answer |
| 2.Summeriza    | ation and Presentation of Data   |                    |           |   |
| BIPH2.1        | Explain the importance of organizing data to understand its types and ranges, describe the use of frequency distribution in organizing a dataset into exclusive intervals. selects appropriate tables and graphs for different types of clinical data.                       |                    |           | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH2.2        | Explain the advantages of using graphs for data presentation, including simplicity, clarity, and visual impact explain the advantages of using graphs for data presentation, including simplicity, clarity, and visual impact  | K                  |           | , comprising<br>multiple choice<br>questions, single<br>best answer |

| Number     | Learning Objective   | Domain<br>K/S/A/C* | Teaching<br>Learning<br>Methods | Assessment<br>Methods   |
|------------|--|--------------------|---------------------------------|---|
| 3.Measures | of Central Tendency  |                    |                                 |   |
| ВІРНЗ.1    | Explain the concept of a distribution in statistics and its relevance to medical data, define the mean and describe how it is calculated.  Calculate and interpret mean values for patient characteristics (e.g., average age, average blood pressure) and understand its use in clinical studies. | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH3.2    | Define the median and describe how it is calculated, define the mode and describe how it is identified.  Select and justify the use of the appropriate measure of central tendency in different clinical scenarios and research contexts.  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| 4. Measure | s of Variability   |                    |                                 |   |
| BIPH4.1    | Define variability and its importance in the context of medical data, define the range and describe how it is calculated.  understand how the range is used to describe the spread of values in patient data, such as age ranges or ranges in lab values.  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH4.2    | . Define the interquartile range (IQR) and describe how it is calculated Learn how IQR is applied in clinical settings, such as in interpreting growth charts or understanding variability in treatment response.  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| 5. Measure | s of Variability2  | •                  |                                 |   |
| BIPH5.1    | Define variance and describe how it is calculated.     Interpret variance in the context of clinical data, such as variability in patient response to treatment.   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH5.2    | <ul> <li>Define standard deviation and explain its relationship to variance.</li> <li>Apply standard deviation to understand the typical deviation from the mean in patient data, lab values, and research results.</li> </ul>   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH5.3    | . Define the standard error of the mean Understand the role of standard error in assessing the reliability of sample means and its implications for generalizing research findings to a broader population.  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |

| Number                | Learning Objective  | Domain<br>K/S/A/C* | Teaching<br>Learning<br>Methods | Assessment<br>Methods   |  |  |
|-----------------------|---|--------------------|---------------------------------|---|--|--|
| 6.Confidence Interval |   |                    |                                 |   |  |  |
| BIPH6.1               | <ul><li>Define a confidence interval and explain its purpose in statistical inference.</li><li>Apply confidence intervals in the interpretation of medical research findings.</li></ul>   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| BIPH6.2               | . Explain that a confidence interval provides a range of values likely to contain the true population parameter Use confidence intervals to evaluate the statistical significance and clinical importance of treatment effects, diagnostic accuracy, and other relevant measures. | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| 7.Introduction        | on to Nutrition   |                    |                                 |   |  |  |
| BIPH7.1               | . Define nutrition and describe its relationship to health and well-being, explain why nutrition is essential for life, health, and development across all life stages.   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| BIPH7.2               | . Describe how proper nutrition supports wellness and can prevent diseases, explain the role of nutrition in building, repairing, and maintaining tissues.  | K                  | Large group lecture             | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| 8.Energy Re           | equirements   |                    |                                 |   |  |  |
| ВІРН8.1               | a. Explain the human body's continuous need for a regular supply of nutrients. b. Identify the purposes for which the body requires energy, including body processes, growth, and physical activity.  | K                  | lecture                         | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| BIPH8.2               | . Identify the components of total energy requirements (TER), including basal metabolic rate (BMR), physical activity, specific dynamic action of food (SDA) (or thermic effect of food (TEF)), and other factors like growth, pregnancy, lactation, and temperature regulation.  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |

| Number      | Learning Objective  | Domain<br>K/S/A/C* | Teaching<br>Learning<br>Methods | Assessment<br>Methods   |
|-------------|---|--------------------|---------------------------------|---|
| 9.Assessem  | ent of Nutritional Status   |                    | TVICETOGS                       |   |
| ВІРН9.1     | . Define nutritional status as the balance between nutrient intake and requirement, emphasizing how this balance affects patients' health Explain how to apply direct assessment methods (clinical, biochemical, anthropometric, and biophysical techniques) to evaluate individual patients' nutritional status.   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH9.2     | . Explain the clinical importance of nutritional status in patient care, including its role in recovery, disease management, and overall health outcomes.  . Describe the use of indirect assessment methods (socioeconomic, dietary, and cultural factors) in understanding factors that influence patients' nutritional health                                  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| ВІРН9.3     | <ul> <li>a. Identify factors that commonly affect nutritional status in patients, such as acute and chronic diseases, eating disorders, psychological stress, and economic limitations.</li> <li>b. Explain how these factors can influence nutrient intake, absorption, and utilization, and discuss strategies to address them in clinical practice.</li> </ul> | K                  | Large group lecture             | , comprising<br>multiple choice<br>questions, single<br>best answer |
| 10.Nutrient | Requirement\Carbohydrate  |                    |                                 |   |
| BIPH10.1    | . Describe the functions of simple and complex carbohydrates: Identify monosaccharides, and disaccharides, as simple carbohydrates and explain their roles as quick energy sources. Explain that polysaccharides, are complex carbohydrates and describe their different roles in energy storage (starch and glycogen) and digestion (fiber).                     | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH10.2    | Describe the health effects of carbohydrates: . Explain how carbohydrates are digested and used for energy (ATP) in the body Discuss the importance of complex carbohydrates over simple carbohydrates for sustained energy and better health.  |                    | Large group lecture             | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH10.3    | a. Define glycemic index. b. Explain the concept of the glycemic index (GI) and its use in ranking foods based on their effect on blood glucose levels.   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |

| Number       | Learning Objective  | Domain<br>K/S/A/C* | Teaching<br>Learning<br>Methods | Assessment<br>Methods   |  |  |
|--------------|---|--------------------|---------------------------------|---|--|--|
| 11.Nutrition | 1.Nutritional Disorder (Malnutrition)   |                    |                                 |   |  |  |
| BIPH11.1     | Define malnutrition and its various forms, emphasizing the global burden and epidemiological significance of malnutrition. This includes understanding the definitions of undernutrition (wasting, stunting, underweight), micronutrient deficiencies, and over nutrition, as well as the prevalence and distribution of these conditions worldwide and in specific populations.  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| BIPH11.2     | . Identify populations at risk for malnutrition and analyze the multifactorial causes of malnutrition in different clinical settings.   | K                  | Large group lecture             | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| BIPH11.3     | <ul> <li>a. Describe the clinical manifestations, diagnostic criteria, and complications of specific malnutrition disorders, including protein-energy malnutrition and micronutrient deficiencies. This includes differentiating between conditions like kwashiorkor and marasmus.</li> <li>b. recognizing the signs and symptoms of vitamin and mineral deficiencies, and understanding the impact of malnutrition on organ systems and overall health.</li> </ul> | K                  | Large group lecture             | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| BIPH11.4     | <ul> <li>a. Apply public health principles to the prevention and control of malnutrition, including screening, nutritional interventions, and health education.</li> <li>b. Discuss the treatment and management of malnourished patients, emphasizing the importance of interdisciplinary care and follow-up.</li> </ul>   | K                  | lecture                         | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |
| 12.Micronut  | rien Related Malnutrition   |                    |                                 |   |  |  |
| BIPH12.1     | a. Define micronutrient malnutrition and assess its global significance, with a focus on vulnerable populations. This includes understanding the difference between micronutrient deficiencies and excesses, b. identifying populations at risk (e.g., pregnant women, children, elderly), and discussing the prevalence and impact of micronutrient malnutrition on global health.   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |  |  |

| Number        | Learning Objective   | Domain<br>K/S/A/C* | Teaching<br>Learning<br>Methods | Assessment<br>Methods   |
|---------------|--|--------------------|---------------------------------|---|
| BIPH12.2      | Identify the most common micronutrient deficiencies (iron, vitamin A, iodine, zinc, folate, and vitamin B12), and analyze their causes, clinical features, and diagnostic approaches.  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH12.3      | Discuss the impact of micronutrient deficiencies on public health outcomes, including morbidity, mortality, and developmental consequences. This includes evaluating the role of micronutrients in preventing diseases, reducing mortality rates (especially in vulnerable groups), and promoting optimal growth and development.  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH12.4      | Outline evidence-based strategies for the prevention and management of micronutrient deficiencies, including supplementation, fortification, dietary interventions, and public health measures. This involves implementing effective interventions to improve micronutrient status at both individual and population levels, such as promoting iron-rich diets, vitamin A supplementation, iodine fortification, and zinc supplementation. | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| 13.Distributi | on   |                    |                                 |   |
| BIPH13.1      | a. Understanding the Normal Distribution: Define the normal distribution and its key characteristics (bell-shaped curve, symmetry, mean, median, mode) b. Explain the clinical significance of skewed data and the appropriate measures of central tendency (median vs. mean).   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH13.2      | Recognize and: Identify real-world examples of data that tend to follow a normal distribution in public health (e.g., blood pressure, height, weight).   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
|               | f measurement  | lv z               | l-                              |   |
| BIPH14.1      | <ul><li>a. Define the four scales of measurement: nominal, ordinal, interval, and ratio.</li><li>b. Explain the properties of each scale, including how they categorize, order, and establish intervals and true zero points.</li></ul>  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |
| BIPH14.2      | Provide real-world examples of each scale in a public health context.  Provide examples of nominal data like blood type and gender, ordinal data like pain scales and satisfaction ratings, interval data like temperature and pH, and ratio data like height, weight, and enzyme activity   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer |

| Number         | Learning Objective  | Domain<br>K/S/A/C* | Teaching<br>Learning<br>Methods | Assessment<br>Methods  |
|----------------|---|--------------------|---------------------------------|--|
| 15. Sampling   | g methods   |                    |                                 |  |
| BIPH15.1       | Describe the two types of sampling methods: probability sampling and non-probability sampling.  | K                  | Large group<br>lecture          | comprising<br>multiple choice<br>questions, single<br>best answer    |
| BIPH15.2       | Identify the four main types of non-<br>probability sample: convenience sampling,<br>voluntary response sampling, purposive<br>sampling, and snowball sampling. | K                  | Large group<br>lecture          | comprising<br>multiple choice<br>questions, single<br>best answer    |
| 16. Statistica | al hypotheses   |                    |                                 |  |
| BIPH16.1       | understand that the goal of research is to investigate relationships between variables within a population  | K                  | Large group<br>lecture          | comprising<br>multiple choice<br>questions, single<br>best answer    |
| BIPH16.2       | formulate a statistical hypothesis, which is a formal way of writing a prediction about a population.   | K                  | Large group lecture             | comprising<br>multiple choice<br>questions, single<br>best answer    |
| 17. Overwei    | ght and obesity   |                    |                                 |  |
| BIPH17.1       | Know the prevalence of obesity in the world, define obesity, its types, and measurements.   | K                  | Large group<br>lecture          | comprising<br>multiple choice<br>questions,<br>single best<br>answer |
| BIPH17.2       | Recognize the etiology, risk factors, and pathophysiology of obesity  | K                  | Large group lecture             | comprising<br>multiple choice<br>questions,<br>single best<br>answer |
| BIPH17.3       | Know prevention and public health strategies for obesity.   | K                  | Large group<br>lecture          | comprising<br>multiple choice<br>questions,<br>single best<br>answer |
| 18. Nutrition  | during pregnancy  |                    |                                 |  |
| BIPH18.1       | Recognize factors effecting on maternal nutrition identify possible outcomes of maternal under nutrition  | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer  |
| BIPH18.2       | Recognize principles of nutritional requirements for pregnant women   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer  |
| 19. Nutrition  | n for elderly   |                    |                                 |  |

| Number      | Learning Objective  | Domain<br>K/S/A/C* | Teaching<br>Learning<br>Methods | Assessment<br>Methods  |
|-------------|---|--------------------|---------------------------------|--|
| BIPH19.1    | explain the nutrient requirements for elderly individuals, including energy, protein, carbohydrates, vitamins, and minerals   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer    |
| BIPH19.2    | describe the role of nutrition in managing<br>neurocognitive disorders in the elderly,<br>including dementia and Alzheimer's disease.   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer    |
| 20. Medical | nutrition therapy of cardiovascular diseases  |                    |                                 |  |
| BIPH20.1    | a. Identify the cardiovascular diseases, pathophysiology, risk factors of CVD and its prevalence. b. recognizes the role of nutrition in cardiovascular disease (CVD) management.                                     | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer    |
| BIPH20.2    | Identify key dietary recommendations for CVD prevention and treatment, identify key dietary recommendations for CVD prevention and treatment.   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions, single<br>best answer    |
| 21. Medical | nutrition therapy for diabetes mellitus   |                    |                                 |  |
| BIPH21.1    | List types of diabetes milletus, prevalence<br>and risk factors, define medical nutritional<br>therapy and its rule in management of<br>Type 1 and 2 Diabetes Mellitus.   | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions,<br>single best<br>answer |
| BIPH21.2    | Explain the impact of MNT on blood glucose control, insulin sensitivity and weight management in diabetic, explain the impact of MNT on blood glucose control, insulin sensitivity and weight management in diabetic. | K                  | Large group<br>lecture          | , comprising<br>multiple choice<br>questions,<br>single best<br>answer |